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Abstract 
Approximately 25% of colorectal carcinomas arise via the serrated neoplasia pathway. 
These cancers develop in serrated type polyps. Removal of these precursor polyps before 
the development of malignancy offers a unique opportunity to interrupt neoplastic 
progression and is the rationale for colonoscopic surveillance.  
Serrated colorectal polyps fall into three major subtypes; namely hyperplastic polyps, 
sessile serrated adenomas and traditional serrated adenomas. Hyperplastic polyps are the 
most numerous, but have limited, if any malignant potential. Sessile serrated adenomas 
give rise to the majority of serrated neoplasia pathway malignancies. Although rare, 
traditional serrated adenomas may be more likely to progress, thus requiring closer 
surveillance. While both are amenable to colonoscopic removal they present unique 
challenges when compared to the polyps of the “traditional” colorectal cancer pathway. In 
particular, sessile serrated adenomas are sessile (hence the name) and difficult to detect 
by colonoscopy, they are frequently misdiagnosed/under-diagnosed by pathologists, 
resulting in inadequate surveillance and their molecular biology is incompletely 
understood. Thus the aims of this PhD were to address issues relating to the diagnostic 
criteria of serrated colorectal polyps and to better define the clinicopathological and 
molecular features of these lesions.  
To this end several study sets were established. Firstly, a cohort to address issues 
surrounding the diagnosis of the sessile serrated adenoma was collected. Although 
recognised as a distinct entity for over ten years, uniform diagnostic criteria for the sessile 
serrated adenoma have not yet been established. In particular the distinction of this polyp 
from a closely related entity, the microvesicular hyperplastic polyp, has not been 
adequately addressed. Thus a central review of a consecutive series of 6340 colorectal 
polyps was undertaken. During the review, the diagnostic criteria of both the WHO and an 
expert panel convened by the American College of Gastroenterologists were applied to the 
diagnoses of all microvesicular hyperplastic polyps and sessile serrated adenomas.  A 
comparison of the clinicopathological features of the patients in these separate groups 
was then performed. This demonstrated a distinct shift in the clinicopathological features 
at the diagnostic threshold set by the expert panel but not at the threshold set by the 
WHO. Thus these findings supported the diagnostic criteria of the expert panel to 
differentiate microvesicular hyperplastic polyps from sessile serrated adenomas. 
Furthermore, 14.7% of all colorectal polyps met the expert panel diagnostic criteria for a 
sessile serrated adenoma. 2
The second study set comprised 200 rigorously diagnosed traditional serrated adenomas. 
A detailed clinicopathological and molecular assessment was performed on all cases. It 
was found that traditional serrated adenomas segregated into two key subtypes based on 
their BRAF or KRAS mutation status. This important molecular distinction underscored a 
substantial difference in both the clinicopathological and molecular features of these 
polyps. In particular BRAF mutated traditional serrated adenomas arose from pre-existing 
sessile serrated adenomas, were more likely to be located in the proximal colon, were 
more likely to have a sessile growth pattern, were more likely to demonstrate the CpG 
island methylator phenotype and were more likely to silence CDKN2A as they progressed 
to carcinoma. Importantly traditional serrated adenomas of all types retained mismatch 
repair enzyme function, meaning that the BRAF mutated subtype is an important precursor 
of the very aggressive BRAF mutated, microsatellite stable subtype of colorectal 
carcinoma. 
The third study set comprised a group of tubulovillous adenomas with serrated 
architectural features. A detailed clinicopathological and molecular assessment of these 
polyps was performed and then compared to control sets of traditional serrated adenomas 
and conventional tubulovillous adenomas. It was found that the serrated tubulovillous 
adenomas could be reliably diagnosed and had features distinct from both of the control 
cohorts. Furthermore, they had very high rates of KRAS mutation and thus appear to be 
an important precursor of the KRAS mutated subtype of colorectal carcinoma.  
The final study set comprised 137 sessile serrated adenomas with dysplasia and or 
carcinoma. These polyps were subjected to a detailed clinicopathological and molecular 
assessment, with a particular emphasis on the distinction between mismatch repair 
deficient and mismatch repair proficient cases. This dichotomy underscores the 
microsatellite instability status of the polyps and has important implications for the 
prognosis of the resultant carcinomas. It was found that mismatch repair proficient cases 
had distinct features. In particular they arose more often in males, at a younger age and 
more often in the distal colon than mismatch repair deficient cases. Furthermore, they 
were less likely to show the CpG island methylator phenotype and were more likely to 
harbour a TP53 mutation. 
In summary, this thesis has provided evidence to direct the diagnosis of the sessile 
serrated adenoma, has identified key molecular subtypes of both sessile serrated 
adenomas and traditional serrated adenomas and has better elucidated the pathways by 3
  
which these polyps progress to carcinoma. Finally a novel polyp subtype, namely the 
serrated tubulovillous adenoma has been proposed that appears to have distinctive 
histological and molecular features. This improved understanding of serrated colorectal 
polyps will contribute to better pathological diagnosis and to a more scientific basis for 
colonoscopic surveillance protocols. 
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Abstract 
Approximately 30% of colorectal carcinomas develop via a serrated neoplasia pathway, 
named for the pattern of crypts in the precursor polyps. Molecular abnormalities 
consistently involve methylation of CpG islands (CIMP) of low (CIMP-L) or high degree 
(CIMP-H) and activating mutations of the mitogen activated protein kinase pathway 
components BRAF or KRAS. Microsatellite instability (MSI) of high level (MSI-H) is often 
present, allowing for a molecular classification of serrated pathway carcinoma as; 1) BRAF 
mutant, CIMP-H with either a) MSI-H or b) microsatellite stable (MSS); and 2) KRAS 
mutant, CIMP-L, MSS.  
Precursor polyps include sessile serrated adenoma (SSA), characterised by proximal 
location, crypt architectural disturbance and BRAF mutation. Microvesicular hyperplasic 
polyp (MVHP) likely precedes the development of SSA and borderline lesions between 
MVHP and SSA occur. Cytological dysplasia in SSA portends advanced genetic 
abnormality and high risk of progression to carcinoma.  The traditional serrated adenoma 
has a predilection for the left colon, tubulovillous architecture, eosinophilic cytoplasm and 
frequent KRAS mutation.  
Serrated morphology carcinoma is a new WHO subtype with well-differentiated, mucinous 
or trabecular patterns. They have frequent KRAS or BRAF mutations and poor prognosis. 
This review provides an insight into the histology and molecular mechanisms driving these 
serrated pathway lesions. 
24
Introduction 
Most colorectal carcinomas (CRCs) are presumed to arise in pre-malignant polyps that are 
amenable to endoscopic resection, yet CRC remains the second leading cause of cancer 
death in the developed world.  At least two distinct molecular pathways underlie most 
CRCs.  Around 70% arise via the well-characterised chromosomal instability pathway1-3 on 
which most screening and treatment decisions are based.  Over the last two decades, 
many of the molecular mechanisms of a ‘serrated neoplasia pathway’ accounting for about 
30% of CRCs have been determined.1, 2  This has been paralleled by improved 
endoscopic and pathological recognition of serrated pathway cancers and polyps.   
This review will outline our understanding of the molecular basis of the serrated neoplasia 
pathway and discuss gaps in the current model.  Pathological features of the polyps and 
cancers arising from this pathway will be presented and areas of contention highlighted. 
Unraveling a new molecular model of colorectal carcinoma 
A series of parallel scientific and medical advances led to the identification of the serrated 
neoplasia pathway.   
SERRATED POLYPOSIS SYNDROME 
The first suggestion of a cancer pathway alternate to that of chromosomal instability came 
from the study of patients with hyperplastic polyposis syndrome (now SPS).  When SPS 
was first described in 1980, HPs, then the only recognised serrated polyps, were 
considered to be benign, non-neoplastic lesions.4   Early reports of an association between 
SPS and CRC received little attention5-9 and it was not until 1996 that Torlakovic and 
Snover demonstrated histological differences between the polyps in SPS and sporadic 
HPs10  Others reported atypical features in sporadic HPs, ‘mixed polyps’ with features of 
both HP and conventional adenoma7 and occasional CRCs arising in HPs.9 
LYNCH SYNDROME 
Lynch syndrome (formerly Hereditary Non-Polyposis Colorectal Cancer Syndrome), an 
autosomal dominant condition characterised by a high risk of cancer in multiple organs, 
25
particularly the large bowel, results from a germ-line mutation in a DNA mismatch repair 
gene.11  Inactivation of the remaining normal allele results in loss of mismatch repair 
function and accumulation of mutations in repeated mono, di or tri-nucleotide DNA 
sequences (termed microsatellites).  Most microsatellites are within non-coding DNA but 
some genes (e.g. TGFβRII and IGFIIR) harbour microsatellites and are particularly prone 
to mutation in Lynch syndrome.12, 13  This propensity is termed microsatellite instability 
(MSI).  
MSI14-16 and the first germ-line mutation in a mismatch repair gene (MSH2)17, 18 were 
identified in 1993, and mutations in other key mismatch repair genes the following year.19-
21 Consensus as to the most appropriate markers to define MSI was achieved in 1997: at 
least two of five target loci showing evidence of mismatch repair deficiency was 
designated MSI high (MSI-H), a single affected locus MSI low (MSI-L) and no affected 
locus microsatellite stable (MSS).22  Overall, about 15% of CRCs were MSI-H but a germ-
line defect in a mismatch repair gene was identified in only 2-3%.  The cause of the other 
12-13% remained unknown.23
DNA METHYLATION 
DNA methylation is a physiologic process with a wide range of functions, including 
genomic imprinting, timing of DNA replication and regulating chromatin structure and gene 
transcription.24, 25  In humans most methylation occurs via the activity of DNA 
methyltransferase, with cytosine residues followed by guanine (CpGs) being particularly 
prone to methylation.  Methylated cytosine is at high risk of deamination to thymine, as 
such, CpG dinucleotides are uncommon in most of the genome, occurring with a 
frequency of 20-25% of that expected by chance.  However, interspersed among the CpG 
depleted DNA are CpG rich regions referred to as CpG islands occurring almost 
exclusively in promoter regions of genes predominantly coding for housekeeping proteins 
involved in cell metabolism and cell structure.  Methylation of CpG dinucleotides in these 
islands often results in gene silencing.24-26   As many tumour suppressor genes (including 
p16 and MLH1) harbour CpG islands in their promoter regions, CpG island methylation is 
a potential mechanism of carcinogenesis.27-29 
In 1999, Toyota et al assessed levels of methylation in 30 CpG islands from 50 CRCs.30  
They found two patterns they designated type A (age-related), low level methylation that 
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increased incrementally with age, and type C (cancer-related) with high-level methylation 
of a distinct subset of CpG islands sufficient to result in gene silencing.  Frequent type C 
methylation occurred in 27% of the CRCs and these were termed CpG island methylator 
phenotype (CIMP) tumours.  Critically, the CIMP group encompassed virtually all cases of 
sporadic MSI-H cancers.  This was accurately attributed to methylation induced silencing 
of MLH1, providing an explanation for MSI carcinomas occurring outside of Lynch 
syndrome. 
Two major ‘CIMP panels’ are used for classifying CRCs26, 31 and many groups use their 
own panels.  This makes comparison of CIMP between studies difficult and is partly 
responsible for the reported variability in tumour numbers arising via the serrated 
neoplasia pathway.  High rates of synchronous or metachronous MSI cancers in patients 
with serrated polyps and SPS,32, 33 and CRCs arising in serrated-type polyps34 that 
exhibited CIMP, MLH1 silencing and MSI supported the existence of a serrated neoplasia 
pathway but one crucial molecular mechanism remained to be discovered. 
MAPK PATHWAY ACTIVATION 
The mitogen activated protein kinase (MAPK) pathway is a critical mechanism for cell 
signal conduction; mediating responses to extracellular signals relating to cell growth, 
differentiation and apoptosis.35  Mutations of components of this pathway have been 
identified in many types of cancer.  Activation of BRAF or KRAS, components of the MAPK 
signaling cascade, in response to upstream signaling results in increased cell division and 
reduced apoptosis.  Activating mutations of either BRAF or KRAS lead to constitutive 
activation of this pathway.   
KRAS mutations, common in the chromosomal instability pathway, have also been 
identified in a subset of cancers arising via the serrated neoplasia pathway.  Rajagopalan 
et al first described BRAF mutations in CRC in 2002.36  Importantly, they also found that 
BRAF and KRAS mutations are mutually exclusive and that BRAF mutations strongly 
correlate with both MSI and CIMP. 
DEFINING THE SERRATED NEOLASIA PATHWAY 
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Drawing on the above information, the defining molecular features of the serrated 
neoplasia pathway are: 1) MAPK pathway activation, and 2) CIMP.  MAPK pathway 
activation occurs primarily by either BRAF or KRAS mutation and CIMP can be either low 
level (CIMP-L) or high level (CIMP-H).  Although important, MSI is not a requirement of the 
serrated neoplasia pathway. 
The current model of serrated pathway carcinomas 
As can be inferred from the above, carcinomas arising via the serrated pathway are a 
heterogenous group.  In 2007 Jass proposed three broad molecular profiles for serrated 
pathway carcinomas, which have been modified slightly as follows:1 
1. CIMP-H, BRAF mutant
a) MSI-H
b) MSS
2. CIMP-L, MSS, KRAS mutant
Group one is the most strongly linked with the serrated neoplasia pathway.  These cancers 
most likely arise in sessile serrated adenoma/polyps (SSAs) and are typically CIMP-H 
regardless of the panel used to define CIMP.  Group two cancers are less strongly 
associated with the serrated neoplasia pathway, primarily because of a lack of consensus 
regarding what defines CIMP. They are postulated to arise in traditional serrated 
adenomas (TSAs). 
Precursor lesions 
Currently, three major categories of serrated polyp are recognised in the WHO 
classification; namely the HP, the SSA and the TSA.37   This classification is based 
predominately on the work of Torlakovic and Snover.38  However, there is continued 
debate regarding the diagnostic criteria and degree of malignant potential of these polyps. 
HYPERPLASTIC POLYPS 
HPs are common, accounting for 25-30% of resected large intestinal polyps.39-43  They 
have an estimated prevalence of 10-20% in Western adult populations.44  BRAF or KRAS 
are frequently mutated and are likely initiating events in the majority of HPs.40  Three HP 
subtypes are recognised, namely the microvesicular hyperplastic polyp (MVHP), the goblet 
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cell hyperplastic polyp (GCHP) and the mucin-poor hyperplastic polyp (MPHP).  MVHPs 
and GCHPs are the most common38 while MPHPs are rare.  The malignant potential of 
HPs is likely to be insignificant and under current guidelines no additional surveillance is 
required.45  
Microvesicular Hyperplastic Polyp 
Most MVHPs occur in the distal colon or rectum (74%),41 are asymptomatic and as such 
typically represent incidental findings during colonoscopy.   
Pathological Features 
At endoscopy most MVHPs are less than 5mm in diameter, light tan, small and flat (Figure 
1).41   Magnification chromoendoscopy identifies stellate crypt openings (common to 
MVHPs and SSAs).46  Although large and/or proximal MVHPs may occur, the pathologist 
should look carefully in such lesions for features of SSA. 
MVHPs are characterised by a serrated gland profile and an ordered ‘test-tube’ 
arrangement of the crypts that taper from the luminal to the basal aspect (Figure 2A).44  
Serration is predominantly superficial and most cells have microvesicular mucin droplets 
that impart a hazy, basophilic quality to the cytoplasm (Figure 2B).38  The superficial 
subepithelial basement membrane and muscularis mucosae are thicker than in the 
adjacent normal mucosa and vertically oriented strips of smooth muscle are seen in-
between crypts in some cases.38, 47   
The proliferative zone of the crypts are symmetrically expanded compared with adjacent 
non-lesional mucosa and may show minor nuclear atypia, stratification and mitoses.38, 47  
Immunohistochemistry shows regularly expanded proliferative and luminal compartments 
with Ki67 and CK20 respectively.48  p16 staining is frequently observed in the crypt 
bases49, 50 and MVHPs are usually positive for the mucin core proteins MUC2 and 
MUC5AC and variably for MUC6.51-53 
Molecular Features 
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The fundamental molecular alteration in most MVHPs is the V600E BRAF mutation40, 54 
which induces constitutive activation of the MAPK pathway resulting in a burst of 
proliferative activity and inhibition of apoptosis.  The process of activation-induced 
senescence is then postulated to curtail proliferation.55-58  Failure of apoptosis as the 
colonocytes reach the epithelial surface, with resultant epithelial crowding is thought to be 
responsible for the serrated morphology.59 
Goblet Cell Hyperplastic Polyp 
GCHPs are typically diminutive lesions (92% less than 5mm) and occur predominantly in 
the distal colon and rectum (68%).41  Around half harbour a KRAS mutation.41  Whether 
GCHPs have the ability to progress to carcinoma is not clear.  By endoscopy GCHPs tend 
to be pale and sessile and are easily overlooked.  The pathological features are similarly 
innocuous and the first impression is often of normal mucosa.  Closer inspection reveals a 
thickened mucosa with crowded crypts containing a disproportionately high number of 
mature goblet cells (Figures 2C and D).38  Serration is often minimal or limited to the upper 
third of the crypt, but tufting of the epithelial surface is frequent (Figure 2D).  Thickening of 
the basement membrane and muscularis mucosae is usually prominent.38 
Mucin-Poor Hyperplastic Polyp 
These rare polyps probably are not a distinct entity, most likely representing a damaged 
MVHP.2  They share many histological features with MVHPs but show a relative lack of 
goblet cells and microvesicular mucin  (Figures 2E and F).38  The superficial cells are low 
columnar or cuboidal, the nuclei are frequently hyperchromatic, and mild regenerative 
atypia may be present (Figure 2F). 
SESSILE SERRATED ADENOMA/POLYP 
Torlakovic and Snover coined the term SSA in 1996 to describe atypical HPs in patients 
with SPS.10  Their rates in colonoscopic series are highly variable (range 1.7% to 9% of all 
polyps).41, 60  The figure of 9% was attained with colonoscopies performed by a single 
operator with meticulous technique and histology reviewed by a single expert pathologist 
and is likely to represent a close approximation to actual polyp prevalence in Western 
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centres.41  The SSAs mostly occurred proximally (75%) and showed considerable variation 
in size (36% ≤5mm, 47% 6-10mm and 17% ≥11mm). 
The origin of SSAs is debated.61  We see SSAs with as few as four crypts, suggesting that 
at least some arise de novo.  Supporting an origin from MVHPs are the histological 
similarities and common association with BRAF mutation; against are the markedly 
different distributions and the minimal malignant risk associated with HPs in population-
based studies.62  There does appear to be a histological continuum from MVHP to SSA to 
SSA with dysplasia (SSAD) and finally to invasive carcinoma suggesting that these lesions 
represent a biological spectrum.  A provisional category of borderline SSA has been 
proposed by some authors to describe a lesion intermediate between MVHP and SSA.  
The pathological features of the SSA, borderline SSA and SSAD are discussed separately 
below, followed by a unified discussion of their molecular features. 
Pathological Features 
By endoscopy SSAs are sessile and often yellow with a mucus cap that must be removed 
to allow adequate visualization; they also frequently show rims of bubbles and debris, 
alteration of fold contour and interruption of the underlying mucosal vascular pattern.46, 63  
Magnifying chromoendoscopy shows stellate crypt openings46, and more recently, wider 
more rounded stellate pits have been described.64  Macroscopically most SSAs are subtle 
and easily missed on casual inspection, appearing as pale, ill-defined lesions that 
frequently extend over multiple mucosal folds (Figure 3A). 
The most obvious features of SSAs are architectural.  These include dilated crypts as well 
as crypts with horizontal growth of the bases in L or inverted T shapes along the 
muscularis mucosae (Figures 4A-C).47, 61  Crypt spacing is typically irregular and crypt 
branching is frequent.38  Luminal serration usually extends into the basal third of the crypts  
(Figure 4C).38, 47  Increased intraluminal and intracellular mucin is common (Figure 4B) and 
displaced crypts can be seen herniating into the submucosa (Figure 4D).65  At higher 
power, disturbance to proliferation and maturation is evident, with asymmetric proliferative 
zones and maturation towards both the luminal and basal aspects of the crypts.  That is 
mature goblet and foveolar cells extending both towards the luminal and basal aspects of 
the crypt (Figure 4C).38, 47, 66  Dystrophic goblet cells are frequent.  The cytology is typically 
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quite bland but a minor degree of nuclear atypia is allowable, particularly in the crypt 
bases.38   
By immunohistochemistry the proliferative and mature compartments of the crypt are 
disorderly and frequently overlap.48  Similar to MVHPs, SSAs usually express MUC2, 
MUC5AC and basal MUC6.51-53  This degree of overlap makes mucin 
immunohistochemistry impractical for discriminatory purposes.52  Table 1 compares the 
histological and immunohistochemical features of MVHPs and SSAs. 
The natural history of SSAs without dysplasia is not well defined.67  It has been estimated 
that 1 in 17 SSAs progress to malignancy, a malignant potential at least equivalent to a 
conventional adenoma.68  In a retrospective follow-up study of patients with SSAs, of those 
having another colonoscopy, all but one had further polyps/tumours (including one CRC) 
supporting surveillance colonoscopies in these patients.69  
Borderline sessile serrated adenoma/polyp 
Most SSAs are easily diagnosed but a subset with minimal changes occurs and the 
borderline between SSA and MVHP becomes blurred (Figure 4E).  Some authors have 
proposed an intermediate category for these cases and publications pertaining to this 
issue are outlined in table 2.51, 65, 70  We follow the WHO guidelines stating that at least 
three crypts or two adjacent crypts showing SSA features are sufficient for the diagnosis of 
SSA.37  This seems a reasonable compromise but molecular and follow-up data supporting 
this and other positions is lacking. 
SESSILE SERRATED ADENOMA/POLYP WITH DYSPLASIA 
The SSAD is a critical lesion in the serrated neoplasia pathway, heralding an advanced 
phase in polyp progression.  These lesions show an abrupt transition from otherwise 
typical SSA to cytologically dysplastic glandular epithelium  (Figures 5A-C).62, 67  The 
natural history is not well defined but they are postulated to progress rapidly to 
malignancy2 based on their relative rarity compared to BRAF mutant, CIMP-H carcinomas 
and the relatively frequent finding of early invasive carcinomas in small polyps (Figures 3B 
and 5A).67  In a large population based study, 13.2% of SSAs showed dysplasia, 
accounting for 0.17% of all colorectal polyps.60  In a recent prospective audit of polyps at 
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our practice, SSADs represented a similar proportion of all colorectal polyps (unpublished 
data).  They are more common in women (59%) and occur at a median age of 67.60
Pathological Features 
The endoscopic appearances of SSADs have not been described, but given the small size 
of the dysplastic focus in the vast majority; they may indistinguishable from ordinary SSAs.  
In three small series of SSAs with dysplasia or early carcinoma the mean size of polyps 
was 8.5mm, 8.9mm and 11.3mm respectively, comparable to SSAs without dysplasia.62, 67,
71  Importantly, three of the polyps were 5mm or less in size, including one with invasive 
carcinoma.67 
Two types of dysplasia are described.62, 71 So-called ‘conventional adenomatous dysplasia’ 
is similar to that seen in conventional adenomatous polyps (Figures 5A and F).  It is 
characterised by increased nuclear pleomorphism, stratification and loss of polarity, 
atypical mitoses and basophilic cytoplasm with changes extending to the polyp surface; 
however in our experience some evidence of serration usually remains.  Caution is 
warranted when assessing poorly oriented sections to prevent over-interpretation of the 
proliferative compartment as dysplastic.  The second pattern is serrated dysplasia (Figures 
5B-D, G and H).62  In this pattern the glands retain a serrated architecture, the cells have 
ample eosinophilic cytoplasm and the nuclei are typically vesicular and basally located.  
Not infrequently SSAs show focal ‘eosinophilic change’ resembling the eosinophilic cells in 
TSAs.  This finding is often superficial and shows a gradual transition from the surrounding 
SSA.  We do not consider this appearance sufficient to justify a diagnosis of SSAD.  
Grading of dysplasia in serrated lesions is not advocated in the WHO classification, the 
rationale being that once dysplasia of any grade has developed, the polyp has declared 
itself as biologically aggressive.37  In many cases the SSA transitions abruptly to high-
grade dysplasia (Figure 5A) but in other cases, clear demarcations between SSA, low-
grade dysplasia and then high-grade dysplasia can be identified (Figures 5B-D).   
Molecular Features 
Similar to MVHPs, the initiating event in SSAs is thought to be a BRAF mutation, present 
in 70-81% of SSAs.41, 72  Methylation induced silencing of p16 was proposed to allow 
progression from MVHP to SSA via escape from oncogene-induced senescence,73  but 
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more recently it has been shown that loss of p16 staining coincides with development of 
high-grade dysplasia or invasive carcinoma, late in polyp progression.49, 50  MLH1 
silencing, one of the best-characterised features of SSAs, is restricted to SSADs29, 67 and 
loss of staining for the MLH1 protein is usually limited to areas of high-grade dysplasia  
(Figures 5D and E).62, 67 
Activation of the Wnt signaling pathway, typically associated with the chromosomal 
instability pathway, has also been implicated in the progression of SSAs.74  A proportion of 
SSADs show aberrant nuclear staining for β-catenin; however in nearly all instances the 
CTNNB1 gene (encoding β-catenin) is wild type, implicating upstream mechanisms for 
pathway activation.75  In particular, methylation of the Wnt pathway antagonists SFRP 1, 2 
and 5 has been demonstrated in some SSAs.74  Methylation of the MGMT gene, which 
codes for a DNA repair protein, has also been identified in a subset of SSAs and may be 
of particular relevance in BRAF mutant MSS CRC. 
Of note, nearly all the molecular changes described occur in advanced polyps.  Currently 
only BRAF mutations have been consistently identified in early SSAs, thus the molecular 
distinction between MVHP and early SSA remains unclear.  We favour the hypothesis that 
MVHPs are unlikely to progress to SSAs unless critical molecular changes are acquired, 
such as methylation of key tumour suppressor genes.76  This is more likely to occur in the 
proximal bowel where CIMP is most common.   
TRADITIONAL SERRATED ADENOMA 
In 1990 Longacre and Fenoglio-Preiser described the ‘serrated adenoma’, a polyp 
characterised by serrated architecture and uniform, characteristic cytological atypia.77   
Subsequent confusion with MVHPs, SSAs, SSADs and tubulovillous adenomas with 
serrated features (sTVAs) occurred and only after renaming as TSA by Torlakovic et al in 
2003, did it re-emerge as a distinct entity.38  TSAs are the least frequent serrated polyp 
accounting for around 1% of colorectal polyps (range 0.6-1.9%).41, 43, 77  They can occur 
throughout the large bowel but have a predilection for the distal colon and rectum.  
Pathological features 
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At endoscopy TSAs have a pinecone-like or raised two-tier appearance while magnifying 
chromoendoscopy shows a stellar or fern-like pit pattern.78   Macroscopically they may be 
either sessile (33%), particularly proximally, or polypoid in appearance (67%) (Figures 6A 
and B).79  Most exceed 5mm.   
The histopathological features of TSAs are quite characteristic resulting in high diagnostic 
reproducibility.48  They typically display tubulovillous architecture, eosinophilic tall 
columnar epithelium with prominent serration (Figures 7A and B) and ectopic crypt foci 
(ECF) (Figure 7C).48  Serration in TSAs differs from that in MVHPs and SSAs, taking two 
forms: deep narrow ‘slit-like’ indentations from the luminal surface similar to those seen in 
normal small intestinal villi, more prominent in right sided BRAF mutated lesions with SSA 
components (Figure 7A), and surface indentations associated with ECF (Figure 7C).  ECF 
maintain their orientation towards the bowel lumen but lose their connection to the 
underlying muscularis mucosae, speculated to allow protuberant growth.48, 80  The villous 
tips in TSAs are frequently bulbous (tennis racquet-like) and sometimes linked by mucosal 
bridges.48  The characteristic epithelial cells have abundant pink cytoplasm and centrally 
located palisaded, pencillate nuclei with dispersed chromatin (Figure 7C);48, 77 frequently 
referred to as dysplastic, they may represent senescent cells.2  As similar cells can occur 
focally in MVHPs, SSAs, TVAs and regenerative epithelium,2 ECF are suggested as a 
more reproducible diagnostic feature.48  Mitoses are typically rare.  Areas of goblet cell 
differentiation are fairly common in TSAs (Figure 7D) and in occasional cases goblet cells 
are the predominant cell type.  Progression to high-grade dysplasia and carcinoma, 
usually with serrated morphology, is also not unusual (Figure 7E). 
By immunohistochemistry the Ki-67 proliferative index is typically very low in eosinophilic 
cells but elevated in ECF; conversely CK20 staining is positive in the surface cells but not 
ECF.48 
Molecular Features 
Due to their rarity and confusion with other polyps, the molecular genetics of TSAs are 
poorly defined and studies are conflicting. Contrary to the current WHO classification,37  
we and others see TSAs (particularly right-sided) with components of MVHP or SSA 
(Figure 7A);81  high rates of MLH1 methylation are present in these lesions, particularly 
when foci of high-grade dysplasia or malignancy are present.  In the same series, KRAS 
35
and BRAF mutations were frequent (29% and 55% respectively), KRAS mutation and 
MGMT silencing (63%) were particularly common in advanced lesions, and high-grade 
serrated and conventional adenomatous dysplasia and invasive malignancy (26.7%, 
18.8% and 8% respectively) were frequent; all carcinomas showed serrated morphology.  
CIMP-H has been reported in as many as 79% of TSAs by some but is much lower in 
other series, the variance likely reflecting discrepancies in histological diagnosis and the 
panels of methylation markers used to define CIMP.82, 83   
Filiform Serrated Adenoma 
Filiform serrated adenoma83, 84 accounts for 4% of TSAs, occurs distally and is 
characterised by very long (filiform) villi (Figure 8A) with marked lamina propria oedema  
(Figures 8A and B) and frequent epithelial erosions.  The epithelium is typically an 
admixture of eosinophilic cells and goblet cells as seen in TSAs.  Twenty-two percent 
show high-grade dysplasia and 6% contain a focus of adenocarcinoma. 
The immunohistochemical and molecular features appear to be similar to TSAs.  In one 
series, BRAF or KRAS mutations occurred in 71%, MSS in 58% and MSI-L in 42%; MSI-H 
and loss of MLH1 was not seen.84  In another, all lesions were MSS, CIMP-H occurred in 
38% and most of the remainder were CIMP-L.83 
Although filiform serrated adenomas appear pathologically and molecularly similar to 
TSAs, we have also seen filiform change in TVAs.  We believe this change is the result of 
polyp trauma and prolapse. 
Tubulovillous adenoma with serration 
In our experience, serrated TVAs (sTVAs) are common and their histological appearances 
overlap with those of TSA.  They may also have molecular features such as a high 
frequency of KRAS mutation, more in common with TSA than conventional adenoma.85  
As we not infrequently see serrated-morphology CRC arising in sTVAs, we propose that 
sTVA, along with TSA, may be the precursors of this group of CRC.  Detailed histological, 
immunohistochemical and molecular evaluation of this potential alternate precursor to the 
serrated pathway is required. 
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FIBROBLASTIC POLYP 
The fibroblastic polyp is intimately associated with MVHPs and SSAs.86-90  First described 
in 2004, they are typically small and distal.  Although subsequently demonstrated to be 
mucosal perineuriomas, the term fibroblastic polyp remains entrenched in the literature.87,
90 Fibroblastic polyps are benign and do not require any specific follow-up. 
Histologically they show expansion of the lamina propria by a bland spindle cell 
proliferation with a pushing margin  (Figures 9A and B).86  Superficially the uniform spindle 
cells with oval nuclei lie parallel to the luminal surface.  Elsewhere they are less orderly but 
frequently whorl around vascular and epithelial structures.86, 88  A component of fibroblastic 
polyp is reported in 6.5% of SSAs;89 this frequent occurrence is in line with our experience. 
The spindle cells stain positively for vimentin, EMA (often weak), Glut-1, collagen IV and 
Claudin-1, which is typical of perineurial differentiation.86, 87, 90  BRAF mutations occur in 
the associated serrated epithelial component, demonstrating that the epithelium is 
neoplastic rather than reactive in nature.89  It is suggested the cells are fibroblasts that 
have undergone perineurial differentiation, possibly induced by the associated serrated 
polyp epithelium.89 
MIXED POLYPS 
Mixed polyp has been used to describe any number of polyp combinations including, until 
recently, SSADs.  As such the term has been a source of confusion and has been 
removed from the current WHO classification.37  Despite this, ‘mixed’ polyps’ not otherwise 
accounted for in the classification do occur (Figures 10A and B).  In these instances we 
name the component parts rather than use the unqualified term ‘mixed polyp’. 
Serrated neoplasia pathway carcinomas 
Serrated pathway carcinomas with the three broad molecular profiles of Jass1 are now 
discussed. 
1. a) BRAF MUTANT / CIMP-H / MSI-H
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Accounting for 9-12% of CRC and constituting the ‘classic’ tumours derived from the 
serrated neoplasia pathway,1 this group tends to occur in elderly women and has a 
marked predilection for the right colon.  Frequently they present with high tumour stage but 
without nodal or distant metastases.  Residual SSA may rarely be identified adjacent to the 
cancer.  The histology is well characterised and includes pushing margins, poor or 
mucinous differentiation, peri-tumoural Crohn’s-like inflammatory infiltrate, tumour 
infiltrating lymphocytes and a clonal growth pattern.91  Many of these features seem to be 
related to MSI and as such are shared with Lynch syndrome tumours.92, 93  The precursor 
SSA undergoes progressive methylation of key promoter regions, in particular MLH1, the 
silencing of which typically coincides with development of high-grade cytological dysplasia 
and MSI.94  The acquisition of these genetic changes may herald a rapid progression to 
malignancy and subsequently account for a disproportionate number of interval 
carcinomas.2, 95  The tumours have a favourable prognosis compared to stage matched 
controls but are resistant to most non-surgical treatments, including 5-fluorouracil (5-FU) 
and the monoclonal epidermal growth factor receptor (EGFR) inhibitors, cetuximab and 
panitumumab.96, 97  Identification of mutant BRAF in these cancers excludes Lynch 
syndrome. 
1. b) BRAF MUTANT / CIMP-H / MSS
Sessile serrated adenomas with dysplasia but without loss of MLH1 expression are the 
proposed precursors of this subgroup and account for 6-8% of CRCs.  They are also more 
frequent in the right colon.1  The carcinomas are often poorly differentiated and 
mucinous.98 Signet ring cell morphology and the rare cribriform-comedo subtype have 
been associated with this molecular category.99  These tumours have higher rates of 
tumour budding, lymphatic, vascular and perineural invasion and lymph node metastases 
than other CRCs.98  The accumulation of genetic abnormalities in these cancers also 
occurs via CIMP with methylation of different gene promoters than in MSI-H cancers; 
silencing of p16 and Wnt pathway genes has been proposed.1  Mutation of p53 is more 
common compared with BRAF mutant MSI-H carcinomas.100  In most series they have a 
poor prognosis.98, 101, 102 
2. CIMP-L / MSS / KRAS MUTANT
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This is potentially the largest and certainly the most controversial group and may account 
for 15-20% of all CRCs.1  They are generally thought to arise in TSAs, but as these 
adenomas are relatively rare, there must be other precursors that we suggest are sTVAs 
progressing via a serrated-ike pathway.  Although there is currently no marker panel 
available to specifically detect CIMP-L, the genetic changes of KRAS mutation and MGMT 
methylation frequently segregate with CIMP-L cancers, suggesting they form an important 
molecular subgroup.103-107 Because these tumours have not been clearly defined, there is 
limited clinicopathological data pertaining to them. 
Comparison of the serrated neoplasia molecular pathways with other putative molecular 
pathways to CRC is shown in Figure 11. 
Serrated morphology carcinomas 
The term ‘serrated carcinoma’ has been used to refer to all tumours arising via the 
serrated neoplasia pathway as well as to describe a subset of cancers with a distinctive 
serrated morphology.  In this review we use the term ‘serrated pathway carcinoma’ for all 
serrated pathway cancers (regardless of morphology) and ‘serrated morphology 
carcinoma’ for the histologically distinct serrated subset.  The WHO classification now 
recognises serrated morphology carcinomas as a CRC subtype.37   These carcinomas 
were first described by Jass108 and the histological criteria refined by Makinen and 
Tuppurainen et al.34, 109  Seven to twelve percent of CRCs have serrated morphology.34, 109,
110  Given that 30% of CRC is attributed to the serrated neoplasia pathway, then about one 
third of these cancers display serrated morphology.  
Serrated morphology carcinomas are more frequent in women with over half arising in the 
caecum or ascending colon and about one third in the rectum.35  No specific macroscopic 
features have been described.  Three major histological patterns are recognised.35, 109  
Well to moderately differentiated adenocarcinoma with prominent serrations comprising 
epithelium only or epithelium with basement membrane is most common (Figures 12A and 
B).  The epithelial cell cytoplasm is typically intensely eosinophilic and abundant and the 
nuclei vesicular and basal (Figure 12C).  Necrosis is usually absent and mucinous 
differentiation at the deep aspect of the tumour common.  An unequivocal diagnosis of 
serrated carcinoma is said to require at least six of the first seven features listed in Table 
3; cases with only five features or with 10-20% necrosis are considered equivocal.110 
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The second pattern, accounting for 20% of cases is mucinous adenocarcinoma (Figure 
12D).35, 109   Extracellular mucin constitutes at least 50% of the cross-sectional area and by 
definition they are poorly differentiated.  Serrations can usually be identified, at least 
focally, and typical serrated carcinoma cytology is retained.  Cell balls and papillary rods 
floating in the mucin are common and characteristic of this pattern (Figure 12E). 
The final pattern is trabecular, constituting around 7% of cases.35, 109  These tumours are 
poorly differentiated with tumour cells growing in a trabecular fashion; epithelial serrations 
are typically lost (Figure 12F).  Micropapillary structures are sometimes seen and 
lymphatic invasion is common.  Serrated morphology carcinoma cytology remains 
apparent.  This pattern is often a minor component of other subtypes, usually at the 
advancing edge of the tumour. 
Serrated morphology carcinomas segregate as a distinct molecular subset, strengthening 
the assertion they represent a reproducible and distinctive subtype of CRC.111  KRAS and 
BRAF mutations have been identified in 45% and 33% of cases respectively;112 MSS in 
50%, MSI-H in 16% and MSI-L in 30%.110  These figures suggest that serrated pathways 
1b and 2, described above, are over-represented. 
More recently serrated morphology carcinomas have been shown to have a poor 
prognosis compared to stage-matched conventional-type CRC.113  Tumour budding, 
infiltrative growth pattern and lymphatic invasion are all more frequently identified in these 
tumours and are likely to be contributive.113 
Serrated morphology carcinomas in our experience arise from TSAs and sTVAs.  
Refinement of diagnostic criteria for these carcinomas with a greater emphasis on 
histological and molecular features and less on origin from a serrated polyp may result in 
more robust clustering of these cancers with even greater prognostic relevance.   
Treatment issues relevant to serrated pathway carcinomas 
Although 5-FU with either oxaliplatin or irinotecan remains the mainstay of medical 
treatment in advanced stage CRCs114, targeted treatment options are now in clinical 
practice or being evaluated in trials.  Monoclonal EGFR inhibitors are currently widely 
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used.  The EGFR signaling pathway, involved in cellular proliferation and apoptosis via 
either the MAPK or phosphatidylinositol 3-kinase (PI3K) pathways, is integral to serrated 
neoplasia. Blocking the EGFR receptor has proven effective114 but mutations in 
downstream effectors of the EGFR pathway block tumour response.  The best 
characterised are activating KRAS mutations, seen in 30-40% of CRCs.115  As such KRAS 
mutation testing is mandatory prior to treatment with these expensive and potentially toxic 
medications. 
BRAF acts immediately after KRAS in the MAPK signaling cascade and activating BRAF 
mutations, seen in about 10% of CRCs, could also nullify the benefits of anti-EGFR 
therapy; however unresponsiveness is less obvious than for KRAS mutant tumours.97  In 
the alternate EGFR signaling pathway PI3K activation and PTEN inactivation also confer 
resistance to anti-EGFR therapy and may account for a proportion of non-responders with 
wild type KRAS and BRAF.97 
Following from its success in metastatic melanoma, the V600E mutant specific, BRAF 
inhibitor vemurafinib has been trialed in CRC.116  Unfortunately less than 5% of BRAF 
mutant CRCs demonstrate a response, likely secondary to rapid feedback activation of 
EGFR.116  Cell lines dual treated with vemurafinib and an EGFR inhibitor showed 
substantial tumour suppression116 and clinical trials using dual therapy are planned. 
Future directions 
There has been enormous progress in our understanding of the serrated neoplasia 
pathway but many fundamental issues remain unresolved.  The histological distinction of 
MVHP from SSA with minimal features is subjective and lacks reproducibility. Also there 
are no histological or molecular markers to identify a SSA that is likely to progress from 
one which will remain indolent.  Although now generally accepted that a SSAD is an 
aggressive lesion, the significance of subtle serrated dysplasia is unknown. 
From a clinical perspective these issues are frustrating.  MVHPs do not require additional 
surveillance, whereas patients with SSAs are typically surveilled at the same rate as 
conventional adenomas.  SSADs are often managed aggressively, coming to colectomy if 
complete endoscopic resection cannot be achieved.  Thus accurate and reproducible 
diagnosis of serrated polyps is imperative.  Furthermore, long-term prospective studies 
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addressing outcomes after diagnosis of the various types of serrated polyp will be critical 
to developing reliable surveillance guidelines for these lesions. 
There also remain gaps in our knowledge of the underlying molecular mechanisms of the 
serrated pathway.  The primary cause of CIMP remains unclear.  Although irrefutably 
correlated, no mechanistic relationship between CIMP-H and BRAF mutation has been 
established.  While CIMP-H CRC is an established entity, there is continued debate as to 
the significance of CIMP-L. 
Although the classification of Jass1 has proved useful, serrated pathway carcinomas are 
proving more heterogeneous than expected.  As the repertoire of targeted therapies 
expands, there is likely to be increasing emphasis on the underlying molecular alterations 
in CRCs.  Serrated pathway cancers are particularly prone to mutations in pathways 
targeted by these agents. 
Finally the ‘$1000 genome’ is likely to become a reality in the next few years.  Next 
generation sequencing offers the opportunity to completely profile the genome, methylome 
and transciptome of a CRC.  Mining this data will be an enormous bioinformatics challenge 
but will doubtless yield an array of potential biomarkers and targets for molecular-based 
therapy. 
Conclusions 
The serrated neoplasia pathway is a critical route to CRC.  Furthermore it serves as a 
model of the importance of epigenetics in carcinogenesis.  In the last few years most 
pathologists and clinicians have become comfortable with the concept of an alternative 
pathway to CRC but many diagnostic and prognostic issues persist.  The imminent arrival 
of complete genetic profiling of tumours will create an enormous amount of data pertaining 
to all types of cancer.  However, interpretation of this information can only be informative in 
combination with accurate clinical, pathological and follow-up information.  The pathologist 
is suitably positioned to integrate pathological and molecular information into a single 
comprehensive report.  Thus it will be incumbent on pathologists to keep themselves 
abreast of the important information these evolving molecular techniques provide. 
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Histological / Immunohistochemical Feature Polyp Type 
MVHP SSA 
Architectural features 
- Basal crypt dilation - +++
- Basal serration - ++
- Branched crypts - ++
- Horizontal crypt growth - ++
- Increased epithelial:stromal ratio (>50%) -/+ ++
- Displaced crypts -/+ +
Cytological features 
- Vesicular nuclei -/+ + 
- Rounding of nuclei -/+ + 
- Mitoses in the mid and upper zones of the crypt - +
Immunohistochemical features 
- Ki67 symmetric and limited to the lower half of the crypt ++ -/+ 
- CK20 limited to the mature compartment of the crypt ++ -/+ 
- MUC2 +++ +++ 
- MUC5AC +++ +++ 
- MUC6 ++ +++ 
Other features 
- Prominence of intracellular and extracellular mucin + ++
- Prominent basement membrane +++ -/+
- Vertical strips of smooth muscle in lamina propria ++ -/+
Table 1. Comparison of MVHP and SSA.   
Note that architectural features are the most discriminatory. 
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Study 
 
 
Polyp 
category 
 
Diagnostic criteria 
 
Chung et al 
 
SSA 
 
- Polyp >10mm 
- Polyp proximal to the hepatic flexure and 
- At least four of exaggerated serration, 
crypt dilation, increased crypt 
branching/horizontal growth, cytological 
atypia, mitoses in upper half of the crypt, 
increased cytoplasmic mucin and 
epithelial:stromal ratio of >50% 
 
 Intermediate 
between 
MVHP and 
SSA 
 
- Polyp <10mm 
- Polyp anywhere in the large bowel 
- At least four of the above criteria 
 MVHP 
 
- Three or fewer of the above criteria 
 
Mohammadi et al 
 
SSA 
 
- At least two of basal crypt dilation, basal 
crypt serration, crypt branching or 
horizontal crypt growth 
 
 Borderline 
SSA 
- Only one of the above criteria, or 
- Equivocal evidence of two of the above 
criteria 
 
 MVHP - None of the above criteria, or 
- One equivocal criterion 
 
 
WHO 2010 
 
SSA 
 
- At least two adjacent crypts or three 
individual crypts with features of SSA 
 
 MVHP - Not meeting above criteria 
 
 
Aust et al 
 
SSA 
 
- Two of basal crypt serration, horizontal 
crypt growth, inverted crypts and basal 
crypt dilation 
- Above features in at least two crypts 
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MVHP - Not meeting the above criteria
Table 2.  Differing diagnostic criteria for SSA, borderline SSA and MVHP 
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1. Epithelial serrations 
2. Eosinophilic or clear cytoplasm 
3. Abundant cytoplasm 
4. Vesicular nuclei with peripheral chromatin condensation and a single 
prominent nucleolus 
5. Distinct nucleoli 
6. Absence of necrosis (or less than 10% necrosis) 
7. Intracellular and extracellular mucin 
8. Cell balls and papillary rods* 
 
Table 3. Histological criteria of serrated morphology carcinomas.38 
*Typically only seen in mucinous carcinomas 
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Figure legends 
Figure 1.  Hyperplastic polyps.  (bar = 20mm). 
Figure 2.  Hyperplastic polyps.  A and B.  MVHP.  B.  Microvesicular mucin droplets and 
superficial goblet cells.  C and D.  GCHP showing crowded crypts, dominance of goblet 
cells and minimal superficial serration (D).  E and F.  MPHP with cuboidal to low columnar 
epithelial cells, mucin depletion, lack of goblet cells and fine ‘saw-tooth’ serration. 
Figure 3. A. Sessile serrated adenoma.  Arrows mark edges of SSA.  B. SSA with early 
carcinoma.  The erythematous/ulcerated area represents the early carcinoma; the arrows 
indicate the edges of the residual SSA. (bars = 20mm). 
Figure 4. A-D. Sessile serrated adenoma. A.  Typical SSA showing dilated crypts with 
horizontal growth along the muscularis mucosa and deep serration.  B.  Alternate pattern 
with predominance of dilated crypts with abundant luminal mucin.  C.  Same polyp as A 
showing asymmetrical proliferative zone and maturation extending into the deep aspect of 
the crypt characterised by goblet cells in the crypt base. D.  Inverted growth pattern.  E.  
So-called borderline SSA with minimal basal crypt dilation and deep serration.  The 
features are intermediate between a MVHP and a SSA.  By default we revert to a 
diagnosis of HP in these cases. 
Figure 5.  A-H.  Sessile serrated adenomas with dysplasia.  A.  Abrupt transition from 
SSA (*) to high-grade adenomatous dysplasia (**) and early carcinoma (***).  Note the loss 
of the muscularis mucosa at the transition to early invasive carcinoma (arrow).  B-D.  A 
large SSA showing abrupt transition from SSA to low-grade serrated dysplasia (lower right 
arrow and image C) and then to high-grade dysplasia (upper left arrow and image D).  The 
high-grade dysplasia in this case is not typical of either true adenomatous or serrated type 
dysplasia.  E.  Abrupt loss of MLH1 staining at the transition from low-grade serrated 
dysplasia to high-grade dysplasia (immunohistochemistry for MLH1).  F-G.  Cytological 
features of high-grade adenomatous dysplasia (F), low-grade serrated dysplasia (G) and 
high-grade serrated dysplasia (H). 
Figure 6. Traditional serrated adenomas from the sigmoid colon.  A.  Sessile TSA.  B. 
Polypoid TSA. (bars = 10mm). 
59
Figure 7.  A-E.  Traditional serrated adenomas. A. TSA from transverse colon with sessile 
growth pattern and component of SSA, in keeping with proximal location and BRAF 
mutation.  (A BRAF V600E mutation was confirmed in this polyp).  B.  Rectal TSA with 
polypoid growth pattern in keeping with distal location.  C.  Characteristic cytological 
features (abundant eosinophilic cytoplasm and centrally placed, pencillate nuclei) and ECF 
(examples indicated by arrows).  D.  Transition from typical to goblet cell predominant 
pattern of TSA (same polyp as 7B).  E.  High-grade dysplasia in an otherwise typical TSA.  
Note retention of ECF. 
Figure 8.   A and B.   Filiform serrated adenoma. Note elongated ‘filiform’ processes (A) 
with oedematous tips (B). 
Figure 9.  A and B.  Fibroblastic polyp arising in a SSA.  Note bland spindle cells with 
eosinophilic cytoplasm encompassing crypts. 
Figure 10.  A and B.  Mixed polyps.  A.  MVHP (right) and TSA (left).  B.  MVHP (left) and 
tubular adenoma with low-grade dysplasia (right) 
Figure 11.  Putative pathways to colorectal cancer. 
Figure 12.  A-F.  Serrated morphology adenocarcinomas.  A and B.  Well-differentiated 
adenocarcinoma with prominent epithelial serrations.  C. Typical cytology with abundant 
eosinophilic cytoplasm and vesicular, basal nuclei.  D and E.  Mucinous adenocarcinoma.  
This arises in the SSAD depicted in Figure 5B.  E.  Cell balls and papillary rods floating in 
mucin.  F.  Trabecular adenocarcinoma.  Micropapillary clusters and signet ring cells are 
also evident. 
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Conclusions 
The serrated neoplasia pathway is relatively recently described and is the subject of 
ongoing intensive research. A remarkable amount has been achieved regarding the 
pathology and molecular biology of serrated polyps and carcinomas; however much 
remains to be resolved. It is clear that there are ongoing issues relating to the 
histopathological diagnosis of the sessile serrated adenoma and its troublesome 
distinction from microvesicular hyperplastic polyps. The biological progression of these 
polyps also requires clarification. It is increasingly apparent that traditional serrated 
adenomas can arise in sessile serrated adenomas, but the implications of this event are 
unclear. Furthermore, the frequency of MLH1 methylation in sessile serrated adenomas 
with dysplasia is not clear and the implications for the resultant polyps and cancers are not 
completely understood.  
The traditional serrated adenoma remains something of an enigma. Although thought to be 
quite simple to diagnose, the distinction from a subset of tubulovillous adenomas can be 
challenging. In particular the presence of ectopic crypt formations may not be as definitive 
in the diagnosis of traditional serrated adenomas as was previously believed. A lack of 
uniform diagnosis may underscore the variability in molecular biological features described 
for the traditional serrated adenoma. In particular the BRAF and KRAS mutation status 
and the CpG island methylator phenotype status vary widely in the literature. In addition 
detailed study of traditional serrated adenomas developing discrete areas of overt 
cytological dysplasia are limited and typically include few cases. Thus the molecular 
biology involved in the progression of traditional serrated adenomas is not clear and the 
nature of the cancers they give rise to has been inadequately addressed.  
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Hypotheses: 
With the above framework in mind, we plan to clarify and build upon the current model of 
serrated colorectal polyps. My hypotheses are as follows. 
1. Serrated polyps, in particular sessile serrated adenomas, are more common than is
currently reported in the literature
2. A single unequivocal sessile serrated adenoma-type crypt is sufficient for diagnosis
3. There are histological, immunohistochemical and molecular features that can
predict aggressive biology in traditional serrated adenomas and sessile serrated
adenomas
4. A subset of tubulovillous adenomas with serrated histology can progress to
malignancy via the serrated pathway
5. Serrated polyps represent distinct precursors of the molecular subtypes of CRC
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Aims: 
1. To develop a large cohort of consecutive polyps to provide information regarding
the prevalence of serrated polyps in our community
2. To attempt to determine an appropriate diagnostic threshold for the sessile serrated
adenoma based on a detailed clinicopathological assessment
3. To determine the BRAF, KRAS, CIMP and immunohistochemical status of
histologically well-categorised cohorts of serrated polyps
4. To provide a detailed clinicopathological and molecular analysis of large cohort of
sessile serrated adenomas and traditional serrated adenomas
5. To demonstrate molecular similarities between a subset of TVAs and polyps of the
serrated neoplasia pathway (in particular the TSA)
6. To determine the polyp precursors of the different molecular subtypes of serrated
pathway colorectal carcinomas
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Chapter 2: Critical appraisal of the diagnosis of the sessile serrated adenoma 
As published in American Journal of Surgical Pathology as: 
Bettington M, Walker N, Rosty C, et al. Critical appraisal of the diagnosis of the sessile 
serrated adenoma. Am J Surg Pathol. 2014; 38:158-166. 
Relevance to the aims of the thesis: 
This chapter addresses thesis aims 1 and 2. The frequency of sessile serrated adenoma 
diagnoses in the pathology literature is quite conflicted with rates ranging from 1.1-
10.1%.1-5 This broad variance likely reflects a range of factors, including the patient 
population, skill and experience of the colonoscopists and the diagnostic criteria of the 
reporting anatomical pathologist.6 In our experience, using current diagnostic criteria, we 
felt that sessile serrated adenomas were more common than was being reported in the 
literature. If true, this has significant clinical implications. A low rate of sessile serrated 
adenoma diagnoses may reflect either failure to remove the lesions at colonoscopy, or 
under-reporting as microvesicular hyperplastic polyps by the pathologist. Both of these 
scenarios carry a risk of interval colorectal carcinoma, defined as the development of 
carcinoma within the colonoscopic surveillance interval. Interval colorectal cancers 
represent approximately 5% of all colon cancer diagnoses and serrated pathway cancers 
are over-represented in this group.7, 8 Thus high quality colonoscopy and accurate 
pathological diagnosis of sessile serrated adenomas should help reduce interval colorectal 
carcinoma. 
1. Spring KJ, Zhao ZZ, Karamatic R, et al. High prevalence of sessile serrated
adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy.
Gastroenterology. 2006;131(5):1400-7.
2. Lash RH, Genta RM, Schuler CM. Sessile serrated adenomas: prevalence of
dysplasia and carcinoma in 2139 patients. J Clin Pathol. 2010;63(8):681-6.
3. Gurudu SR, Heigh RI, De Petris G, et al. Sessile serrated adenomas: demographic,
endoscopic and pathological characteristics. World J Gastroenterol. 2010;16(27):3402-5.
4. Carr NJ, Mahajan H, Tan KL, Hawkins NJ, Ward RL. Serrated and non-serrated
polyps of the colorectum: their prevalence in an unselected case series and correlation of
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BRAF mutation analysis with the diagnosis of sessile serrated adenoma. J Clin Pathol. 
2009;62(6):516-8. 
5. Pohl H, Srivastava A, Bensen SP, et al. Incomplete polyp resection during
colonoscopy-results of the complete adenoma resection (CARE) study. Gastroenterology.
2013;144(1):74-80 e1.
6. Kaminski MF, Regula J, Kraszewska E, et al. Quality indicators for colonoscopy and
the risk of interval cancer. N Engl J Med. 2010;362(19):1795-803.
7. Arain MA, Sawhney M, Sheikh S, et al. CIMP status of interval colon cancers:
another piece to the puzzle. Am J Gastroenterol. 2010;105(5):1189-95.
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ABSTRACT 
The sessile serrated adenoma (SSA) is a relatively recently described polyp that can 
present diagnostic difficulties for the practicing pathologist.  The frequency of SSA 
diagnoses varies dramatically in the reported literature.  In addition the histological 
interface between the microvesicular hyperplastic polyp (MVHP) and the SSA continues to 
be a diagnostic problem.  The trend in recent years has been to a lower threshold for SSA 
diagnosis.  Herein we have performed a cross-sectional study of 6340 colorectal polyps 
received at a high volume community-based pathology practice over a three-month period.  
After central review, with strict application of the diagnostic criteria outlined in the 2010 
edition of the WHO Classification of Tumours of the Digestive Tract, we found that SSAs 
represented 12.1% of all polyps.  In addition we developed novel diagnostic subcategories 
in an attempt to determine the most appropriate cut-off for the interface between the 
MVHP and the SSA. We found that serrated polyps (MVHPs or SSAs) with any SSA-like 
crypts had clinical features more in common with the SSA than the MVHP and that this 
diagnostic cut-off showed good reproducibility between pathologists.  This supports the 
position of a recent consensus publication proposing that polyps with as few as one SSA 
type crypt should be diagnosed as a SSA.  Applying these criteria to our cohort yield an 
overall SSA rate of 14.7%.  In summary, we believe that SSAs continue to be under-
diagnosed in pathological practice and that this may result in inadequate surveillance and 
thus contribute to interval colorectal carcinomas. 
Key Words: Colorectal neoplasms; Colorectal polyps; Sessile serrated adenoma; 
Microvesicular hyperplastic polyp; Diagnosis 
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INTRODUCTION 
Colorectal carcinoma (CRC) is the second leading cause of cancer death in the developed 
world.  Approximately 20-30% of CRC occurs via the serrated neoplasia pathway1.  Most 
of these cancers are thought to have their origins in a relatively recently described polyp, 
the sessile serrated adenoma/polyp2-5. For simplicity we will use the term sessile serrated 
adenoma (SSA) throughout this paper. 
Despite its well-documented importance as a precursor lesion of CRC, the proportion of 
colorectal polyps that are SSAs is currently unclear.  A review of the literature identified 
eleven papers that addressed this issue, in which SSAs ranged almost ten-fold from 1.1-
10.1%6-16.   
The reported variability may result because serrated polyps occur on a diagnostic 
spectrum with plain microvesicular hyperplastic polyp (MVHP) at one end and frank SSA 
at the other.  A diagnostic ‘grey-zone’ exists in the middle.  In the 4th edition (2010) of the 
WHO Classification of Tumours of the Digestive System, guidelines were given for the 
diagnosis of the SSA, stating that if a serrated polyp shows two or three contiguous SSA-
type crypts then a diagnosis of SSA can be made17.  More recently an expert panel 
including gastroenterologists, scientists and pathologists published a consensus document 
pertaining to serrated polyps18.  In particular they made the recommendation that serrated 
polyps with as few as one SSA-type crypt should be diagnosed as a SSA.  Inevitably this 
has resulted in some confusion amongst pathologists as to the most appropriate cut-off for 
the diagnosis of a SSA.  Some pathologists may have more readily adopted the 
recommendations of the consensus document, whereas other pathologists may not have 
been aware of the consensus document or may be reluctant to change their diagnostic 
criteria without supporting evidence.  
Thus the primary aim of this study was to provide comprehensive colorectal polyp rates in 
a community-based, Australian gastrointestinal pathology practice with a particular 
emphasis on the contribution of the SSA.   We secondarily sought to evaluate the 
guidelines for SSA diagnosis as provided in the WHO Classification and the recent 
consensus paper, by dividing all MVHPs and SSAs into subgroups based on the extent of 
colonic crypt abnormalities.  Finally, we sought to validate the newly determined cut-off for 
the diagnosis of a SSA by conducting a reproducibility study using our revised diagnostic 
criteria. 
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We found that SSAs, as currently defined by the WHO, represented 12.1% of all colorectal 
polyps in this large, prospective series.  Furthermore, we demonstrated that serrated 
polyps with only one abnormal SSA-type crypt had clinical features more closely related to 
typical SSAs than the plain MVHP, thus supporting a further relaxation of the current 
diagnostic criteria of the SSA as proposed in the consensus document.   This new cut-off 
for SSA diagnosis showed good interobserver agreement amongst the study pathologists. 
 
This trend to increasing SSA diagnoses is of great importance to patients, clinicians, 
researchers and health economists.  In contrast to MVHPs, SSAs are recognised pre-
malignant lesions2, 4, 5.  Over-diagnosis of SSAs results in unnecessary, invasive and 
costly endoscopic surveillance, whereas under-diagnosis may contribute to interval 
colorectal carcinoma. 
 
MATERIALS AND METHODS 
 
Case collection and pathological review 
Colonic polyp tissue specimens were collected in a prospective fashion at a single 
institution (Envoi Specialist Pathologists) in Brisbane, Australia over a three-month period 
from the 30th of January to the 29th of April 2012.  Envoi Specialist Pathologists is a 
community-based, gastrointestinal histopathology practice that receives specimens from 
over 60 gastroenterologists and surgeons. Only polyps identified endoscopically were 
included in the study.  This study was approved by the institutional review board of The 
Queensland Institute of Medical Research.   
 
Demographic data were collected from the information provided on the pathology request 
form.  Polyp location was determined from the colonoscopy report when available or from 
the request form and specimen container label.  Location was divided into proximal, distal 
and rectal.  Proximal location was defined as cecum, ascending colon and transverse 
colon; distal location as the splenic flexure, descending colon and sigmoid colon.  In 
statistical analyses rectal location was included in the distal category. 
 
Where possible, the polyp size and number was extracted from the colonoscopy report.  
When endoscopic correlation was not possible, separate fragments were reported as a 
single polyp if all pieces were histologically similar and as separate polyps if different polyp 
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subtypes were evident within the separate tissue fragments. Because of the unreliable 
nature of estimating polyp size from the fragmented tissue received in the laboratory, size 
measurements were based only on endoscopic reports. 
 
All polyps were initially reviewed by a single pathologist (MB).  To simulate normal 
reporting conditions, the review diagnoses were based only on the material available to the 
original reporting pathologist, that is, three haematoxylin and eosin stained sections for 
each polyp along with any additional levels or stains performed during the reporting 
process.  No additional levels or stains were performed for the purposes of review.  
 
When applicable, the polyp diagnoses were based on the current WHO criteria17.  
Diagnostic categories included conventional adenomas (including tubular adenoma, 
tubulovillous adenoma and villous adenoma), serrated polyps (including microvesicular, 
mucin-poor and goblet cell hyperplastic polyps, sessile serrated adenoma, sessile serrated 
adenoma with dysplasia, traditional serrated adenoma and serrated polyp unclassifiable) 
and others (including a variety of non-neoplastic and non-epithelial lesions).  Polyps falling 
into the ‘other’ category were not included in the analysis.   
 
Conventional adenomas were diagnosed on the combination of conventional 
adenomatous dysplasia and proportion of villous component.  As per the WHO 
classification17, cases with 0-25% villosity were diagnosed as TA, 25-75% villosity as 
tubulovillous adenomas (TVA) and >75% villosity as villous adenomas (VA). The diagnosis 
of a SSA was based on the criteria from the 4th edition of the WHO Classification of 
Tumours of the Digestive System17 which states that two or three contiguous SSA-type 
crypts is sufficient for the diagnosis of SSA.  An SSA-type crypt is described as “dilated 
and assume abnormal shapes including L-shapes and inverted T-shapes. Serration may 
be very prominent and is often seen at the base of the crypts, rather than superficially as 
for HPs.”.   
 
For the purposes of this study we sought to more precisely define crypt architectural 
changes that are diagnostic of SSA as; 1) any horizontal growth along the muscularis 
mucosae, 2) dilation of the crypt base (basal third of the crypt) such that it is wider than the 
luminal opening, 3) serration extending into the crypt base or 4) asymmetric proliferation 
(figure 1).  Serrated polyps displaying any of these features in at least two contiguous or 
three non-contiguous crypts were classified as SSAs.  Serrated polyps not meeting these 
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minimum criteria were classified as MVHPs.  Because prolapse can produce similar crypt 
abnormalities, evidence of significant prolapse effect precluded the diagnosis of a SSA-
type crypt. This was recognised by either smooth muscle proliferation in the lamina propria 
or by the presence of diamond-shaped crypts as recently described by Huang et al19.  
Cytological features were not used to discriminate MVHP from SSA.  
 
The diagnosis of sessile serrated adenoma with cytological dysplasia (SSAD) required an 
abrupt transition from typical SSA to overt cytological dysplasia within a single tissue 
fragment. 
 
Subdivision of MVHPs and SSAs 
For the second part of the study, all MVHPs and SSAs were further subdivided into a total 
of seven subcategories dependent on the number of SSA-type crypts (table 1 and figure 
2). This subdivision was based only on the histology of the individual polyps and was 
blinded to all clinical and demographic data.  When a diagnosis could not be achieved, 
typically because of poor section orientation that did not display the bases of the crypts, a 
designation of serrated polyp unclassified (SPUC) was rendered.  The provisional SSA 
(pSSA) type 3 group represented polyps in which there were three or more crypts with 
equivocal SSA-type changes, that is crypts in which the base was dilated compared to the 
mid-crypt but of similar width to the luminal aspect or if there was undulation of the 
epithelium in the basal aspect of the crypt but without the tufted appearance seen in a 
typical SSA-type crypt (figure 2).  Horizontal growth along the muscularis mucosa and 
asymmetric proliferation were not permitted in this group.  
 
Diagnostic Concordance Between Pathologists 
To assess diagnostic reproducibility, 30 consecutive MVHP, 30 consecutive pSSA types 1-
3 and 30 consecutive SSA types 1-3 were selected from the series, giving a total of 90 
polyps for review.  A panel of four gastrointestinal pathologists (MB, NW, CR, IB) 
independently reviewed these polyps blinded to all clinical information and based their 
diagnoses only on the criteria outlined above and in table 1.  These review diagnoses were 
required to be either MVHP or SSA (encompassing pSSA types 1-3 and SSA types 1-3).   
 
Statistical Analysis 
These groups were then subjected to statistical analyses to validate the new WHO 
diagnostic criteria.  To remove the confounding effect of person, the presence or absence 
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of each polyp within each person was analysed. To test whether a particular type of polyp 
was more likely found proximal or distal/rectal, every person with at least one of the polyp 
type of interest was recorded as having their polyp(s) proximal, distal/rectal, or in both 
locations. McNemar’s test was then used to determine if the proportion in either the 
proximal or distal/rectal location was significantly different.  Pearson’s chi-squared test was 
used to assess whether the presence of at least one of the polyp of interest was 
significantly associated with gender.  Clustering on the presence and absence of each 
polyp per person (excluding serrated polyp unclassified and goblet cell hyperplastic 
polyps) was performed using Jaccard’s distance metric, and Ward’s clustering method.  
Diagnostic consistency and reproducibility was assessed using Fleiss’s kappa and 
intraclass correlation.  The clustering was implemented using hclust in the statistical 
package R. All other analysis was performed in SPSS v. 19.  
RESULTS 
Histological, Demographic and Anatomic Distribution Data of Colonic Polyps 
During the three-month study period, 6340 polyps were received from 3603 patients (mean 
1.76 polyps per patient, range 1-11).  1879 (52.2%) patients were males.  The mean age 
for males was 60.7 years (standard deviation 13.1 years) and for females was 60.2 years 
(standard deviation 14.3 years). The number, location and size of each polyp type are 
provided in table 2.  Demographic data is provided in table 3. 
Conventional adenomatous polyps represented 48.7% of all colorectal polyps.  The 
majority (86.4%) were TAs.  TAs occurred more often in the proximal large bowel (58.9% 
proximal vs. 39.7% distal/rectal, 1.5% site not specified), however the majority of 
tubulovillous and villous adenomas occurred in the distal large bowel (43.7% proximal vs. 
55.3% distal/rectal, 1.0% site not specified) 
Using the WHO criteria, hyperplastic polyps represented 34.2% of all polyps.  MVHPs 
accounted for 1343 of these and goblet cell hyperplastic polyps (GCHP) 825.  The majority 
of hyperplastic polyps were distal/rectal (15.3% proximal vs. 83.5% distal, 1.2% site not 
specified).   
Using the WHO criteria, SSAs accounted for 12.1% of all colorectal polyps and 16.6% of 
patients had at least one SSA.  SSAs were more common in females.  The mean age of 
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patients with at least one SSA (but no SSADs) was significantly younger than for patients 
with at least one SSAD (but no SSAs) (58.5 years vs. 68.9 years; p=0.0025).  Of note, 
there was no trend for SSADs to be larger than SSAs that contrasts with adenomatous 
polyps where advanced features are associated with larger size (table 2). 
Subcategories of MVHP and SSA with Associated Clinical Features 
2084 polyps fell into the categories of MVHP, pSSA or SSA.  With MVHP accounting for 
1180 (56.6%), pSSA 163 (7.8%) and SSA 741 (35.6%).  On a per patient basis the 
MVHPs were more often distal/rectal (p=<0.001) and showed no significant association 
with gender (tables 4 and 5).  In contrast, pSSA type 1 and 2 showed no statistically 
significant association with location and the pSSA type 3 were more often proximal 
(p=0.013).  As a group, the pSSAs were more often proximal (p=0.01) and more often 
occurred in females (p=0.037 and tables 4 and 5 and figure 3).   
Of the SSAs, 178 (23.2%) had two to four SSA-type crypts, 199 (25.9%) had five to nine 
SSA-type crypts, 364 (47.4%) had ten or more SSA-type crypts and 27 (3.5%) were 
SSADs.  SSAs (types 1-3) were also more likely to be proximal and to occur in females 
(tables 4 and 5).  The mean size of these polyps tended to increase with increasing 
numbers of SSA-type crypts (table 6). 
Clustering Analysis 
Using the Jaccard distance metric and Ward’s hierarchical clustering method the patients 
segregated into five clusters based on the presence or absence of each type of polyp 
(table 7). Cluster one represents patients with only TAs, cluster two includes patients with 
pSSAs, SSAs, conventional type polyps and MVHPs, cluster three is patients with only 
TAs and MVHPs, cluster four is patients with only TAs and TVAs and cluster five is 
patients with only MVHPs.  Diagnostics show a significant association between gender 
and the clusters (table 8; p-value <0.001). Cluster one and five have gender distributions 
similar to the entire population, however clusters three and four under-represent females, 
whilst cluster two over-represents females.  The age distribution is also found to be 
significantly different between clusters (table 9; p-value <0.001). The clustering suggests 
that those with only one MVHP tend to be the youngest (cluster five). Those with only 
TVAs, or TVAs and at least one TA tend to be the oldest (cluster four). The other clusters 
do not significantly differ compared to the overall average.   
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Diagnostic Concordance Between Pathologists for MVHP Versus SSA 
Four pathologists reviewed 90 polyps of interest. The overall Fleiss’s kappa score was 
0.66 indicating good concordance between pathologists (table 10).  There was 100% 
agreement between all four pathologists in 63/90 (72%) cases, including all polyps in the 
SSA types 1-3 categories.  At least three of the four pathologists agreed on the diagnosis 
of 26/30 (87%) MVHP cases and in 27/30 (90%) pSSA cases. 
DISCUSSION 
The diagnosis and reported prevalence of serrated colorectal polyps, in particular the SSA, 
continues to evolve.  This is unsurprising given the increasing detection of proximal sessile 
polyps by gastroenterologists and the relatively recent pathological description of the SSA 
as a distinct entity20. The diagnostic criteria for any new entity are expected to be refined 
as the salient clinical, pathological and molecular features come to light.    
The primary aim of this paper was to determine the proportion of colorectal polyps that are 
SSAs using the diagnostic criteria of both the 2010 WHO Classification and the recent 
consensus document.  The rates of 12.1 and 14.7% obtained in this study are the highest 
in the reported literature. These results are based on central pathological review with 
clearly defined criteria for diagnosis.  These findings have been further validated in the 
concordance arm of the paper and as such the results are considered robust.   
In previous publications the basis for the diagnosis of a SSA has not been clearly defined.  
Many studies based the diagnosis on the criteria outlined by Torlakovic and Snover in their 
seminal description of the SSA in 200320 or on the features described in the excellent 
review of Snover et al of 200521. However, because the SSA was a new entity at the time 
of these publications, they could not provide strict definitions as to what constitutes a SSA-
type crypt or how many SSA-type crypts are required for diagnosis.  In other papers very 
restrictive criteria were applied and as such SSAs were diagnosed only infrequently22.   
The 2010 WHO classification and the consensus document go some way to addressing 
this issue but are understandably restricted by a lack of published evidence in the area.  
The works of Mohammadi et al and Aust et al, also provide more didactic criteria for 
diagnosing a SSA13, 23.  However, to the best of our knowledge, no publication to date has 
strictly defined and applied in a systematic fashion, both what constitutes a SSA-type crypt 
and how many SSA-type crypts are required to diagnose a SSA.  We believe that this lack 
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of strict criteria is a key factor in the marked variability of SSA diagnosis in the published 
literature and for the high inter-observer variability in the diagnosis of SSAs10, 24, 25.   
 
There are several possible reasons for our higher rate of SSA diagnosis, compared to 
previous studies.  Firstly, we strictly applied the criteria of the WHO classification and the 
consensus document to make our diagnoses.  In many practices, particularly outside of 
the USA, the criteria used prior to (and since) these publications were more stringent and 
resulted in fewer diagnoses of SSA (and proportionally more MVHPs)21, 22.  Applying 
stricter criteria to our data (accepting only SSAs with five or more SSA-type crypts) would 
result in the percentage of SSAs decreasing from 12.1% to 9.1%.  Secondly, the 
gastroenterological community is becoming increasingly aware of the SSA as an entity. 
Endoscopically, SSAs are subtle polyps and can be easily missed.  Recent publications 
highlighting clues to the recognition of SSAs have likely resulted in greater numbers being 
identified and removed at colonoscopy26-28.  Finally, there has been continual improvement 
in technical factors relating to colonoscopy, including but not limited to quality targets 
(adenoma detection rates, withdrawal times, caecal intubation rates), the optical quality of 
colonoscopes, the quality of bowel preparation, cap-assisted colonoscopy, narrow-band 
imaging and magnification chromoendoscopy29.  Although the evidence supporting some 
of these techniques is limited, the overall quality of colonoscopy is almost certainly 
improving, allowing smaller and subtler polyps to be identified and safely removed.   
 
In contrast to our high overall rate of SSAs, we had a relatively low proportion of SSADs 
(3.5% of SSAs).  In previous publications, SSADs accounted for between 7.0% and 17.3% 
of all SSAs7, 8, 16.  A likely explanation for this discrepancy is the lower rate of SSAs 
diagnosed in these studies, resulting in a higher relative proportion of dysplastic SSAs.  
This explanation is supported by our rate of SSADs amongst all colorectal polyps (0.4%), 
that is similar to previous reports (0.1-0.7%)7, 8, 16.  Interestingly, the SSADs in this series 
had a smaller mean size than the SSAs without dysplasia, demonstrating that advanced 
genetic changes frequently occur in small polyps of the serrated pathway. 
 
The second aim of this study was to critically assess the diagnostic criteria set out in both 
the WHO classification and the consensus document to test the hypothesis that less 
stringent criteria may be adequate to diagnose a SSA.  To achieve this, all MVHPs and 
SSAs were divided into unique subcategories dependent on the number of SSA-type 
crypts per polyp and analysed on a per patient basis. We found an increase in proximal 
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location of serrated polyps as the number of SSA-type crypts increased (figure 3).  Of 
particular interest is the sudden shift to distal predominance for MVHPs (p<0.001), 
compared with the pSSAs (types 1-3) that were found significantly more often in the 
proximal colon (p=0.01) (table 4 and figure 3).  In addition, like the SSAs, gender was 
significantly associated with the presence of a pSSA (p=0.037; table 5), whereas there 
was no significant gender relationship for the MVHPs (p=0.209; table 5).  By cluster 
analysis, the presence of a SSA or pSSA seems, along with the other cluster two polyps, 
more strongly associated with females.  These data suggest that serrated polyps with as 
few as one abnormal SSA-type crypt are more closely related to the SSA than to the 
MVHP and support the position of the consensus document.  
 
Finally, we conducted a reproducibility study to validate the proposed cut-off for the 
diagnosis of SSA.  Reproducibility between the study pathologists was good. Discordant 
cases were limited to the interface between MVHP and pSSA types 1-3.  A degree of 
discordance is inevitable when separating lesions occurring on a diagnostic continuum and 
our series is no exception.  However, our reproducibility is higher than previously 
reported25 and this likely reflects the relative simplicity of both our diagnostic cut-off and 
our diagnostic criteria.  
 
At a clinical level these results have significant implications, particularly to surveillance 
colonoscopy.  At present a diagnosis of MVHP does not affect follow-up intervals. In 
contrast, the diagnosis of a SSA is typically followed by colonoscopic surveillance similar 
to that of patients with conventional adenomas30.  The current guidelines for colonoscopic 
surveillance are based on the correct pathological diagnosis of serrated polyps following 
the WHO definition. Failure to adequately diagnose SSAs may contribute to the 
occurrence of interval carcinomas.  The documented association between interval 
carcinomas, proximal location and the serrated neoplasia pathway has been a concern for 
some time31, 32.  Previously the assumption has been that missed polyps, incompletely 
excised polyps and rapid development of de novo carcinomas are the primary reasons for 
these interval carcinomas15, 33, 34.  These results suggest that inappropriate pathological 
classification, with a subsequent lack of surveillance, may be another important 
contributing factor.  
 
This study has several limitations.  Most obvious is the lack of data on negative 
colonoscopies.  This study was performed in a community-based pathology practice with a 
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large number of referring colonoscopists and as such it was not feasible to collect data on 
negative colonoscopies.  Thus prevalence data cannot be ascertained.  Also, this study 
included any patient with a polyp across the three-month study period and is not limited to 
index colonoscopies for screening purposes.  Thus the age-range and indication for 
colonoscopy is very broad and includes patients with inflammatory bowel disease, 
previous CRC and familial CRC syndromes.  We elected not to exclude such cases for two 
reasons.  Firstly, in many instances little clinical history was provided and as such it would 
be impossible to be certain that all relevant cases were excluded and secondly we wanted 
the data to reflect all material coming through a community practice on a day-to-day basis.  
Although reproducibility was good, this study was conducted by specialist gastrointestinal 
pathologists who work in the same practice.   This may bias towards better concordance.  
A multicenter reproducibility study, including non-specialist pathologists, would be required 
to validate our findings.  Finally, although we demonstrate that serrated polyps with as few 
as one SSA-type crypt share gender and location parameters with more typical SSAs, the 
clinical significance of these polyps is not clear.  Similarly, the significance of proximal 
versus distal serrated polyps remains to be clarified.  In particular many authorities place 
less significance on distal polyps, even if they have histological features of a SSA.  Of 
note, 11% of SSADs in this series were from the distal colon, suggesting that at least 
some distal SSAs have malignant potential.  At present however, there is insufficient data 
from prospective studies to adequately address these issues.  Hopefully such studies will 
be performed in the future and will address the key features of size, location and SSA-type 
crypt numbers. 
 
CONCLUSIONS 
In this study, we identified two points of substantial importance to both pathologists and 
gastroenterologists.  First the proportion of colorectal polyps that are SSAs is significantly 
higher than has been previously published.  Second, pSSAs, representing 2.6% of all 
colorectal polyps, have features more in common with the SSA than the MVHP. Our 
findings suggest that serrated polyps with any crypts displaying abnormal SSA-like 
architecture should be classified as a SSA. If these polyps were included with the other 
frank SSAs, the proportion of SSAs is 14.7% of all colorectal polyps.  Further longitudinal 
studies are required to validate the clinical significance of these findings for the risk of 
subsequent SSA and of malignancy.  
 
 
89
REFERENCES 
1. Snover DC. Update on the serrated pathway to colorectal carcinoma. Hum Pathol.
2011 Jan;42(1):1-10.
2. Rosty C, Hewett DG, Brown IS, et al. Serrated polyps of the large intestine: current
understanding of diagnosis, pathogenesis, and clinical management. J Gastroenterol.
2012 Dec 4.
3. Jass JR. Classification of colorectal cancer based on correlation of clinical,
morphological and molecular features. Histopathology.  2007 Jan;50(1):113-130.
4. Bettington M, Walker N, Clouston A, et al. The serrated pathway to colorectal
carcinoma: current concepts and challenges. Histopathology.  2013 Feb;62(3):367-386.
5. Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer
pathogenesis. Gastroenterology.  2010 Jun;138(6):2088-2100.
6. Spring KJ, Zhao ZZ, Karamatic R, et al. High prevalence of sessile serrated
adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy.
Gastroenterology.  2006 Nov;131(5):1400-1407.
7. Lash RH, Genta RM, Schuler CM. Sessile serrated adenomas: prevalence of
dysplasia and carcinoma in 2139 patients. J Clin Pathol.  2010 Aug;63(8):681-686.
8. Carr NJ, Mahajan H, Tan KL, et al. Serrated and non-serrated polyps of the
colorectum: their prevalence in an unselected case series and correlation of BRAF
mutation analysis with the diagnosis of sessile serrated adenoma. J Clin Pathol.  2009
Jun;62(6):516-518.
9. Gurudu SR, Heigh RI, De Petris G, et al. Sessile serrated adenomas: demographic,
endoscopic and pathological characteristics. World J Gastroenterol.  2010 Jul
21;16(27):3402-3405.
10. Hetzel JT, Huang CS, Coukos JA, et al. Variation in the detection of serrated polyps
in an average risk colorectal cancer screening cohort. Am J Gastroenterol.  2010
Dec;105(12):2656-2664.
11. Higuchi T, Sugihara K, Jass JR. Demographic and pathological characteristics of
serrated polyps of colorectum. Histopathology.  2005 Jul;47(1):32-40.
12. Lu FI, van Niekerk de W, Owen D, et al. Longitudinal outcome study of sessile
serrated adenomas of the colorectum: an increased risk for subsequent right-sided
colorectal carcinoma. Am J Surg Pathol.  2010 Jul;34(7):927-934.
90
  
13. Mohammadi M, Garbyal RS, Kristensen MH, et al. Sessile serrated lesion and its 
borderline variant - Variables with impact on recorded data. Pathol Res Pract.  2011 Jul 
15;207(7):410-416. 
14. Sandmeier D, Seelentag W, Bouzourene H. Serrated polyps of the colorectum: is 
sessile serrated adenoma distinguishable from hyperplastic polyp in a daily practice? 
Virchows Arch.  2007 Jun;450(6):613-618. 
15. Pohl H, Srivastava A, Bensen SP, et al. Incomplete polyp resection during 
colonoscopy-results of the complete adenoma resection (CARE) study. Gastroenterology.  
2013 Jan;144(1):74-80 e71. 
16. Pai RK, Hart J, Noffsinger AE. Sessile serrated adenomas strongly predispose to 
synchronous serrated polyps in non-syndromic patients. Histopathology.  2010 
Apr;56(5):581-588. 
17. Bosman FT, World Health Organization., International Agency for Research on 
Cancer. WHO classification of tumours of the digestive system. 4th ed. Lyon: International 
Agency for Research on Cancer; 2010. 
18. Rex DK, Ahnen DJ, Baron JA, et al. Serrated lesions of the colorectum: review and 
recommendations from an expert panel. Am J Gastroenterol.  2012 Sep;107(9):1315-
1329; quiz 1314, 1330. 
19. Huang CC, Frankel WL, Doukides T, et al. Prolapse-related changes are a 
confounding factor in misdiagnosis of sessile serrated adenomas in the rectum. Hum 
Pathol.  2013 Apr;44(4):480-486. 
20. Torlakovic E, Skovlund E, Snover DC, et al. Morphologic reappraisal of serrated 
colorectal polyps. Am J Surg Pathol.  2003 Jan;27(1):65-81. 
21. Snover DC, Jass JR, Fenoglio-Preiser C, et al. Serrated polyps of the large 
intestine: a morphologic and molecular review of an evolving concept. Am J Clin Pathol.  
2005 Sep;124(3):380-391. 
22. Chung SM, Chen YT, Panczykowski A, et al. Serrated polyps with "intermediate 
features" of sessile serrated polyp and microvesicular hyperplastic polyp: a practical 
approach to the classification of nondysplastic serrated polyps. Am J Surg Pathol.  2008 
Mar;32(3):407-412. 
23. Aust DE, Baretton GB. Serrated polyps of the colon and rectum (hyperplastic 
polyps, sessile serrated adenomas, traditional serrated adenomas, and mixed polyps)-
proposal for diagnostic criteria. Virchows Arch.  2010 Sep;457(3):291-297. 
91
  
24. Glatz K, Pritt B, Glatz D, et al. A multinational, internet-based assessment of 
observer variability in the diagnosis of serrated colorectal polyps. Am J Clin Pathol.  2007 
Jun;127(6):938-945. 
25. Farris AB, Misdraji J, Srivastava A, et al. Sessile serrated adenoma: challenging 
discrimination from other serrated colonic polyps. Am J Surg Pathol.  2008 Jan;32(1):30-
35. 
26. Burke CA, Snover DC. Editorial: sessile serrated adenomas and their pit patterns: 
we must first see the forest through the trees. Am J Gastroenterol.  2012 Mar;107(3):470-
472. 
27. Tadepalli US, Feihel D, Miller KM, et al. A morphologic analysis of sessile serrated 
polyps observed during routine colonoscopy (with video). Gastrointest Endosc.  2011 
Dec;74(6):1360-1368. 
28. Kimura T, Yamamoto E, Yamano HO, et al. A novel pit pattern identifies the 
precursor of colorectal cancer derived from sessile serrated adenoma. Am J 
Gastroenterol.  2012 Mar;107(3):460-469. 
29. Brooker JC, Saunders BP, Shah SG, et al. Total colonic dye-spray increases the 
detection of diminutive adenomas during routine colonoscopy: a randomized controlled 
trial. Gastrointest Endosc.  2002 Sep;56(3):333-338. 
30. Lieberman DA, Rex DK, Winawer SJ, et al. Guidelines for colonoscopy surveillance 
after screening and polypectomy: a consensus update by the US Multi-Society Task Force 
on Colorectal Cancer. Gastroenterology.  2012 Sep;143(3):844-857. 
31. Arain MA, Sawhney M, Sheikh S, et al. CIMP status of interval colon cancers: 
another piece to the puzzle. Am J Gastroenterol.  2010 May;105(5):1189-1195. 
32. Sawhney MS, Farrar WD, Gudiseva S, et al. Microsatellite instability in interval 
colon cancers. Gastroenterology.  2006 Dec;131(6):1700-1705. 
33. Kaminski MF, Regula J, Kraszewska E, et al. Quality indicators for colonoscopy and 
the risk of interval cancer. N Engl J Med.  2010 May 13;362(19):1795-1803. 
34. Baxter NN, Goldwasser MA, Paszat LF, et al. Association of colonoscopy and death 
from colorectal cancer. Ann Intern Med.  2009 Jan 6;150(1):1-8. 
 
 
 
 
 
 
92
  
 
Table 1.  Diagnostic subcategories for microvesicular hyperplastic polyps and 
sessile serrated adenomas. 
Subcategory Definition 
MVHP  No SSA-type crypts 
pSSA (type 1) One SSA-type crypt 
pSSA (type 2) Two non-adjacent SSA-type crypts 
pSSA (type 3) Multiple crypts with poorly-developed SSA-type 
features 
SSA (type 1) Minimal WHO criteria to four SSA-type crypts 
SSA (type 2) Five to nine SSA-type crypts 
SSA (type 3) Ten or more SSA-type crypts 
MVHP – microvesicular hyperplastic polyp; pSSA – provisional SSA; SSA – 
sessile serrated adenoma 
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Table 2. Number, location and average size of the polyps by type using WHO 
diagnostic criteria* 
Polyp type (n=6340) Total number Proximal Distal Rectum 
Mean 
size 
Subtype n (%) n (%) n (%) n (%) (mm) (sd) 
All adenomatous 
polyps 
Tubular adenoma 
(LGD) 
2648 
(41.8) 
1559 
(59) 
854 
(32) 196 (7)
5.8 
(3.0) 
Tubular adenoma 
(HGD) 20 (0.3) 10 (50) 9 (45) 1 (5)
7.3 
(4.0) 
Tubulovillous 
adenoma (LGD) 
363 
(5.7) 168 (46) 
123 
(34) 68 (19) 
12.9
(9.0) 
Tubulovillous 
adenoma (HGD) 49 (0.8) 15 (31) 22 (45) 12 (24) 
17.3 
(10.1) 
Villous adenoma 
(LGD) 6 (0.1) 0 (0) 4 (67) 2 (33) na 
Villous adenoma 
(HGD) 5 (0.1) 1 (20) 2 (40) 2 (40) 
20.0 
(na) 
All serrated polyps    
Hyperplastic polyp 
GCHP 825 (13) 129 (16) 418 
(51) 
266 
(32) 
4.5 
(2.4) 
MVHP 1343 (21.2) 202 (15) 
593 
(44) 
533 
(40) 
4.6 
(2.4) 
Sessile serrated 
adenoma 
741 
(11.7) 594 (80) 
128 
(17) 11 (1)
8.5 
(4.1) 
Sessile serrated 
adenoma with 
dysplasia 
27 (0.4) 21 (78) 3 (11) 0 (0) 7.8 (3.6) 
Traditional serrated 
adenoma 57 (0.9) 18 (32) 22 (39) 17 (30) 
10.6 
(6.8) 
Serrated polyp 
unclassifiable 20 (0.3) 14 (70) 6 (30) 0 (0) 
4.7 
(1.5) 
Malignant polyp 23 (0.4) 8 (35) 12 (52) 3 (13) 20 (12.7) 
*Some percentages do not add to 100 as site data was not supplied in all cases;
LGD – low grade dysplasia; HGD – high grade dysplasia
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Table 3. Incidence of polyps in the study population using WHO diagnostic 
criteria 
PER PATIENT (n=3603)    Polyp type  Total number Mean age Male 
Has at least one: Subtype n (%)  (sd) n (%) 
All adenomatous polyps  
Tubular adenoma (LGD) 1908 (53.0) 62.3 (12.5) 1078 (56.5) 
Tubular adenoma (HGD) 20 (0.6) 67.8 (11.0) 12 (60.0) 
Tubulovillous adenoma 
(LGD) 318 (8.8) 64.0 (11.6) 
189 
(59.4) 
Tubulovillous adenoma 
(HGD) 47 (1.3) 67.0 (12.6) 
33 
(70.2) 
Villous adenoma (LGD) 6 (0.2) 61.8 (21.5) 1 (16.7) 
Villous adenoma (HGD) 5 (0.1) 64.2 (6.1) 4 (80.0) 
All serrated polyps  
Hyperplastic polyp 
GCHP 669 (18.6) 59.7 (13.0) 356 (53.2) 
MVHP 1068 (29.6) 58.2 (14.3) 559 (52.3) 
Sessile serrated 
adenoma 
579 (16.1) 58.6 (15.0) 258 
(44.6) 
Sessile serrated 
adenoma with dysplasia 25 (0.7) 69.4 (12.6) 
11 
(44.0) 
Traditional serrated 
adenoma 54 (1.5) 61.9 (13.4) 
27 
(50.0) 
Serrated polyp 
unclassifiable 19 (0.5) 63.4 (15.0) 8 (42.1) 
Malignant polyp 23 (0.6) 66.5 (14.4) 9 (39.1) 
LGD – low grade dysplasia; HGD – high grade dysplasia 
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Table 4. Location of serrated polyps on a per patient basis, sub-categorised by sessile 
serrated adenoma-type crypts. 
Proximal Distal/Rectal Both Total McNemar's Test 
MVHP  67 (7) 854 (90) 27 (3) 948 <0.001 
pSSA (type 1) 17 (53) 15 (47) 0 (0) 32 0.86 
pSSA (type 2) 22 (61) 14 (39) 0 (0) 36 0.24 
pSSA (type 3) 55 (63) 31 (36) 1 (1) 87 0.013 
pSSA (types 1-3) 92 (60) 59 (39) 2 (1) 153 0.01 
SSA (type 1) 121 (74) 38 (23) 5 (3) 164 <0.001 
SSA (type 2) 145 (81) 32 (18) 3 (2) 180 <0.001 
SSA (type 3) 245 (82) 42 (14) 13 (4) 300 <0.001 
MVHP – microvesicular hyperplastic polyp; pSSA – provisional SSA; SSA – sessile 
serrated adenoma 
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Table 5. Gender of serrated polyps sub-categorised by sessile serrated 
adenoma-type crypts. 
F M 
Chi-squared 
test 
Has MVHP  443 (46%) 
516 
(54%) 0.209 
Has pSSA (type 1-3) 87 (56%) 68 (44%) 0.037 
Has SSA (type 1-3) 321 (55%) 
258 
(45%) <0.001 
Has SSA (type 1-3)/pSSA 
(type 1-3) 399 (56%) 
315 
(44%) <0.001 
MVHP – microvesicular hyperplastic polyp; pSSA – provisional SSA; SSA – 
sessile serrated adenoma 
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Table 6. Average sizes for MVHPs and SSAs. 
Crypts Mean N Std. Deviation 
    MVHP (type 0) 4.5 224 2.1 
pSSA (type 1) 5.8 5 2.5 
pSSA (type 2) 7.1 9 5.1 
pSSA (type 3) 5.4 15 2.3 
SSA (type 1) 7.5 38 3.4 
SSA (type 2) 7.6 47 3.3 
SSA (type 3) 9.6 67 4.7 
MVHP – microvesicular hyperplastic polyp; pSSA – provisional SSA; SSA – sessile 
serrated adenoma 
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Table 7. Patients segregated using the Jaccard distance metric and Ward’s hierarchical 
clustering method.  
Cluster 1 2 3 4 5 
TA 1314 281 216 113 0 
TVA 0 84 0 270 0 
SSAD 0 25 0 0 0 
VA 0 11 0 0 0 
TSA 0 54 0 0 0 
MVHP  0 231 216 0 512 
pSSA (type 1-3) 0 155 0 0 0 
SSA (type 1) 0 165 0 0 0 
SSA (type 2) 0 183 0 0 0 
SSA (type 3) 0 303 0 0 0 
TA – tubular adenoma; TVA – tubulovillous adenoma; SSAD – sessile serrated adenoma 
with dysplasia; VA – villous adenoma; TSA – traditional serrated adenoma; MVHP – 
microvesicular hyperplastic polyp; pSSA – provisional SSA; SSA – sessile serrated 
adenoma 
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Table 8. Gender distribution amongst the clusters.  
Cluster   1 2 3 4 5 
Gender F 590 (45%) 448 (55%) 81 (38%) 107 (40%) 245 (48%) 
 
M 725 (55%) 370 (45%) 135 (62%) 162 (60%) 267 (52%) 
Pearson’s Chi-squared test statistic reveals a significant difference between the groups 
(p<0.001) 
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Table 9. Age distribution amongst the clusters.  
 Mean Std. Dev 95 % CI 
  age   LB UB 
1 62.3 12.3 61.6 63.0 
2 59.1 14.7 58.1 60.1 
3 61.0 13.4 59.2 62.8 
4 64.5 12.1 63.1 66.0 
5 57.3 14.4 56.0 58.5 
Total 60.7 13.6 60.3 61.2 
One-way ANOVA indicates there is a significant difference between the groups (p<0.001); 
LB – lower boundary; UB – upper boundary 
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Table 10. Overall interobserver agreement between pathologists (30 MVHP, 30 pSSA 
(type 1-3) and 30 SSA (type 1-3)) 
Statistic p-value Interobserver agreement 
Fleiss's kappa 0.66 <0.01 Good 
Intraclass Correlation 
- Agreement 0.89 (0.85 -0.92) <0.01 
- Consistency 0.67 (0.58 -0.75) <0.01 
MVHP – microvesicular hyperplastic polyp; pSSA – provisional sessile serrated adenoma; 
SSA – sessile serrated adenoma 
102
FIGURE LEGENDS 
Figure 1. Features of a sessile serrated adenoma-type crypt. Horizontal growth along the 
muscularis mucosa, deep serration and asymmetric proliferation (A), dilation of the crypt 
bases (B).  Haematoxylin and eosin stain. 
Figure 2.  Examples of study microvesicular hyperplastic polyp (A) and provisional sessile 
serrated adenomas type 1-3 (B-D).  Haematoxylin and eosin stain. 
Figure 3. Location of subcategories of microvesicular hyperplastic polyp, provisional 
sessile serrated adenomas and sessile serrated adenomas by percentage on a per polyp 
basis. 
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Chapter 3: A clinicopathological and molecular analysis of 200 traditional serrated 
adenomas 
As published in Modern Pathology as: 
Bettington M, Walker N, Rosty C, et al. A clinicopathological and molecular analysis of 
200 traditional serrated adenomas. Mod Pathol; 2015; 28: 414-427 
Relevance to aims of the thesis: 
This chapter addresses parts of aims 3, 4 and 6. The traditional serrated adenoma is a 
rare colorectal polyp.1-4 The clinicopathological and molecular features have been 
assessed in several papers; however these studies have suffered from low numbers, 
somewhat limited investigations and possibly contamination by other polyp subtypes (in 
particular tubulovillous adenomas).4-7 As a result the data in the literature is often 
contradictory. The distribution and origins of traditional serrated adenomas are quite 
variable and the proportions with BRAF or KRAS mutation and the CpG island methylator 
phenotype are not clear.5, 6, 8, 9 Perhaps more importantly, the molecular events leading to 
malignant transformation have only been partially addressed.5, 10 In this chapter we 
gathered a series of 200 traditional serrated adenomas for detailed analysis. The large 
size of the cohort, the strict inclusion criteria and the thorough molecular assessment has 
allowed a thorough assessment of the clinicopathological and molecular features of these 
polyps and has provided insights into the molecular subtypes of colorectal carcinoma that 
arise from traditional serrated adenomas. 
1. Spring KJ, Zhao ZZ, Karamatic R, et al. High prevalence of sessile serrated
adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy.
Gastroenterology. 2006;131(5):1400-7.
2. Carr NJ, Mahajan H, Tan KL, Hawkins NJ, Ward RL. Serrated and non-serrated
polyps of the colorectum: their prevalence in an unselected case series and correlation of
BRAF mutation analysis with the diagnosis of sessile serrated adenoma. J Clin Pathol.
2009;62(6):516-8.
3. Bettington M, Walker N, Rosty C, et al. Critical appraisal of the diagnosis of the
sessile serrated adenoma. Am J Surg Pathol. 2014;38(2):158-66.
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4. Longacre TA, Fenoglio-Preiser CM. Mixed hyperplastic adenomatous
polyps/serrated adenomas. A distinct form of colorectal neoplasia. Am J Surg Pathol.
1990;14(6):524-37.
5. Fu B, Yachida S, Morgan R, Zhong Y, Montgomery EA, Iacobuzio-Donahue CA.
Clinicopathologic and genetic characterization of traditional serrated adenomas of the
colon. Am J Clin Pathol. 2012;138(3):356-66.
6. Kim KM, Lee EJ, Kim YH, Chang DK, Odze RD. KRAS mutations in traditional
serrated adenomas from Korea herald an aggressive phenotype. Am J Surg Pathol.
2010;34(5):667-75.
7. Torlakovic EE, Gomez JD, Driman DK, et al. Sessile serrated adenoma (SSA) vs.
traditional serrated adenoma (TSA). Am J Surg Pathol. 2008;32(1):21-9.
8. Kim MJ, Lee EJ, Suh JP, et al. Traditional serrated adenoma of the colorectum:
clinicopathologic implications and endoscopic findings of the precursor lesions. Am J Clin
Pathol. 2013;140(6):898-911.
9. Ha SY, Lee SM, Lee EJ, et al. Filiform serrated adenoma is an unusual, less
aggressive variant of traditional serrated adenoma. Pathology. 2012;44(1):18-23.
10. Tsai JH, Liau JY, Lin YL, et al. Traditional serrated adenoma has two pathways of
neoplastic progression that are distinct from the sessile serrated pathway of colorectal
carcinogenesis. Mod Pathol. 2014.
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Abstract 
The traditional serrated adenoma is the least common colorectal serrated polyp. The 
clinicopathological features and molecular drivers of these polyps require further 
investigation. We have prospectively collected a cohort of 200 ordinary and advanced 
traditional serrated adenomas and performed BRAF and KRAS mutational profiling, CpG 
island methylator phenotype analysis and immunohistochemistry for a panel of seven 
antibodies (MLH1, β-catenin, p53, p16, Ki67, CK7 and CK20) on all cases. The mean age 
of the patients was 64 years and 50% were female. 71% of polyps were distal. Advanced 
histology (overt dysplasia or carcinoma) was present in 19% of cases. BRAF mutation was 
present in 67% and KRAS mutation in 22%. BRAF mutant traditional serrated adenomas 
were more frequently proximal (39% versus 2%; p=<0.0001), were exclusively associated 
with a precursor polyp (57% versus 0%; p=<0.0001) and were more frequently CpG island 
methylator phenotype high (60% versus 16%; p=<0.0001) than KRAS mutant traditional 
serrated adenomas. Advanced traditional serrated adenomas retained MLH1 expression in 
97%, showed strong p53 staining in 55% and nuclear β-catenin staining in 40%. P16 
staining was lost in the advanced areas of 55% of BRAF mutant traditional serrated 
adenomas compared to 10% of the advanced areas of KRAS mutant or BRAF/KRAS wild 
type traditional serrated adenomas. BRAF and KRAS mutant traditional serrated 
adenomas are morphologically related but biologically disparate polyps with distinctive 
clinicopathological and molecular features. The overwhelming majority of traditional 
serrated adenomas retain mismatch repair enzyme function indicating a microsatellite 
stable phenotype. Malignant progression occurs via TP53 mutation and Wnt pathway 
activation regardless of mutation status. However, CDKN2A (encoding the p16 protein) is 
silenced nearly exclusively in the advanced areas of the BRAF mutant traditional serrated 
adenomas. Thus the BRAF mutant traditional serrated adenoma represents an important 
precursor of the aggressive BRAF mutant, microsatellite stable subtype of colorectal 
carcinoma.   
Key words: Traditional serrated adenoma; serrated neoplasia pathway, colorectal 
carcinoma, colorectal polyps, BRAF, KRAS, CpG island methylator phenotype 
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Introduction 
The serrated neoplasia pathway accounts for 15 to 35% of colorectal carcinoma.(1-3) Well 
established molecular drivers of this pathway are MAP kinase pathway activation, a critical 
early event resulting from either activating BRAF or KRAS mutation(4) and the CpG island 
methylator phenotype, a co-ordinate methylation of CpG islands in the promoter regions of 
many genes that results in gene silencing.(4-6) The CpG island methylator phenotype is 
particularly relevant to carcinogenesis when affecting tumour suppressor genes.(5) MLH1 is 
the best known of these, with silencing leading to microsatellite instability. This is 
frequently observed in the malignant transformation of sessile serrated adenomas. 
However, MLH1 methylation and microsatellite instability are not pre-requisites of serrated 
neoplasia. 
Traditional serrated adenomas remain the least understood of the serrated polyps, 
probably reflecting their rarity, accounting for less than 1% of colorectal polyps in most 
series.(7-10) They were first defined by Longacre et al(7) as serrated adenomas, describing 
polyps with mixed hyperplastic and adenomatous features, a subset of which showed what 
is now considered the ‘typical cytology’ of a traditional serrated adenoma, namely cells 
with abundant eosinophilic cytoplasm and centrally placed pencillate nuclei.(7) Since then, 
a diverse range of polyps including sessile serrated adenoma, sessile serrated adenoma 
with dysplasia and tubulovillous adenoma with prominent serration have been 
misclassified as traditional serrated adenomas.(11) Publications by Torlakovic et al(12, 13) in 
2003 and 2008 improved diagnostic reproducibility by characterizing the sessile serrated 
adenoma and identifying key features of the traditional serrated adenoma, in particular 
ectopic crypt formations. The 4th edition of the WHO Classification of Tumours of the 
Digestive Tract emphasizes protuberant and villiform growth patterns and ectopic crypt 
formations in the diagnosis of the traditional serrated adenoma.(11) Typical cytology is 
recognised as a frequent but not requisite feature.  
In our experience, polyps with flat growth and absent ectopic crypt formations, but with 
classical traditional serrated adenoma cytology and slit-like serration are relatively 
common but inconsistently classified. Many pathologists consider the typical eosinophilic 
cell of the traditional serrated adenoma to be inherently dysplastic, yet these cells are not 
morphologically atypical, do not display mitotic activity and show absent or minimal 
proliferative activity by Ki67 staining.(11, 13) Moreover, a subset of traditional serrated 
adenomas develop discrete areas of morphologically overt dysplasia.(14-16) How to classify 
111
these advanced traditional serrated adenomas and how to separate them from ordinary 
traditional serrated adenomas in routine practice has been inadequately addressed. The 
origin of the traditional serrated adenomas is also unclear. While some probably arise de 
novo, many appear to arise in a precursor polyp, especially microvesicular hyperplastic 
polyps or sessile serrated adenomas.(13, 16-18)  
The traditional serrated adenoma also shows more molecular heterogeneity than most 
other polyps. The frequency of BRAF and KRAS mutation and CpG island methylator 
phenotype-high versus CpG island methylator phenotype-low or negative is variable in the 
literature, which is unusual for a polyp that, above issues aside, is morphologically fairly 
uniform.(14, 16, 17, 19, 20) The reasons for, and the significance of, this heterogeneity have not 
been investigated. Finally, the pathways by which traditional serrated adenomas progress 
to carcinoma have not been extensively studied.  
Herein, we provide a detailed clinicopathological, morphological and molecular 
examination of a series of 200 traditional serrated adenomas. We aimed to address the 
above morphological issues and to interrogate the molecular features of these polyps, with 
a two-part focus on 1) BRAF versus KRAS mutant traditional serrated adenomas and 2) 
ordinary versus advanced traditional serrated adenomas. We find that traditional serrated 
adenomas can be flat and frequently arise in a precursor microvesicular hyperplastic polyp 
or sessile serrated adenoma. Furthermore, although BRAF and KRAS mutant traditional 
serrated adenomas are morphologically related, they are biologically distinct polyps, with 
differing clinicopathological and molecular features that culminate in different subtypes of 
colorectal carcinoma.  
Materials and Methods 
Patients and Samples 
Two hundred traditional serrated adenomas from 196 patients were included in the study. 
Cases were prospectively collected between June 2007 and June 2013 during routine 
reporting by one author (NW) at Envoi Specialist Pathologists. All cases were reviewed by 
two pathologists (MB, NW) and included only if both pathologists were in agreement on the 
diagnosis. The series included traditional serrated adenomas removed by polypectomy, 
endoscopic mucosal resection, transanal endoscopic micro-surgery and colectomy.  
Cases from patients with known inflammatory bowel disease or a polyposis syndrome 
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were excluded. Clinicopathological data including patient age, gender, polyp size and 
location were collected from a combination of the pathology request form, specimen 
container and pathology report. In this study proximal includes caecum, ascending colon, 
hepatic flexure and transverse colon; distal includes splenic flexure, descending colon, 
sigmoid colon and rectum. Fifty tubulovillous adenomas without morphological evidence of 
serration were collected as a control group. Tubulovillous adenomas were selected as the 
control group as they more closely simulate the morphology of the traditional serrated 
adenoma than do tubular adenomas. The study was approved by the ethics committee of 
QIMR Berghofer Medical Research Institute (P1298). 
 
Histopathological Inclusion Criteria 
Inclusion criteria were based on previously published features.(3, 7, 11-13) All polyps 
displayed at least two of the following three features; 1) typical cytology 2) slit-like 
epithelial serrations and 3) ectopic crypt formations; with at least one feature evident in 
>50% of the polyp (Figure 1a-b).  
 
Typical cytology referred to cells with abundant brightly eosinophilic cytoplasm with 
centrally placed, pencillate nuclei(7) (Figure 1b); slit-like epithelial serrations referred to 
narrow slits in the epithelium similar to normal small intestinal mucosa(3) (Figure 1b) and 
ectopic crypt formations referred to epithelial buds with their bases not seated adjacent to 
the muscularis mucosae (Figure 1b).(13)  
 
Diagnosis and validation of flat growth pattern 
Each polyp was assessed for growth pattern (flat versus protuberant). A flat growth pattern 
was diagnosed when the majority of the polyp was elevated less than twice the height of 
the normal mucosa and lacked prominent viliform projections (Figure 1c-f). 
 
Because flat growth in a traditional serrated adenoma is controversial, we further validated 
the diagnostic reproducibility of this subtype. A panel of four gastrointestinal pathologists 
(MB, NW, CR, IB), blinded to all clinicopathological information, independently assessed 
the flat traditional serrated adenomas along with 50 sessile serrated adenomas randomly 
selected from a previous study set.(10) The diagnosis of traditional serrated adenoma was 
based on the criteria outlined above and the diagnosis of sessile serrated adenoma was 
based on previously published criteria.(10, 21)  
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Identification of a precursor component 
After reaching the inclusion criteria for the study, each traditional serrated adenoma initially 
identified as having a precursor component by the principal author (MB) was additionally 
assessed for the presence of a precursor polyp of any type by three additional pathologists 
(NW, CR, IB). The precursor component was required to represent a discrete area of the 
lesion with clear morphological distinction from the traditional serrated adenoma 
component either at the edge or underlying the traditional serrated adenoma (figure 2a-
c).(16) Diagnosis of a sessile serrated adenoma precursor required the presence of at least 
one unequivocal sessile serrated adenoma-type crypt.(10, 21) A precursor component was 
diagnosed if there was consensus between all four pathologists. 
 
Diagnosis of advanced traditional serrated adenoma 
The cohort was divided into ‘ordinary’ and ‘advanced’ traditional serrated adenomas based 
on the presence or absence of dysplasia or carcinoma. Dysplasia required an abrupt 
transition from typical traditional serrated adenoma to overt cytological dysplasia (Figure 
2d). Cytological features included increased nuclear size, frequent and atypical mitoses, 
nuclear crowding, complete loss of polarity and pseudo-stratification with nuclei extending 
into the upper half of the neoplastic cell.(11, 14, 15)  Architectural features were crowding of 
glands, cribriform glands and intraluminal necrosis. Carcinoma was recognised by breach 
of the muscularis mucosae by cytologically dysplastic cells in concert with desmoplastic 
stroma.  
 
All advanced areas were assessed for serrated morphology. In areas of dysplasia we used 
the criteria outlined in the WHO of cuboidal cells with eosinophilic cytoplasm, vesicular 
nuclei and prominent nucleoli.(11) For areas of carcinoma we used the criteria of Makinen 
et al(22) and required five features for a diagnosis of serrated morphology. 
 
Immunohistochemistry 
Immunohistochemistry was performed from the formalin fixed paraffin embedded blocks.  
Sections were cut at 4µm then dewaxed and rehydrated.  Antigen retrieval for MLH1, CK7, 
p16 and Ki67 was performed by incubation in high pH antigen retrieval solution (pH9.0, 
Dako, Glostrup, Denmark) at 112°C for seven minutes.  Antigen retrieval for β-catenin, p53 
and CK20 was performed by incubation in low pH antigen retrieval solution (pH6.0, 
Biocare Medical, Concord, CA, USA) at 112°C for seven minutes.   
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Sections were manually stained following the manufacturers instructions. Antibodies used 
were: MLH1 (clone G168-15, 1:100, BD Pharmingen, Franklin Lakes, NJ, USA), β-catenin 
(1:600, Cell Marque, Rocklin, CA, USA), p53 (clone DO-7, 1:150, Biocare Medical, 
Concord, CA, USA), p16 (clone JC8, 1:150, Santa Cruz Biotechnology, Dallas, Texas, 
USA), Ki67 (clone MIB-1, 1:100, Dako, Glostrup, Denmark), CK7 (clone OV-TL12/30, 
1:100, Dako, Glostrup, Denmark), CK20 (clone Ks20.8, 1:150, Biocare Medical, Concord, 
CA, USA). Slides were counterstained with Mayer’s haematoxylin.  
  
Each marker was assessed for both intensity and extent of staining in the following 
compartments; basal zone, typical eosinophilic cells, ectopic crypt formations, goblet cells, 
dysplastic components and invasive carcinoma components. Intensity was scored as 0-3 
(0=no staining, 1=weak staining, 2=moderate staining, 3=strong staining) and extent as 0-
4 (0=no staining, 1=1-10% of cells, 2=11-50% of cells, 3=51-90% of cells, 4=>90% of 
cells). When intensity was variable, an average of the intensity was used. A final score 
was determined by multiplying the intensity and extent scores (minimum score=0, 
maximum=12). 
 
Interpretation of each marker was as follows. Normal MLH1 expression required the 
presence of nuclear staining with a score of ≥3 in each compartment. Positive β-catenin 
required nuclear staining with a score of ≥2 in any compartment. Loss of membrane 
staining and cytoplasmic staining were not considered positive.(14, 23) Positive p53 required 
nuclear staining with a score of ≥6 in any compartment.(14) Positive P16 required either 
cytoplasmic or nuclear staining with a score of ≥3 in any compartment.(24) Positive Ki67 
required nuclear staining with a score of ≥9 in any compartment. Positive cytokeratin 7 and 
cytokeratin 20 required cytoplasmic staining with a score of ≥3 in any compartment. For 
ordinary traditional serrated adenomas, the compartment with the highest score was used 
for analysis. For advanced traditional serrated adenomas, the score only in the areas of 
dysplasia or carcinoma was used for analysis. 
 
DNA Extraction 
DNA was extracted from the formalin fixed paraffin embedded blocks using the Chelex-
100 extraction method (Bio-Rad Laboratories, Hercules, CA, USA).  In brief, three 10µm 
sections were cut from the FFPE blocks and heated to 90°C in 200uL of 0.5% Tween-20 in 
1xTE and then digested with 80mg of proteinase K at 55°C for three hours.  After 
digestion, 200uL of 5% Chelex-100 was added to the samples and they were heated to 
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99°C, centrifuged then cooled on ice and the paraffin layer removed.  200uL of chloroform 
was added, the samples centrifuged for 15 minutes and the final product from the surface 
phase removed by manual pipette.  DNA concentration was established by 
spectrophotometry (NanoDrop 2000, Thermo Scientific, Fremont, CA, USA). In cases 
where there was contamination of the formalin fixed paraffin embedded block by non-
polypoid tissue, manual microdissection was performed using a sterile scalpel blade with a 
marked haematoxylin and eosin stained section as a guide. 
 
BRAF and KRAS mutation detection 
The BRAF V600E mutation was detected by allele-specific polymerase chain reaction  as 
previously described.(25) KRAS mutations were assessed by high-resolution melt analysis 
as previously described.(26)  
 
CpG Island Methylator Phenotype Determination 
Polyp genomic DNA was treated with sodium bisulfite using the Epitect Fast Bisulfite 
Conversion Kit (Qiagen, Duesseldorf, Germany) according to the manufacturers 
instructions. CpG island methylator phenotype status was determined using the 
MethyLight technique as previously described by Weisenberger et al.(27) The CpG island 
methylator phenotype panel genes consisted of CACNA1G, IGF2, NEUROG1, RUNX3 
and SOCS1. The output from this assay was percent of sample DNA methylated relative to 
a DNA reference sample, to give a percentage of methylated reference. Using previously 
published criteria,(27) samples with ≥3 markers with a percentage of methylated reference 
of >10 were considered CpG island methylator phenotype-high, samples with one or two 
markers with a percentage of methylated reference >10 were considered CpG island 
methylator phenotype-low and samples with no markers >10 were considered CpG island 
methylator phenotype-negative. Completely methylated genomic DNA from pooled blood 
samples was used to generate a standard curve for each gene. Negative controls were run 
on each plate and the ALU gene was used to ensure the quality of each samples bisulfite 
treated DNA. As previously published, we considered samples to have failed if the ALU 
cycle threshold value (Ct) was >23.(28) In addition we required the ALU representative 
calculated concentration to be >1000. The methylation status of the MLH1 promoter region 
was also assessed using MethyLight using the same technique as described above. The 
probe and primer sequences are as described previously.(29) 
 
Statistical Analysis 
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Categorical variables were compared by Fisher’s exact test and continuous variables by 
Student’s t-test. A p-value of ≤0.05 was considered significant. Inter-rater agreements of 
diagnoses by different pathologists were estimated using Fleiss’s kappa and intraclass 
correlation coefficients were also obtained. SPSS version 19, R version 3.0.2 and 
GraphPad Prism version 6.02 were used for statistical analyses. 
Results 
Clinicopathological data 
The clinicopathological data are presented according to the presence or absence of 
advanced histology and by mutation status in tables 1 and 2. Advanced traditional serrated 
adenomas were larger (mean 25mm) and less often associated with a precursor polyp 
(13%) than ordinary traditional serrated adenomas (mean 16mm, 38% precursor polyp). 
Most traditional serrated adenomas had mutation of either BRAF (67%) or KRAS (22%) 
and these mutations were mutually exclusive (table 2). BRAF mutant traditional serrated 
adenomas were more often proximal (39%) and had more frequent origin in a precursor 
polyp (57%) than KRAS mutant traditional serrated adenomas, which were rarely proximal 
(2%) and never associated with a precursor polyp (table 2).  
Table 3 outlines the inclusion criteria relative to polyp size. Smaller polyps were less likely 
to have ectopic crypt formations. Similarly, 19 of 76 (25%) flat traditional serrated 
adenomas did not have ectopic crypt formations; in contrast only 3 of 124 (2%) 
protuberant traditional serrated adenomas did not show ectopic crypt formations (p-value 
<0.0001). Table 4 demonstrates the relationship between polyp location, mutation status 
and flat morphology. BRAF mutant and proximal polyps were more likely to be flat than 
distal polyps. However, after accounting for anatomical location, no difference was 
observed by mutation status alone. Reproducibility of the diagnosis of flat traditional 
serrated adenomas compared to sessile serrated adenomas was excellent; with a kappa 
value of 0.93 (p-value <0.001) and the intraclass correlation coefficients absolute 
agreement was 0.981 (95% confidence interval 0.975-0.986; p-value <0.001)  
All advanced areas were assessed for serrated morphology (Table 5). The majority of 
cases had serrated morphology. All cases with both dysplasia and invasive carcinoma 
showed the same morphology in both components. No significant associations could be 
identified between serrated morphology and molecular or immunohistochemical profile.  
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Mutation status and the CpG Island Methylator Phenotype 
BRAF and KRAS mutation were present in 67% and 22% of polyps respectively. BRAF 
mutant, KRAS mutant and BRAF/KRAS wild type polyps were CpG island methylator 
phenotype high in 60%, 16% and 17% respectively, low in 28%, 44% and 48% 
respectively and negative in 11%, 40% and 35% respectively. The control tubulovillous 
adenomas were CpG island methylator phenotype high, low and negative in 0%, 6% and 
94% respectively. BRAF mutation was more frequent than KRAS mutation (p-value 
<0.0001) and was more often associated with CpG island methylator phenotype-high than 
KRAS mutation (p-value <0.0001), however, KRAS mutant traditional serrated adenomas 
were more frequently CpG island methylator phenotype-high than control tubulovillous 
adenomas (p-value 0.0034). 75% (44/59) of proximal traditional serrated adenomas were 
CpG island methylator phenotype-high, compared to 35% (48/139) of distal traditional 
serrated adenomas (p-value <0.0001) and in addition 83% (43/59) of proximal BRAF 
mutant traditional serrated adenomas were CpG island methylator phenotype-high, 
compared to 46% (38/82) of distal BRAF mutant traditional serrated adenomas (p-value 
<0.0001). Despite this, distal BRAF mutant traditional serrated adenomas remained more 
likely to be CpG island methylator phenotype-high than distal KRAS mutant traditional 
serrated adenomas (p-value 0.0025). The CpG island methylator phenotype-low status 
was present in 44% and 48% of KRAS mutant and BRAF/KRAS wild type traditional 
serrated adenomas respectively but was seen in only 6% of control tubulovillous 
adenomas. Advanced traditional serrated adenomas showed no statistically significant 
association with mutation status or CpG island methylator phenotype when compared to 
ordinary traditional serrated adenomas. No BRAF mutations were identified in the control 
tubulovillous adenomas. 
MLH1 promoter methylation was present in 7% (9/134) of the BRAF mutant traditional 
serrated adenomas (eight ordinary and one advanced), but in none of the KRAS mutant or 
BRAF/KRAS wild type traditional serrated adenomas. Only the single advanced traditional 
serrated adenoma with MLH1 methylation showed concordant loss of MLH1 expression by 
immunohistochemistry. 
Immunohistochemistry 
Table 6 outlines the immunohistochemical features of the study polyps. Amongst the 
ordinary traditional serrated adenomas, BRAF mutant traditional serrated adenomas were 
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more likely than KRAS mutant traditional serrated adenomas to have a high Ki67 
proliferative index in the basal compartment. No other statistically significant differences in 
staining patterns were identified between the ordinary traditional serrated adenomas when 
stratified according to mutation status. Advanced traditional serrated adenomas showed 
significantly increased nuclear staining for β-catenin (Figure 3a and b) and p53 (Figure 3c) 
compared to the ordinary traditional serrated adenomas. MLH1 nuclear staining was 
retained in all but one case. P16 staining was lost in 42% of the dysplastic components 
and 89% of the invasive components in advanced BRAF mutant polyps (Figure 3d). In 
contrast, p16 staining was lost in only 8% of dysplastic and 17% of invasive components in 
the KRAS mutant and BRAF/KRAS wild type polyps. 
 
Discussion 
This clinicopathological, morphological and molecular appraisal of a large series of 
rigorously categorised traditional serrated adenomas was undertaken with the aim of 
clarifying areas of morphological and molecular uncertainty related to these polyps. We 
focused on identifying features that discriminated BRAF and KRAS mutant cases and on 
identifying pathways by which traditional serrated adenomas progress to carcinoma. 
 
Due to the variability in traditional serrated adenoma morphology and its evolution as they 
enlarge, absolute diagnostic criteria are difficult to define, although typical cytology, ectopic 
crypt formations, slit-like luminal serrations and protuberant or villiform growth have proven 
useful. Slit-like serrations are possibly the most specific, differentiating traditional serrated 
adenomas from morphologically similar tubulovillous adenomas with prominent 
serration.(30) To ensure all polyps in the study group were traditional serrated adenomas, 
we required all cases to show at least two of the first three features listed, with at least one 
present in 50% of the polyp. Table 3 shows the relative contribution of each of these 
features. Of note, smaller polyps are less likely to show ectopic crypt formations. 
 
We specifically did not include protuberant or viliform growth as an inclusion criterion, as 
we regularly identify traditional serrated adenomas with a flat growth pattern. Because the 
concept of a flat traditional serrated adenoma is contentious, we performed a 
reproducibility study to determine whether we could reliably distinguish these polyps from 
sessile serrated adenomas. In this study we achieved an excellent level of inter-observer 
concordance, indicating that flat traditional serrated adenomas can be reliably 
distinguished from sessile serrated adenomas. Flat traditional serrated adenomas are 
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typically (but not exclusively) proximal, BRAF mutant and arise in sessile serrated 
adenomas. While proximal polyps are more likely to be flat, this is unrelated to mutation 
status, with distal BRAF and KRAS mutant traditional serrated adenomas showing similar 
rates of flat and protuberant growth. This correlates with a previous study showing that 
distal sessile serrated adenomas can also be protuberant,(31) thus flat versus protuberant 
morphology is probably secondary to location rather than being an intrinsic element of the 
traditional serrated adenoma. 
 
Our clinicopathological data are in agreement with recent publications(14-17), although in our 
series, precursor polyps were limited to microvesicular hyperplastic polyps and sessile 
serrated adenomas and were exclusively associated with BRAF mutation. BRAF mutant 
traditional serrated adenomas were also more likely to be proximal than KRAS or 
BRAF/KRAS wild type traditional serrated adenomas. Other than the association with a 
precursor polyp, no differences in morphology were identified based on mutation status 
alone. 
 
A critical morphological issue is the distinction between traditional serrated adenoma 
arising in a sessile serrated adenoma from a sessile serrated adenoma with cytological 
dysplasia. Based on our data, there are important biological differences between these two 
lesions, particularly relating to mismatch repair enzyme function, thus histological 
distinction is important. When the traditional serrated adenoma component is obvious, the 
diagnosis should not be difficult, however it is fairly common to see a small but discrete 
focus with traditional serrated adenoma-type cytology arising in an otherwise typical 
sessile serrated adenoma. In our opinion, this may represent senescent change, or 
possibly early traditional serrated adenoma arising in the sessile serrated adenoma. Some 
pathologists consider such change serrated dysplasia, warranting a diagnosis of sessile 
serrated adenoma with dysplasia. In an audit of our own practice, a subset of sessile 
serrated adenomas with dysplasia (mostly prior to 2012) showed this change (unpublished 
data). In our more recent opinion, rendering a diagnosis of sessile serrated adenoma with 
dysplasia in this situation will imply a significantly greater degree of malignant risk than is 
warranted. True sessile serrated adenomas with dysplasia have been demonstrated to 
show Wnt pathway activation(23), loss of mismatch repair function(32), CDKN2A silencing(24) 
and sometimes TP53 mutation(33). In contrast, from our data, ordinary traditional serrated 
adenomas arising in a sessile serrated adenoma do not have these advanced features. 
Thus, in our opinion, calling these lesions sessile serrated adenoma with dysplasia risks 
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diminishing the significance of true sessile serrated adenoma with dysplasia and 
potentially leading to erroneous conclusions regarding surveillance.  
 
The final important morphological point is the diagnosis of dysplasia arising in a traditional 
serrated adenoma. In our series we found a very high rate of both serrated type dysplasia 
and carcinoma amongst our advanced polyps. This is in keeping with the work of Makinen 
et al, who defined serrated adenocarcinoma primarily from cancers arising in traditional 
serrated adenomas.(22, 34) In a subsequent paper, Stefanius et al, showed that both KRAS 
and BRAF mutations are common in serrated adenocarcinomas.(35) Our findings are in 
keeping with these earlier studies but are different to those more recently published by 
Tsai et al.(15)  
 
In addition, we are of the opinion that the typical traditional serrated adenoma cytology 
does not represent a serrated dysplastic change(11). This is a controversial issue; the 
reasons for our opinion are as follows. Firstly, the typical traditional serrated adenoma 
cytology is not overtly atypical, secondly these cells do not show mitoses and have a very 
low proliferative index by Ki67 staining and thirdly they do not show the advanced features 
seen in the overtly dysplastic cells of advanced polyps; namely positive nuclear staining for 
β-catenin and p53 and loss of staining for p16. Instead of routinely describing dysplasia in 
traditional serrated adenomas, we propose that the nomenclature be brought into line with 
that of the sessile serrated adenoma, whereby the ordinary traditional serrated adenoma is 
simply designated traditional serrated adenoma, with no mention of cytological dysplasia, 
and advanced traditional serrated adenomas are designated traditional serrated adenoma 
with dysplasia or carcinoma as appropriate. Although different patterns of dysplasia occur, 
the key point is to identify traditional serrated adenomas with advanced biology and a 
higher risk of malignant progression as evidenced by the Wnt pathway activation, TP53 
mutation and CDKN2A loss demonstrated in this study. Thus, similar to the sessile 
serrated adenoma, reporting the presence of overt dysplasia is the critical issue. At this 
time, assigning a grade or dividing dysplasia into serrated versus conventional types has 
no clinical utility and may only introduce confusion into the nomenclature. 
 
The second major aim of this paper was to give a thorough account of the molecular 
features of the traditional serrated adenoma. To this end, we performed BRAF, KRAS and 
CpG island methylator phenotype analysis on all polyps in the series. In line with recent 
publications(16, 17) we found that BRAF mutant traditional serrated adenomas represented 
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about two thirds of all cases and the vast majority of proximal traditional serrated 
adenomas. In contrast, KRAS mutant traditional serrated adenomas were almost 
exclusively distal, with a particular predilection for the rectum. BRAF/KRAS wild type cases 
were more closely aligned with KRAS mutant polyps than BRAF mutant cases and may 
have as yet undefined up-regulation of MAP kinase signaling. 
 
CpG island methylator phenotype-high status, as expected, correlated strongly with both 
proximal location and BRAF mutation. However, 16% of KRAS mutant traditional serrated 
adenomas were CpG island methylator phenotype-high and 44% were CpG island 
methylator phenotype-low, indicating that methylation may still play an important role in the 
malignant progression of these polyps. Also, the level of CpG island methylator phenotype 
in the KRAS mutant and BRAF/KRAS wild type traditional serrated adenoma was 
significantly more than seen in the control tubulovillous adenomas.  
 
Some authors have questioned the validity of including traditional serrated adenomas as 
part of the serrated neoplasia pathway; however, the combination of MAP kinase pathway 
activation and CpG island methylator phenotype is strong evidence to support their 
continued inclusion. Part of this confusion may stem from the lack of reliability of CpG 
island methylator phenotype data reported in the literature. Unfortunately, no uniform panel 
for the CpG island methylator phenotype assessment has been utilized. Also, in many 
studies, no controls were included or the control cases show the CpG island methylator 
phenotype far outside of what could reasonably be expected based on the reported 
histological diagnosis.(15, 19, 20, 36) This calls into question the CpG island methylator 
phenotype results for some of these studies.  In the present study we used the well-
validated panel described by Weisenberger et al.(27) In this series the vast majority of 
control tubulovillous adenomas were CpG island methylator phenotype-negative (94%) 
and none were CpG island methylator phenotype-high, which is the expected outcome and 
provides strong support for the validity of our results.  
 
The final aim of this study was to interrogate the pathways by which traditional serrated 
adenomas progress to carcinoma. We stained each polyp with seven 
immunohistochemical markers. The ordinary traditional serrated adenomas were 
remarkably uniform in their staining patterns. Ki67 and cytokeratin 20 predominantly 
showed the pattern described by Torlakovic et al, with a high Ki67 index in the ectopic 
crypt formations and basal crypts but very limited in the typical surface cells and the 
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opposite pattern with cytokeratin 20. The Ki67 index was high in essentially all areas of 
dysplasia or early carcinoma. A proportion of ordinary and advanced traditional serrated 
adenomas, particularly BRAF mutant cases, showed an aberrant cytokeratin 7 and 
cytokeratin 20 immunophenotype. A previous study of BRAF mutant colorectal carcinomas 
showed similar aberrations(37), but were most evident in the microsatellite unstable group. 
This knowledge can be important when working up malignancies of unknown origin, but is 
not informative in the diagnosis of individual polyps.  
Perhaps the most important feature of the advanced traditional serrated adenomas was 
the almost uniform retention of staining for MLH1, replicating the findings of a recent 
publication restricted to advanced traditional serrated adenomas, in which no loss of 
mismatch repair function was observed in 60 cases.(15) This indicates a crucial biological 
difference in the pathways by which traditional serrated adenomas and sessile serrated 
adenomas with dysplasia progress to carcinoma. In the majority of sessile serrated 
adenomas with dysplasia, MLH1 silencing is a critical step in malignant progression, 
resulting in microsatellite instability and is associated with an improved prognosis.(38) In 
contrast essentially all colorectal carcinomas arising from traditional serrated adenomas 
are microsatellite stable. 
β-catenin is the final transcription factor of the Wnt signaling pathway; activation results in 
increased transcription of a variety of proliferation promoting genes.(39) In conventional 
chromosomal instability type colorectal carcinoma, the Wnt pathway is activated by APC 
mutation. However, APC mutation is uncommon in serrated pathway carcinomas, instead 
a variety of Wnt suppressors can be silenced by promoter methylation allowing activation 
of Wnt signaling.(39) A shift from membranous to nuclear staining of β-catenin is indicative 
of canonical Wnt pathway activation irrespective of cause and is an effective surrogate for 
identifying Wnt signaling. Advanced areas of the traditional serrated adenomas showed a 
highly significant increase in nuclear β-catenin staining, indicating Wnt pathway activation 
as an important step in malignant progression. This finding is concordant with other 
studies of advanced traditional serrated adenomas.(14, 15) 
TP53 and CDKN2A (encoding p16) are critical tumour suppressor genes with loss of 
function demonstrated in a wide range of malignancies. Strong nuclear staining for p53 is 
an effective surrogate for TP53 gene mutation and was seen in the majority of advanced 
traditional serrated adenomas in this series.(40) In contrast, increased cytoplasmic or 
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nuclear p16 staining indicates increased production of functional protein.(24) Normal colonic 
mucosa is p16 negative, whereas the basal crypts and the ectopic crypt formations of 
ordinary traditional serrated adenomas show weak and patchy p16 staining; advanced 
areas frequently show strong p16 expression. This incremental pattern is postulated to 
represent increasing efforts to control cell proliferation by up-regulation of CDKN2A 
expression. However, in the majority of BRAF mutant but not KRAS mutant or 
BRAF/KRAS wild type traditional serrated adenomas, p16 expression is abruptly lost in 
areas of dysplasia and/or carcinoma. This loss is attributed to methylation induced 
silencing of the CDKN2A gene and appears to be an important step in the development of 
adenocarcinoma in these polyps. TP53 mutation has been reported previously, both as a 
feature of BRAF mutant, microsatellite stable colorectal carcinoma and specifically in 
advanced traditional serrated adenomas.(14, 15, 33) However, to the best of our knowledge, 
loss of p16 staining has not previously been reported in advanced traditional serrated 
adenomas. A detailed outline of the proposed molecular pathways by which traditional 
serrated adenomas progress to carcinoma is provided in figure 4. 
 
This study has limitations. Firstly, the series is not consecutive, but instead includes cases 
that we considered classical traditional serrated adenomas. Our inclusion criteria are those 
we consider to be the most diagnostically specific. Admittedly, this is based on scant 
evidence and needs to be confirmed in a series specifically addressing diagnostic 
features. The 2008 paper of Torlakovic et al(13) is the best of this kind to date, but was 
limited to some extent by the nature of the study polyps, in particular, a limited number of 
tubulovillous adenomas resulting in a greater emphasis placed on ectopic crypt formations 
than perhaps is warranted. Secondly, our series has a definite bias towards larger polyps 
because ectopic crypt formations were selected as one of our inclusion criteria and 
because cases were only included if a complete molecular and immunohistochemical 
analysis could be performed. Generally, this is more achievable in larger polyps. This may 
have resulted in a greater proportion of advanced traditional serrated adenomas than 
might be seen in a consecutive series of traditional serrated adenomas. 
 
In our opinion, however, these weaknesses do not detract from the important conclusions 
of the study. Furthermore, the clinicopathological and molecular data are very similar to 
that presented in other recent large series.(15-17) Perhaps most relevant, in a recent study 
from our group that included 57 consecutive traditional serrated adenomas (1% of all 
colorectal polyps), the mean size (11mm), mean age (62), gender distribution (50% 
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female) and anatomical distribution (68% distal) were similar to what we see in this 
series.(10) Advanced histology was not recorded in that study for comparison. Given these 
similarities, we believe that the data presented here can be inferred to be a reasonable 
representation of traditional serrated adenomas generally. 
 
Conclusions 
In this study we have built on the current understanding of the morphology and molecular 
biology of the traditional serrated adenoma. The critical morphological findings are the 
definite occurrence of traditional serrated adenomas arising in sessile serrated adenomas 
and microvesicular hyperplastic polyps and the important distinction between this process 
and development of sessile serrated adenomas with dysplasia. In addition, overt dysplasia 
arising in a traditional serrated adenoma requires distinction from the senescent change 
seen in ordinary traditional serrated adenomas.  Thus we believe that the nomenclature of 
the traditional serrated adenoma should be unified with that of the sessile serrated 
adenoma, so that the diagnostic categories are traditional serrated adenoma (including 
traditional serrated adenoma arising in sessile serrated adenoma or microvesicular 
hyperplastic polyp) and traditional serrated adenoma with dysplasia (to encompass cases 
with a discrete focus of overt dysplasia). Similar to the sessile serrated adenoma, this 
approach will simplify the nomenclature and is also more representative of the underlying 
biology. 
 
At a molecular level, traditional serrated adenomas can be broadly divided into BRAF and 
KRAS mutant subtypes (with BRAF/KRAS wild type cases segregating better with KRAS 
mutant polyps). This distinction has clinicopathological and biological significance. BRAF 
mutant traditional serrated adenomas are more often proximal, are regularly associated 
with a precursor polyp and are more frequently CpG island methylator phenotype-high. 
Also, CDKN2A silencing appears to be critical to malignant progression of BRAF mutant 
traditional serrated adenomas but not KRAS or BRAF/KRAS wild type traditional serrated 
adenomas. 
 
More broadly, essentially all advanced traditional serrated adenomas show retention of 
MLH1 staining, implying a near universal microsatellite stable phenotype. This is expected 
for KRAS and BRAF/KRAS wild type traditional serrated adenomas but was unexpected 
for BRAF mutant cases. This finding is particularly important given that the BRAF mutant, 
microsatellite stable subtype of colorectal carcinoma is known to be highly aggressive. 
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Thus BRAF mutant traditional serrated adenomas are an important precursor of these 
aggressive cancers. 
At present advanced traditional serrated adenomas are not formally recognised. As such 
the surveillance guidelines issued by the US multi-society task force for colorectal 
carcinoma also do not include this entity.(41) Given the rarity of these polyps it is unlikely 
that high quality evidence to direct surveillance will become available; however based on 
our molecular results, advanced traditional serrated adenomas are potentially aggressive 
lesions and we believe that in the rare instances when these polyps are identified, 
complete resection with close surveillance is required.  
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Table 1. Clinicopathological features by advanced histology 
All traditional 
serrated 
adenomas 
(n=200) 
Ordinary 
traditional 
serrated 
adenomas 
(n=162) 
Advanced 
traditional 
serrated 
adenomas 
(n=38) 
P-value
(ordinary
versus
advanced)
Age 64 (27-89) 64 (27-89) 65 (27-85) 0.8069 
Female 50% 51% 45% 0.5891 
Mean size (mm) 16 (3-95) 
(median 12) 
14 (3-95) 
(median 11) 
25 (5-70) 
(median 21) 
<0.0001 
Distal location 71% 68% 82% 0.1153 
Precursor polyp 38% 44% 13% 0.0003 
- sessile serrated
adenoma
31% 36% 11% 0.0018 
- microvesicular
hyperplastic 
polyp 
7% 8% 3% 0.4769 
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Table 2. Clinicopathological features by mutation status 
Feature BRAF 
mutation 
(n=134) 
KRAS 
mutation 
(n=43) 
BRAF/KRAS wild-
type (n=23) 
P-value (BRAF
versus KRAS)
Age 64 (27-89) 65 (36-86) 62 (36-87) 0.8611 
Female 49% 49% 57% 1.000 
Mean size (mm) 14 (3-70) 
(median 12) 
18 (3-60) 
(median 13) 
20 (4-95) (median 
13) 
0.0550 
Distal location 61% 98% 74% <0.0001 
Precursor polyp 57% 0% 0% <0.0001 
- sessile serrated
adenoma
46% 0% 0% <0.0001 
- microvesicular
hyperplastic polyp 
10% 0% 0% 0.0233 
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Table 3. Inclusion criteria by polyp size 
Size Ectopic crypt formations Slit-like serrations Typical cytology 
Absen
t 
<50% >50% Absen
t 
<50% >50% Absen
t 
<50% >50%
<10mm 
(n=65) 
22% 49% 29% 2% 45% 54% 0 5% 95% 
>10mm
(n=135)
6% 41% 53% 2% 44% 54% 0 4% 96% 
P-value
(<10
versus
>/=10mm
)
0.0028 0.288
0 
0.001
5 
1.0000 1.000
0 
1.000
0 
1.0000 1.000
0 
1.000
0 
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Table 4. Flat morphology relative to location and mutation status 
Flat morphology All cases Proximal location Distal location 
All cases 76/200 (38%)  37/59 (63%)  39/141 (28%) 
BRAF mutant 57/134 (43%)  33/52 (64%) 24/82 (29%) 
KRAS mutant* 10/41 (24%) 0/1 (0%) 10/40 25% 
Wild type 9/23 (39%) 4/6 (67%) 5/17 (29%) 
P-value (BRAF 
versus KRAS 
mutant) 
0.0436 0.3774 0.6726 
*Location was not available for two of the KRAS mutant TSAs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
134
  
 
 
Table 5. Morphology of the advanced traditional serrated adenomas 
 Conventional morphology  Serrated morphology  
BRAF mutant   
- dysplastic component 4/19 15/19 
- invasive component 2/9 7/9 
KRAS mutant   
- dysplastic component 3/7 4/7 
- invasive component 0/4 4/4 
BRAF/KRAS wild type   
- dysplastic component 1/6 5/6 
- invasive component 0/2 2/2 
Note: The study cohort included 38 advanced traditional serrated adenomas, including 22 
with BRAF mutation, 10 with KRAS mutation and 6 BRAF/KRAS wild type. In some polyps 
both dysplasia and carcinoma were present and these components were assessed 
separately. In all cases displaying both dysplasia and carcinoma the two components had 
the same morphology. 
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Table 6. Immunohistochemistry results of ordinary and advanced traditional serrated 
adenomas and control tubulovillous adenomas 
Antibody Ordinary 
traditional 
serrated 
adenoma 
(n=162) 
Advanced 
traditional 
serrated 
adenoma (n=38) 
Tubulovillous 
adenoma (n=50) 
P-value 
(ordinary 
versus 
advanced) 
MLH1 loss*     
- all polyps 0% 3% 0% 0.35 
- BRAF mutant  0% 5%   0.31 
- KRAS 
mutant  
0% 0%  1.000 
- BRAF/KRAS 
wild type 
 
0% 0%  1.000 
Nuclear β-
catenin*  
    
- all polyps 7%  39% 84% <0.0001 
- BRAF mutant 5%  32%   0.0011 
- KRAS 
mutant 
12%  60%  0.0048 
- BRAF/KRAS 
wild type  
 
6%  50%  0.0401 
P53*      
- all polyps 6%  55%  10%  <0.0001 
- BRAF mutant 7%  45%   <0.0001 
- KRAS 
mutant 
0% 70%  <0.0001 
- BRAF/KRAS 
wild type  
 
6%  67%  0.0078 
P16*      
- all polyps 73% 63%  86% 0.24 
- BRAF mutant 74%  45%   0.0113 
- KRAS 
mutant 
76%  90%  0.6591 
- BRAF/KRAS 
wild type  
 
59% 83%  0.3690 
Ki67*      
- all polyps 53% 84%  92%  0.0004 
- BRAF mutant 59%  82%   0.0056 
- KRAS 
mutant 
33% 90%   0.0027 
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- BRAF/KRAS
wild type
53% 83% 0.3401 
CK7*  
- all polyps 38% 32% 16% 0.5758 
- BRAF mutant 40% 36% 0.8147 
- KRAS
mutant
48% 20% 0.1529 
- BRAF/KRAS
wild type
0% 33% 0.0593 
CK20*  
- all polyps 98% 79% 92% 0.0002 
- BRAF mutant 97% 73% 0.0006 
- KRAS
mutant
97% 90% 0.2874 
- BRAF/KRAS
wild type
100% 83% 0.2609 
*Immunohistochemical scoring as per materials and methods
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Figure Legends 
 
Figure 1. (a) and (b) BRAF mutant traditional serrated adenoma from the rectum with 
typical villiform projections. (b) Higher power better demonstrating typical cytology, slit-like 
serrations (arrowheads) and ectopic crypt formations (arrows). (c) and (d) BRAF mutant 
traditional serrated adenoma from the sigmoid colon with flat growth pattern. Sessile 
serrated adenoma-type crypts underlie traditional serrated adenoma with typical cytology 
and slit-like serrations better demonstrated at higher power in (d). (e) and (f) KRAS mutant 
traditional serrated adenoma from the rectum with flat growth pattern. (f) Higher power of 
(e) showing ectopic crypt formations (arrowheads) and typical cytology in the surface 
epithelium. 
 
Figure 2. (a) and (b). A protuberant BRAF mutant traditional serrated adenoma from the 
sigmoid colon with adjacent sessile serrated adenoma better demonstrated at higher 
power in (b). (c) A small but protuberant BRAF mutant traditional serrated adenoma from 
the rectum arising from a microvesicular hyperplastic polyp. (d) An advanced BRAF 
mutant traditional serrated adenoma from the transverse colon (left) with abrupt transition 
(arrow) to high grade serrated dysplasia (right). This polyp also had a small focus of 
invasive carcinoma (not shown); however note the carcinoma within the lymphatics of the 
mucosa and submucosa (asterisks). 
 
Figure 3. (a) High power of the normal β-catenin staining pattern in an ordinary traditional 
serrated adenoma. Note the distinct membrane staining without cytoplasmic or nuclear 
staining, including in the ectopic crypt formations. (b) Abnormal pattern of β-catenin in an 
area of carcinoma showing strong nuclear and cytoplasmic staining. (c) Traditional 
serrated adenoma showing strong nuclear p53 staining in the advanced component (left) 
and lack of staining in the ordinary component (right). (d) Traditional serrated adenoma 
showing positive staining for p16 in the ordinary component (left), particularly in the 
proliferative basal compartment and abrupt loss of staining in the advanced component 
(right). 
 
Figure 4. Proposed molecular pathways of malignant progression in BRAF and KRAS 
mutant traditional serrated adenoma. 
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Chapter 4: Clinicopathological and molecular features of sessile serrated adenomas 
with dysplasia and carcinoma differ by mismatch repair status 
Submitted 
Relevance to aims of the thesis: 
This chapter addresses parts of aims 3, 4 and 6. As demonstrated in chapter 2, the sessile 
serrated adenoma is a common polyp.1-3 It is the precursor of the majority of serrated 
neoplasia pathway carcinomas and may also be the precursor of a disproportionate 
number of interval colorectal carcinomas.4, 5 Advanced sessile serrated adenomas (sessile 
serrated adenomas with dysplasia and/or carcinoma) are rare polyps.2, 6 As a result we do 
not have a clear picture of the clinicopathological and molecular features of these polyps. 
In particular the mismatch repair enzyme status of advanced sessile serrated adenomas is 
critical to their subsequent development;7, 8 however the frequency of this occurrence is 
not known and the clinicopathological implications of mismatch repair deficiency versus 
mismatch repair proficiency have not been investigated. These are important issues, as 
mismatch repair proficient advanced sessile serrated adenomas give rise to an aggressive 
subtype of colorectal carcinoma.9, 10 A thorough understanding of the clinical, pathological 
and molecular features of these polyps may help to prevent these cancers. 
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Abstract 
Background and Aims: Sessile serrated adenomas (SSA) are now recognized as 
important precursors of colorectal carcinoma but their biology is still incompletely 
understood.  Study of the rare SSAs “caught in the act” of malignant transformation may 
provide insight into this process. The aim of this study was to perform a detailed 
clinicopathological and molecular analysis of a large number of advanced sessile serrated 
adenomas defined as sessile serrated adenomas (SSA) with dysplasia and/or carcinoma 
and to better define the pathways by which they progress to colorectal carcinoma.  
Methods: This study represents a prospective series of 137 advanced SSAs diagnosed at 
a community gastrointestinal pathology practice in Brisbane, Australia. We performed a 
clinicopathological and molecular assessment of all cases. Molecular features included 
BRAF and KRAS mutation testing, CpG island methylator phenotype (CIMP) status (IGF2, 
RUNX3, CACNA1G, NEUROG1, SOCS1) and immunohistochemistry for MLH1, p53, p16, 
β-catenin, Ki67, MGMT. 
Results: The mean age of the study patients was 75.4 years and 60.6% were female. The 
median polyp size was 9mm and 86.5% occurred in the proximal colon. BRAF V600E 
mutation was present in 92.7% and KRAS Codons 12 and 13 mutations in 0.7%. 94.0% 
were CIMP-high. 74.5% of cases lost expression of MLH1 indicating mismatch repair 
deficiency (MMRD). MMRD cases had significantly different clinicopathological and 
molecular features compared to mismatch repair proficient (MMRP) cases. MMRD cases 
occurred at an older age (76.8 versus 71.5 years; p=0.0036), were more common in 
women (69.3% versus 36.1%; p=0.0007), were more often proximal (91.5% versus 71.9%; 
p=0.0130), were more often CIMP-high (98.0% versus 86.1%; p=0.0137) and were less 
likely to show staining for p53 (6.9% versus 33.3%; p=0.0003). Loss of expression of p16 
and MGMT and gain of nuclear β-catenin staining were common in both groups. 
Conclusions: Advanced SSAs are predominantly small polyps (<10mm) and are most 
frequently found in individuals in their eighth decade. They can be divided into two major 
subtypes based on their mismatch repair status. MMRD status is associated with older 
age, female gender and proximal location and these polyps are the likely precursors of 
MMRD carcinomas with good prognosis.  Both subtypes are strongly associated with 
mutation in BRAF rather than KRAS. Activation of the WNT signaling pathway and 
silencing of the p16/RB tumor suppressor pathway occurs in both subtypes as they 
progress towards malignancy.  Inactivation of the TP53 tumour suppressor is associated 
with the MMRP pathway, which has been shown to have a worse clinical prognosis. 
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Introduction 
The serrated neoplasia pathway is a major contributor to colorectal carcinoma, with 
approximately 25% of cases arising via this route.1-4 These cancers have their origins in 
serrated polyps, including sessile serrated adenomas (SSA) and traditional serrated 
adenomas (TSA).4, 5 Of these, the SSA is by far the most prevalent and accounts for the 
majority of serrated neoplasia pathway carcinomas. 
Sessile serrated adenomas tend to be subtle polyps that can be difficult to detect 
colonoscopically, are frequently incompletely excised and have the hypothesized potential 
for rapid malignant degeneration.4, 6-8 For the pathologist, misdiagnosis or under-diagnosis 
of SSA as a microvesicular hyperplastic polyp remains an issue.9-13 This combination of 
factors has substantial clinical implications, the most significant of which is interval 
carcinoma. This can occur due to missed lesions, incompletely excised lesions, rapid 
progression of de novo lesions or inadequate surveillance due to misdiagnosis by the 
pathologist. Several studies have demonstrated that serrated pathway carcinomas are 
over-represented amongst interval cancers, confirming that some, if not all, of these 
factors are contributing to this occurrence.14, 15  
SSAs occur predominantly in the proximal colon and in older women.9, 16 At colonoscopy 
they are subtle, sessile lesions with a “cloud-like” surface.17 They are frequently covered 
by a mucus cap and rimmed by bubbles and debris.18, 19 The borders of the SSA can be 
difficult to identify.7 Histologically they are characterised by abnormal crypt architecture, 
but without overt cytological dysplasia in the early form of the lesion.16, 20 Oncogenic 
mutation of the BRAF gene and development of the CpG island methylator phenotype 
(CIMP) are characteristic molecular features.21, 22 Progression to the sessile serrated 
adenoma with dysplasia (SSAD) heralds an aggressive phase in polyp development and is 
accompanied by underlying molecular events.23, 24 The most common of these is 
methylation induced silencing of the tumour suppressor gene MLH1, resulting in loss of 
immunohistochemical expression of the MLH1 protein and DNA mismatch repair 
deficiency (MMRD). Loss of mismatch repair function allows for a rapid accumulation of 
mutations in genes with microsatellites (particularly microsatellites composed of mono and 
bi-nucleotide repeats) and thus underlies microsatellite instability (MSI). The proportion of 
advanced SSAs that are MMRD is not clear. In the literature, based on either MLH1 loss 
by immunohistochemistry or by significant MLH1 promoter methylation, this ranges 
between 15 and 72%.23, 25-27 However, these studies are often confounded by small size 
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and older methods of polyp classification. Colonoscopically, the dysplastic component of 
SSADs can be difficult to detect.8, 28 Although an exophytic component has been proffered 
as evidence of the development of dysplasia,28 particularly in large SSAs,29 this has not 
been confirmed in more inclusive series.  
Despite these advances, much remains unknown and there has been no large study of the 
clinicopathological and molecular features of SSAs with a focus of dysplasia and/or 
carcinoma. In particular it is unclear what percentage of advanced SSAs methylate MLH1. 
This is of critical importance as this feature underscores the MSI status of the resultant 
carcinomas and has major implications for treatment and prognosis.30-32 BRAF mutated, 
microsatellite unstable cancers may not respond to conventional chemotherapy but have a 
good prognosis, whereas BRAF mutated, microsatellite stable cancers have a very poor 
prognosis.30, 31, 33, 34 Additionally the contribution of p16, WNT pathway activation and 
TP53 mutation have not been thoroughly addressed in a large series of advanced SSAs. 
Herein we investigated the clinicopathological and molecular features of a series of 137 
advanced SSAs, with a particular emphasis on the dichotomy between mismatch repair 
deficient (MMRD) and mismatch repair proficient (MMRP) cases. 
Materials and Methods 
Case Selection and Study Design 
This study represents a prospective series collected by one of the authors (NW) during 
routine reporting over a period of six years at Envoi Specialist Pathologists in Brisbane, 
Australia. Envoi is a high-volume community gastrointestinal pathology practice, staffed by 
expert gastrointestinal pathologists. Referral cases were not included in the study. All 
potential cases underwent pathological review by two of the authors (MB and NW). For 
inclusion the cases were required to show 1) a component of ordinary SSA at the edge of 
the lesion comprising at least three crypts, one of which must show SSA-type histology9; 
2) an abrupt transition from ordinary SSA to overt cytological dysplasia or carcinoma within
the one tissue fragment and 3) exclusion of cases representing TSA arising in an SSA.35
These criteria were used to ensure that the series represented a homogenous group.
Criteria one was designed to guarantee origin in an SSA, criteria two to ensure that the
dysplasia or carcinoma was arising in the SSA of interest rather than being from a
separate conventional adenoma collected in the same specimen jar and criteria three to
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exclude the recently described phenomenon of TSA arising in an SSA.35-37 TSA arising in 
SSA can be easily misdiagnosed as SSAD but is a separate entity with distinct 
clinicopathological and biological features, thus requiring exclusion from the current 
study.35 Cases were additionally excluded if there was insufficient material to perform the 
molecular and immunohistochemical analysis. The cases included lesions removed either 
colonoscopically or by surgical resection and included lesions clinically considered as 
polyps as well as overt carcinomas. Patients with serrated polyposis syndrome were not 
excluded. 
Ethics approval was obtained from the ethics committee of the QIMR Berghofer Medical 
Research Institute (P1298). 
Clinicopathological Data Collection 
Clinical data included patient age and gender, lesion size and lesion location. Lesion 
location was divided into proximal (proximal to the splenic flexure) and distal (including and 
distal to the splenic flexure). Pathological data included the nature of the advanced 
component (dysplasia and/or carcinoma), the size of the advanced components and the 
growth pattern of the advanced component (flat versus exophytic). Carcinoma was defined 
as invasion into the submucosa and specifically excludes intramucosal carcinoma (which 
is included with the dysplastic cases). The advanced component was diagnosed as flat if it 
was less than twice the height of the adjacent SSA. 
Immunohistochemistry 
Immunohistochemistry was performed for MLH1, p53, β-catenin, p16, Ki67 and MGMT as 
previously described on all cases.35  
DNA Extraction 
The DNA extraction was performed on three 10um sections cut from the formalin fixed 
paraffin embedded blocks using the Chelex method as previously described.35  
Molecular Analyses 
All cases were assessed for the BRAF V600E mutation by allelic discrimination and for 
KRAS codons 12 and 13 mutations by high resolution melt analysis as previously 
described.35, 38
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The CIMP status of all cases was assessed using the panel of Weisenberger et al, 
(SOCS1, NEUROG1, RUNX3, IGF2, CACNA1G) by quantitative methylation specific PCR 
as previously described.38 P16, MLH1 and MGMT were also assessed using this 
technique.35 CIMP high required a PMR of >10 in three of the five Weisenberger et al, 
markers. Methylation in the other assessed genes also required a PMR of >10. To ensure 
the validity of the results a Ct value of <23 and an Alu representative calculated 
concentration of >1000 was required.35, 39 
Statistical Analysis 
Categorical variables were compared by Fisher’s exact test and continuous variables by 
Student’s t-test. A p-value of ≤0.05 was considered significant. SPSS version 19, R 
version 3.0.2 and GraphPad Prism version 6.02 were used for statistical analyses. 
Results 
Final Case Mix 
A total of 137 advanced SSAs from 132 patients met the diagnostic inclusion criteria and 
had sufficient material for the immunohistochemical and molecular analyses. These 
included 96 SSADs, 31 SSADCs (sessile serrated adenoma with dysplasia and 
carcinoma) and 10 SSACs (sessile serrated adenoma with carcinoma). 129 were clinically 
recognised as polyps and 8 as carcinomas. 95 were removed colonoscopically and 42 by 
surgical resection. 
Clinicopathological Data 
The clinicopathological data is presented in table 1. The mean age of the patients was 
75.4 years and 61% were female. 86.5% of the polyps were proximal, the median polyp 
size was 9mm (mean 10.7mm) and 54% of the polyps were <10mm.  
By definition all cases had a component of cytological dysplasia, invasive malignancy or 
both. 123/129 cases clinically recognised as a polyp had a dysplastic component, with a 
median size of 3mm (mean 3.6mm). 33/129 cases clinically recognised as a polyp had an 
invasive component, with a median size of 4mm (mean 3.8mm). A protuberant growth 
pattern in any part of the advanced component was present in 22 (16%) of the cases; the 
remainder were flat.  There were no significant differences in the clinicopathological 
features between lesions with dysplasia only and those with an invasive component. 
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Further data regarding the specific location within the colorectum is given in Table 2.  
Although both MMRD and MMRP lesions were mostly proximal, a significant minority, 
especially of MMRP lesions, was found in the sigmoid colon and rectum. 
Immunohistochemical data 
The immunohistochemical data is presented in table 3. All lesions retained a component of 
ordinary SSA without dysplasia and this served as a baseline against which other 
components could be compared.  There were highly significant changes in the staining 
patterns between the ordinary and advanced components of the lesions for all 
immunohistochemical markers. This represented increased staining for β-catenin, p53 and 
Ki67 and loss of staining for MLH1, p16 and MGMT in the advanced components. 
Molecular data 
The molecular data is presented in table 4. 93% of the cases harboured a BRAF V600E 
mutation and 1% had a KRAS codon 12 or 13 mutation. CIMP-high was present in 93% of 
cases.  
Comparison of MMRD to MMRP lesions 
102 (74.5%) of the cases had lost staining for the mismatch repair enzyme MLH1 
indicating a MMRD phenotype. When comparing MMRD to MMRP cases, the MMRD 
cases occurred in older patients (mean age 76.8 versus 71.4; p=0.0033), more often in 
females (70% versus 34%; p=0.0003) and more often in the proximal colon (91% versus 
72%; p=0.0130).  
Table 5 compares the pattern of immunohistochemical staining in the advanced 
components of the lesions divided according to MMR status. MMRD cases were less likely 
to show positive p53 staining than MMRP cases (7% versus 34%; p=0.0002) and were 
more likely to have a high proliferative index (83% versus 69%; p=0.0172). There was no 
significant difference in the staining patterns of β-catenin or p16 between the MMRD and 
MMRP cases. 
MMRD cases were more likely to be CIMP-high than MMRP cases (98% versus 80%; 
p=0.0010) and more likely to show MLH1 methylation (94% versus 11%; p=<0.0001). 
MLH1 expression by immunohistochemistry correlated tightly with MLH1 methylation by 
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MethyLight (p<0.0001). MGMT methylation was not significantly different between the 
MMRD and MMRP groups (42% versus 29%; p=0.1663) but correlated tightly with 
immunohistochemical expression (p<0.0001). 
Discussion 
The SSA is the prototype polyp of the serrated neoplasia pathway and a major contributor 
to the burden of colorectal carcinoma. Thus a thorough understanding of the biology of 
these polyps is critical to improving patient management. This series has addressed 
important issues relating to the clinicopathological and molecular features of advanced 
SSAs with a particular emphasis on the important division between MMRD and MMRP 
cases.  
This study includes only cases diagnosed using strict histological criteria after central 
pathological review by expert gastrointestinal pathologists. This ensures a pure cohort of 
advanced SSAs without contamination by other polyp types. In particular, cases of TSA 
arising in an SSA and admixed tubular adenoma and ordinary SSA have been carefully 
excluded.35 Furthermore this series has sufficient numbers of these rare polyps to identify 
statistically significant subgroups. 
A major problem for colonoscopists is the occurrence of interval colorectal carcinoma. As 
discussed, the factors that may contribute to this event include missed lesions, 
incompletely excised lesions, rapid progression of de novo lesions and inadequate 
surveillance intervals due to pathological misdiagnosis.7-9 For some, if not all of these 
reasons, serrated pathway carcinomas are over-represented in series of interval 
carcinomas. In this series we have identified an additional worrying feature: advanced 
SSAs are predominantly small polyps (54% <10mm).   Small SSAs are more difficult to 
detect than large SSAs, and thus are more likely to be missed at colonoscopy. This is a 
particular concern given the hypothesized potential for advanced SSAs to undergo rapid 
malignant degeneration. Furthermore some colonoscopists may assume that the 
dysplastic component of an SSAD is protuberant making these lesions more obvious 
endoscopically.29 Unfortunately this does not appear to be the case, with only 16% of the 
advanced components showing a protuberant growth pattern. This misconception may 
have developed because of the misdiagnosis of TSA arising in SSA as an SSAD, in which 
the TSA component will frequently display protuberant growth. In most instances the only 
endoscopic clue to the advanced component of an SSA will be a change in the nature of 
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the pit pattern, usually from a Kudo type IIa to a Kudo type III or IV.28, 40 However, because 
the advanced component may be very small, this may be missed. 
Apart from the small size and flat nature of most of the advanced SSAs in this series, 
numerous other clinicopathological features have been demonstrated. Many of these are 
expected based on previous studies of either ordinary SSAs or of BRAF mutated 
carcinomas.41-43 In particular, the older age and the female predominance of the patients 
were confirmed and the predilection for the proximal colon was again striking.  
Due to their prognostic and predictive significance, the BRAF mutation status and MMR 
function of colorectal carcinomas are likely to be routinely incorporated into pathology 
reports at some stage in the future. In fact, many pathology practices, including our own, 
already perform reflexive mismatch repair immunohistochemistry on all new colorectal 
carcinoma diagnoses. A BRAF mutation effectively confirms the serrated origin of a 
colorectal carcinoma. The BRAF mutation status is also becoming increasingly relevant, 
as an adverse prognostic factor.44 This finding is particularly powerful when combined with 
the MMR status of the carcinoma. MMRD cancers have a microsatellite unstable 
phenotype, which confers a good prognosis. When combined with a BRAF mutation these 
cancers still tend to behave well with a reduced propensity to nodal and systemic 
metastases. In contrast, BRAF mutated and MMRP (microsatellite stable) tumours are the 
most aggressive molecular subtype of colorectal carcinoma.30, 31 
Because of this critical dichotomy between MMRD and MMRP serrated pathway 
carcinomas, these two groups were separated for the clinicopathological and molecular 
analyses. Many differences were identified and these may have relevance to patient 
management. At a clinicopathological level the most striking feature was the difference in 
gender distribution. Seventy percent of MMRD advanced SSAs occurred in females 
compared to only 34% of MMRP cases. In addition only 9% of MMRD cases arose in the 
distal colorectum compared to 28% of the MMRP cases. These findings should be borne 
in mind during screening/surveillance colonoscopy. In particular, SSAs in males tend to 
develop into an aggressive subtype of carcinoma. Furthermore, small and distal SSAs 
should not be disregarded, particularly in men. Troublingly, 13% of the MMRP advanced 
SSAs arose in the rectum. By contrast, none of the MMRD cases did so.  
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Ordinary SSAs (i.e. SSAs without dysplasia or malignancy) were not included in this study; 
however previous studies have examined the clinicopathological features of these polyps.9, 
43 In a recent study from our group that included 579 ordinary SSAs diagnosed using the 
criteria of the WHO Classification, the mean age was 58.6 years, 80% of polyps were 
proximal, 56% of the patients were female and the mean polyp size was 8.5mm.9 Thus it 
can be inferred that ordinary SSAs have a similar site and gender distribution to advanced 
SSAs but occur at a younger age and are slightly smaller. The lag between ordinary SSA 
and SSAD appears to be approximately 15 years. Importantly there is no significant 
difference in age of cases with dysplasia versus those with carcinoma. This provides 
further support to the theory that once dysplasia develops there can be a rapid progression 
to malignancy. 
 
In two recent studies of colorectal carcinomas, cases were separated according to 
BRAF/KRAS mutation and mismatch repair status.41, 42 In these series the BRAF mutated, 
MMRD cases occurred at a mean age of 66-67 years, in females in 69-83% of cases and 
in the proximal colon in 93-95% of cases. In contrast the BRAF mutated, MMRP cases 
occurred at a mean age of 63-64 years, in females in 59-71% of cases and in the proximal 
colon in 76-80% of cases. These groups show similar overall differences between the 
MMRD and MMRP cases as in this study but have a younger overall age and less striking 
gender difference to the current series.  
 
The molecular steps involved in the progression from ordinary SSA to cancer is an area of 
intensive research. BRAF mutation is an early and likely initiating event.21, 45 Recent 
evidence suggests that BRAF mutation then directs the development of CIMP.46 The 
occurrence of overt cytological dysplasia is usually accompanied by demonstrable 
molecular events. In MMRD cases, methylation induced silencing of the MLH1 gene 
occurs at this transition and MLH1 immunostaining is lost. In this study, MLH1 promoter 
methylation as measured by quantitative methylation specific PCR (MethyLight), correlated 
tightly with the presence or absence of immunohistochemical staining.  
 
Besides methylation of MLH1, other oncogenic pathways are also involved in serrated 
neoplasia. WNT pathway activation is present in approximately 95% of colorectal 
carcinomas, although the precise role of WNT signaling in SSAs is not clear. Several 
studies have utilised immunohistochemistry for β-catenin to assess this issue. β-catenin is 
the final transcription factor of the canonical WNT signaling pathway and as such is a 
155
  
useful surrogate marker for WNT pathway activation. A shift from the normal 
(membranous) pattern of staining to nuclear staining indicates activation of the WNT 
pathway. Most studies addressing the topic have demonstrated nuclear β-catenin staining 
in a proportion of SSADs, although the range is quite variable (50-100%).47-49 In a 
thorough recent paper, strong or intermediate staining was demonstrated in 60.9% of 
advanced SSAs (similar to our results) and correlated with methylation of the upstream 
WNT antagonists SFRP, MCC and AXIN2.49 This upstream methylation is postulated to be 
the mode of WNT pathway activation in the serrated neoplasia pathway.49-51 In the current 
series nuclear β-catenin staining was uncommon in the ordinary SSA component, 
consistent with previous results, and supporting the notion that WNT signaling is not a 
major factor in the development of SSAs as compared to conventional adenomas.  
However it became frequent in the dysplastic and invasive components of both the MMRD 
and MMRP lesions, further supporting the concept that WNT signaling plays a role in polyp 
progression. 
 
Methylation induced silencing of CDKN2A (encoding p16) is also postulated to play a role 
in progression to malignancy in serrated pathway carcinomas.1 P16 is an important tumour 
suppressor that can induce cell cycle arrest at the G1/S checkpoint in response to 
uncontrolled proliferation. Immunohistochemistry for the p16 protein has been 
demonstrated to be an effective method to interrogate the function of this critical tumour 
suppressor gene. Kriegl et al, have previously demonstrated aberrant p16 staining in 
advanced SSAs.52 In that study they showed increasing p16 expression until the 
development of either high-grade dysplasia or invasive carcinoma, when it was suddenly 
lost in a definite subset of cases, presumably secondary to methylation induced silencing. 
We have previously demonstrated loss of p16 staining late in the malignant progression of 
BRAF mutated (but not KRAS mutated) TSAs.35 Similarly in the current study, loss of p16 
staining tended to occur at a late stage in the progression of advanced SSAs, often at the 
histological step between high-grade dysplasia and carcinoma. There is evidence this is 
due to methylation induced silencing of gene expression.  Despite the difference in CIMP-
high status between MMRD (98%) and MMRP (80%) cases, the rates of p16 loss were 
almost identical between the two groups.  
 
TP53 is a critical tumour suppressor gene. Mutation was assessed using the surrogate of 
p53 immunohistochemistry. Most substitution mutations of TP53 result in markedly 
increased nuclear expression by immunohistochemistry.53 In contrast, nonsense mutations 
156
and insertions/deletions frequently result in absent expression. Overall, p53 
immunohistochemistry has a specificity of 90% and sensitivity of 67% for detecting TP53 
mutation.53 Bond et al, demonstrated significant differences in TP53 mutation rates 
between BRAF mutated microsatellite stable and unstable carcinomas (40.6% versus 
16.9%), with the microsatellite stable group having more frequent mutation.34 This study is 
in agreement with this finding and the presence of a TP53 mutation may be part of the 
explanation for the poor prognosis associated with the MMRP cancers.  
The role of MGMT in advanced SSAs is less clear and has not been extensively 
examined. In this study 28% of cases had areas with loss of staining for MGMT by 
immunohistochemistry. This correlated very tightly with MGMT promoter methylation by 
MethyLight, indicating that methylation induced silencing is a major mode of inactivation. 
MGMT is a DNA repair enzyme separate from the mismatch repair system. It has been 
correlated with KRAS mutations previously, but obviously this is not a factor in SSAs.54, 55 
Loss of function of MGMT may allow additional accumulation of mutations in advanced 
SSAs and as such may contribute to malignant progression in these polyps. 
Mismatch repair proficient SSAs and advanced BRAF mutated TSAs share some 
molecular similarities. In a previous study of TSAs we demonstrated nuclear staining for β-
catenin and p53 and loss of staining for p16 in 32%, 45% and 55% of cases respectively.35 
This is similar to the MMRP SSAs in this study (54%, 34% and 43% respectively). 
Furthermore, both of these polyps give rise to the aggressive BRAF mutated microsatellite 
stable subtype of colorectal carcinoma. Given that the majority of BRAF mutated TSAs 
appear to arise in a pre-existing SSA, it is possible that the MMRP advanced SSAs have 
‘skipped’ the TSA stage in their evolution but are ultimately similar polyps. 
This study does have weaknesses. Firstly, some cases were excluded because of 
insufficient material in the blocks for complete analysis. However, this is unlikely to have 
adversely impacted on the key clinicopathological and molecular findings. If anything, the 
requirement for adequate material will have resulted in a bias towards larger polyps. 
Second, the cases were not microdissected for separate molecular analysis between the 
ordinary and advanced components of the polyps. This is unlikely to have had a material 
impact on the results as BRAF mutation status and CIMP are established early, although it 
is possible that CIMP continues to evolve as the polyps’ progress. Because 
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immunohistochemistry stains at a single cell level, microdissection is not required when 
using this technique. 
 
In summary we have addressed the clinicopathological and molecular features of a large 
series of advanced SSAs with a focus on differences between MMRD and MMRP cases. 
We found that advanced SSAs are mostly small polyps. Although a minority, MMRP cases 
are the precursors of an aggressive subtype of colorectal carcinoma. They occur more 
often in men at a younger age than MMRD cases and a significant subset occur distally. 
Malignant progression of advanced SSAs occurs through a combination of MLH1 and 
CDKN2A silencing, WNT pathway activation and TP53 mutation. These findings may have 
clinical implications. At present the surveillance guidelines for SSAs, as per the US Multi 
Society Task Force, recommend a 5 year surveillance interval after a diagnosis of an 
ordinary SSA <10mm and a 3 year surveillance interval after a diagnosis of either an 
SSAD or an ordinary SSA >10mm. Given the demonstrable molecular events evident in 
SSADs and the frequent small size of these lesions, in our view, the SSAD is a higher risk 
lesion than a large ordinary SSA and may warrant closer surveillance.  
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Table 1. Clinicopathological features of study lesions 
Feature All 
cases 
MMRD 
(all) 
(n=102) 
MMRD 
SSAD 
(n=66) 
MMRD 
SSAD/C 
(n=36) 
MMRP 
(all) 
(n=35) 
MMRP 
SSAD 
(n=30) 
MMRP 
SSAD/C 
(n=5) 
P-
values 
(MMRD 
versus 
MMRP) 
Age 75.4 76.8 77.5 75.5 71.4 71.3 72.0 0.0033 
Gender 
(female) 
83 
(61%) 
71 
(70%) 
46 
(70%) 
25 
(69%) 
12 
(34%) 
11 
(37%) 
1 (20%) 0.0003 
Location* 109/126 
(87%) 
86/94 
(91%) 
55/58 
(95%) 
31/36 
(86%) 
23/32 
(72%) 
18/27 
(67%) 
5/5 
(100%) 
0.0130 
Median 
size# 
9 9 9 11 8.5 9 8 
Mean 
size# 
10.7 11.1 11.1 11.1 9.5 9.3 11.0 0.1950 
Size 
<10mm# 
70/129 
(54%) 
47/95 
(49%) 
36/66 
(55%) 
12/29 
(41%) 
22/34 
(65%) 
18/29 
(62%) 
4/5 
(80%) 
0.1668 
*11 cases did not have location data
#excludes 8 cases presenting clinically as a carcinoma
MMRD – mismatch repair deficient; SSAD – sessile serrated adenoma with dysplasia;
SSADC/C– sessile serrated adenoma with dysplasia and carcinoma or sessile serrated
adenoma with carcinoma; MMRP – mismatch repair proficient;
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Table 2. Specific location of the study polyps 
Location C AC HF TC SF DC SC R 
All (n=112)* 15 
(13%) 
33 
(29%) 
7 (6%) 41 
(37%) 
2 (2%) 6 (5%) 4 (4%) 4 (4%) 
MMRD 
(n=81)* 
14 
(17%) 
23 
(28%) 
5 (6%) 31 
(38%) 
2 (2%) 4 (5%) 2 (2%) 0 (0%) 
MMRP 
(n=31)* 
1 (3%) 10 
(32%) 
2 (6%) 10 
(32%) 
0 (0%) 2 (6%) 2 (6%) 4 (13%) 
C – caecum; AC – ascending colon; HF – hepatic flexure; T – transverse colon; SF – 
splenic flexure; D – descending colon; S – sigmoid colon; R – rectum 
*25 cases did not have a specific location provided
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Table 3. Immunohistochemical features of the lesions divided into ordinary and advanced 
components. 
Stain Ordinary SSA component 
(n=137) 
Advanced components 
(n=137) 
P-value
MLH1 loss 0 (0%) 102 (75%) <0.0001 
P16 loss 13 (9%) 59 (43%) <0.0001 
Positive nuclear β-
catenin 
15 (11%) 76 (55%) <0.0001 
Positive p53 0 (0%) 19 (14%) <0.0001 
Positive Ki67 0 (0%) 107 (78%) <0.0001 
MGMT loss 11 (8%) 38 (28%) <0.0001 
SSA – sessile serrated adenoma 
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Table 4. Molecular features of the study lesions 
Molecular 
feature 
All 
(n=137
) 
MMRD 
(n=102
) 
MMR
D 
SSAD 
(n=66) 
MMRD 
SSADC/
C (n=36) 
MMR
P 
(n=35) 
MMR
P 
SSAD 
(n=30) 
MMRP 
SSADC/
C 
P-value
(MMRD
versus
MMRP)
BRAF 
mutation 
127 
(93%) 
95 
(93%) 
60 
(91%) 
35 (97%) 32 
(91%) 
28 
(93%) 
4 (80%) 0.7154 
KRAS 
mutation 
1 (1%) 1 (1%) 1 (2%) 0 0 0 0 1.000 
CIMP-H 128 
(93%) 
100 
(98%) 
64 
(97%) 
36 
(100%) 
28 
(80%) 
24 
(80%) 
4 (80%) 0.0010 
MLH1 
methylatio
n 
100 
(73%) 
96 
(94%) 
61 
(92%) 
35 (97%) 4 
(11%) 
3 
(10%) 
1 (20%) <0.000
1 
MGMT 
methylatio
n 
53 
(39%) 
43 
(42%) 
26 
(39%) 
17 (47%) 10 
(29%) 
10 
(33%) 
0 0.1663 
MMRD – mismatch repair deficient; MMRP – mismatch repair proficient; SSAD – sessile 
serrated adenoma with dysplasia; SSADC – sessile serrated adenoma with dysplasia and 
carcinoma or sessile serrated adenoma with carcinoma 
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Table 5. Comparison of the immunohistochemical staining patterns of the 
MMRD versus MMRP cases 
IHC stain MMRD (n=102) MMRP (n=35) P-value (MMRD
versus MMRP)
P16 loss 44 (43%) 15 (43%) 1.000 
Positive B-
catenin 
57 (56%) 19 (54%) 1.000 
Positive P53 7 (7%) 12 (34%) 0.0002 
Positive Ki67 85 (83%) 22 (63%) 0.0172 
Positive MGMT 28 (28%) 10 (29%) 1.000 
MMRD – mismatch repair deficient; MMRP – mismatch repair proficient; IHC - 
immunohistochemical 
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Figure legend 
Figure 1. (A) A low power image of a sessile serrated adenoma with dysplasia from the 
proximal colon, demonstrating the frequent small size and flat nature of these polyps. (B) A 
low power image of a larger and protuberant sessile serrated adenoma with dysplasia. 
This appearance is much less common. 
Figure 2. A mismatch repair deficient (A) and a mismatch repair proficient (B) sessile 
serrated adenoma with dysplasia. Both polyps show an abrupt transition from ordinary 
sessile serrated adenoma to overt cytological dysplasia. (C) and (D) are the MLH1 
immunohistochemical stains for each case. Note the loss of staining in (C) compared to 
the retained nuclear expression in (D). (E) and (F) demonstrate the p53 
immunohistochemical staining patterns for the same lesions. The overexpression in (F) is 
indicative of TP53 mutation and highlights a major difference between mismatch repair 
deficient and mismatch repair proficient cases. 
Figure 3. (A) A medium power image of a p16 immunohistochemical stain of a sessile 
serrated adenoma with dysplasia. There is markedly increased staining for p16 in the 
dysplastic area, presumably representing cellular efforts to prevent uncontrolled 
proliferation. (B) A medium power image of a different polyp containing dysplasia (right) 
and carcinoma (left). In this case there is abrupt loss of staining at the transition to 
carcinoma. (C) A medium power magnification of the same area as image (B) this time 
showing β-catenin staining. Scattered nuclear staining is present in the dysplasia but 
becomes uniform in the carcinoma, indicative of WNT pathway activation. 
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Chapter 5: Serrated tubulovillous adenoma of the large intestine 
Under revision (minor) - Histopathology 
Relevance to aims of the thesis: 
This chapter addresses aim 5. At times the distinction of traditional serrated adenomas 
from a subset of tubulovillous adenomas can be difficult.1, 2 In the current pathology 
literature ectopic crypt formations are particularly emphasised as a feature of traditional 
serrated adenomas.3 However a subset of tubulovillous adenomas have ectopic crypt 
formations, along with other features of serration and thus can be difficult to distinguish 
from traditional serrated adenomas. Thus we gathered a consecutive series of 
tubulovillous adenomas with prominent serration and compared these polyps to both 
traditional serrated adenomas and to ordinary tubulovillous adenomas. We aimed to 
identify histological features that could reliably separate these polyps from the control 
groups and to determine if they had molecular features of serrated polyps, in particular 
MAP kinase pathway activation and the CpG island methylator phenotype. 
1. Hafezi-Bakhtiari S, Wang LM, Colling R, Serra S, Chetty R. Histological overlap
between colorectal villous/tubulovillous and traditional serrated adenomas. Histopathology.
2014.
2. Bettington ML, Walker NI, Rosty C, et al. A clinicopathological and molecular
analysis of 200 traditional serrated adenomas. Mod Pathol. 2015;28(3):414-27.
3. Torlakovic EE, Gomez JD, Driman DK, et al. Sessile serrated adenoma (SSA) vs.
traditional serrated adenoma (TSA). Am J Surg Pathol. 2008;32(1):21-9.
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ABSTRACT 
Aims: Most colorectal polyps are readily classified, but a subset of tubulovillous adenomas 
(TVA) with prominent serrated architecture cause diagnostic confusion. We aimed to 1) 
identify histological features that separate serrated TVAs from both conventional TVAs and 
traditional serrated adenomas (TSA) and 2) perform a clinicopathological and molecular 
analysis to determine if the serrated TVA has unique features. 
Methods: We collected 48 serrated TVAs, 50 conventional TVAs and 66 BRAF wild-type 
TSAs for analysis. For each polyp we performed a clinicopathological assessment, BRAF 
and KRAS mutation profiling, CpG island methylator phenotype status, MGMT methylation 
and immunohistochemical assessment of seven markers (MLH1, p16, p53, β-catenin, 
Ki67, CK7 and CK20). 
Results: We found that serrated TVAs can be reliably diagnosed and have features 
distinct from both conventional TVAs and TSAs. Compared to conventional TVAs, serrated 
TVAs are larger, more often proximal, more histologically advanced, show more CpG 
island methylation and more frequent KRAS mutation. Compared to TSAs, they are more 
often proximal, show less CpG island methylation, more frequent MGMT methylation and 
more frequent nuclear staining for β-catenin.  
Conclusions: The serrated TVA can be reliably diagnosed and has unique features. It 
represents a precursor of KRAS mutated, microsatellite stable colorectal carcinoma.  
Key words: Colonic Polyps, Adenoma, Serrated, Tubulovillous Adenoma, Traditional 
Serrated Adenoma  
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INTRODUCTION 
Neoplastic colorectal epithelial polyps fall into two major groups, conventional adenomas, 
comprising tubular adenomas (TA), tubulovillous adenomas (TVA) and villous adenomas 
(VA) and serrated polyps, comprising hyperplastic polyps (HP), sessile serrated adenomas 
(SSA) and traditional serrated adenomas (TSA).1 It is becoming accepted that colorectal 
carcinomas can be divided into 5 molecular subtypes based on BRAF and KRAS mutation 
status, CpG island methylator phenotype (CIMP) and presence or absence of 
microsatellite instability (MSI).2, 3 These subtypes have important predictive and prognostic 
implications and particular polyp subtypes give rise to specific molecular subtypes of 
carcinoma. In general, serrated polyps give rise to BRAF mutated, CIMP-high colorectal 
carcinomas, whereas conventional polyps give rise to BRAF and KRAS wild-type, CIMP-
negative, microsatellite stable (MSS) carcinomas.4-6 The origins of KRAS mutated 
carcinomas are less clear. While many undoubtedly arise from TVAs, Jass et al, reported 
KRAS mutation as being associated with serrated architectural features.7  
We frequently encounter TVAs with serrated architecture, including ECFs, which give rise 
to serrated morphology colorectal carcinomas. These serrated tubulovillous adenomas 
(sTVA) have not been described in the pathology literature but appear morphologically 
distinct from both TSAs and conventional tubulovillous adenomas (cTVA). We anticipate 
that the sTVA is associated with KRAS mutation and is a precursor of KRAS mutated, 
MSS carcinomas. Furthermore, we feel that these polyps are sufficiently distinctive to 
allow reproducible diagnosis by pathologists. 
Thus this study has a two-part focus. First we aimed to identify histological features that 
separated sTVAs from both cTVAs and TSAs and then performed a clinicopathological 
and molecular characterization of these polyps, to determine if the sTVA had unique 
features. Finally, we assessed the molecular pathways by which sTVAs develop into 
colorectal carcinoma. 
MATERIALS AND METHODS 
Sample selection 
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Four polyp cohorts were established, comprising 2 cohorts of sTVAs and 2 control cohorts. 
Cohort 1 comprised consecutive sTVAs (n=27) selected from a series of 412 consecutive 
TVAs accrued between January 30, 2012 and April 29, 2012 at Envoi Specialist 
Pathologists in Brisbane, Australia as part of a separate study.8 Cohort 2 comprised 
sTVAs (n=21) collected during routine sign-out at Envoi Specialist Pathologists, selected 
specifically for the presence of either high-grade dysplasia and/or early carcinoma and 
used to better define the pathways by which sTVAs progress to carcinoma but were 
excluded from data used to compare the polyp groups to prevent selection bias. The 
control cohorts comprised 50 cTVAs (cohort 3), from the same series as cohort one and 
66 BRAF wild-type TSAs (cohort 4) from a separate previously published series.9 The 
control cohorts represent the polyps that are histologically most similar to the study series 
and those with which they are most often confused. The BRAF wild-type TSAs include 
cases with either a KRAS mutation (n=43) or that were BRAF/KRAS wild-type (n=23). 
BRAF mutated TSAs were not included as these lesions have a significantly different 
molecular biology to the study polyps.9  
The polyps were removed by any of polypectomy, endoscopic mucosal resection, 
transanal endoscopic microsurgery or colectomy. Proximal polyps came from sites 
proximal to the splenic flexure; distal polyps from sites including and distal to the splenic 
flexure. For the purposes of this study, advanced histology refers to either high-grade 
dysplasia or carcinoma. Because of the unique cytology of TSAs, advanced histology in 
these cases refers to the development of an area of overt high-grade cytological dysplasia 
or carcinoma in an otherwise typical TSA. Patients with a known history of inflammatory 
bowel disease or a polyposis syndrome were excluded. Patient age, gender, polyp size 
and anatomical location were collected from a combination of the pathology and 
endoscopic reports. The study was approved by the ethics committee of QIMR Berghofer 
Medical Research Institute (P1298). 
Histopathological Inclusion Criteria 
Criteria for the diagnosis of the sTVA have not been previously defined. For the purposes 
of this study sTVAs were diagnosed if they met all the following criteria: 1) >25% villous 
component, 2) morphological serration in >50% of the polyp and 3) TSA-type cytology and 
slit-like serrations in <10% of the polyp. 
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A villous structure is defined as a leaf-like or finger-like projection of epithelium overlying a 
small amount of lamina propria with at least a 25% component required to meet the WHO 
criteria for a diagnosis of TVA.1 Architectural serration included prominent undulation of 
the epithelial lining, ECFs or a maze-like growth pattern (Figures 1A-D). ECFs are 
increasingly recognised as not specific for the diagnosis of TSA.9, 10 It is also recognised 
that small components of TSA type cytology (<10%) can be seen in TVAs.10 In comparison 
with sTVAs, the cTVAs did not show these features in the majority of the polyp (Figure 
2A). The cytology of both the serrated and the conventional TVAs was similar, displaying 
overt dysplasia characterised by basally located, crowded oval nuclei, frequent mitoses 
and basophilic cytoplasm (Figure 2C).1 In contrast, the TSAs showed architectural 
serration and characteristic cytology, typified by cells with abundant intensely eosinophilic 
cytoplasm and centrally placed, palisaded, pencillate nuclei. Serrations were due to both 
ECFs and characteristic slit-like serrations, which refer to superficial sharp clefts in the 
epithelium similar to those seen in the normal small intestine (Figures 2B&D), more 
recently recognised as a specific feature of the TSA.5, 9-11 
 
All polyps included in the study were initially selected by the principal author (MB) and then 
further assessed in a blinded fashion by 3 of the study pathologists (NW, IB, CR) applying 
the criteria outlined above. Each pathologist was required to diagnose each polyp as either 
a cTVA, sTVA or TSA. A Light’s kappa value was ascertained to determine diagnostic 
reproducibility. 
 
After final selection of the cases an additional assessment was made for the presence of 
advanced histology (high-grade dysplasia and carcinoma) based on previously published 
criteria1, 12, 13 and required consensus between all four pathologists after review of the 
slides at a multi-header microscope.  High-grade dysplasia and carcinoma were then 
separately assessed for serrated morphology,1, 14 also requiring consensus between all 
four pathologists (Figures 3A&B).  
 
Immunohistochemistry 
 
Immunohistochemistry was performed using the formalin fixed paraffin embedded (FFPE) 
blocks.  Four micrometer sections were cut, dewaxed and rehydrated.  High pH antigen 
retrieval solution (pH9.0, Dako, Glostrup, Denmark) was used for MLH1, CK7, p16 and 
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Ki67 at 112°C for 7 minutes.  Low pH antigen retrieval solution (pH6.0, Biocare Medical, 
Concord, CA, USA) was used for β-catenin, p53 and CK20 also at 112°C for 7 minutes.   
 
All sections were manually stained following the manufacturers instructions. Antibodies 
used were: MLH1 (clone G168-15, 1:100, BD Pharmingen, Franklin Lakes, NJ, USA), β-
catenin (1:600, Cell Marque, Rocklin, CA, USA), p53 (clone DO-7, 1:150, Biocare Medical, 
Concord, CA, USA), p16 (clone JC8, 1:150, Santa Cruz Biotechnology, Dallas, Texas, 
USA), Ki67 (clone MIB-1, 1:100, Dako, Glostrup, Denmark), CK7 (clone OV-TL12/30, 
1:100, Dako, Glostrup, Denmark) and CK20 (clone Ks20.8, 1:150, Biocare Medical, 
Concord, CA, USA). Slides were counterstained with Mayer’s haematoxylin.  
  
Each marker was assessed for intensity and extent of staining in the following 
compartments as appropriate to the polyp subtype; basal zone, ECFs, eosinophilic cells, 
low-grade dysplastic components, high-grade dysplastic components and invasive 
carcinoma components as previously published.9 Intensity of staining was scored as 0-3 
(0=nil, 1=weak, 2=moderate, 3=strong) and extent of cells stained as 0-4 (0=nil, 1=1-10%, 
2=11-50%, 3=51-90%, 4=>90%). The final score was determined by multiplying the score 
for intensity and extent. 
 
Each marker was interpreted as previously published as follows.9 Abnormal MLH1 
expression required absence of nuclear staining in a distinct portion of the polyp. Abnormal 
β-catenin expression required nuclear staining with a score of ≥2 in any compartment. 
Positive p53 required nuclear staining with a score of ≥6 in any compartment.  Positive p16 
required either cytoplasmic or nuclear staining with a score of ≥3 in any compartment. 
Positive Ki67 required nuclear staining with a score of ≥9 in any compartment. Positive 
cytokeratin 7 and cytokeratin 20 required cytoplasmic staining with a score of ≥3 in any 
compartment. For cases without advanced histology the compartment with the highest 
score was used for analysis. For cases with advanced histology, the score in the areas of 
high-grade dysplasia or carcinoma was used for analysis. 
 
DNA Extraction 
 
DNA was extracted from the FFPE blocks using the Chelex-100 extraction method (Bio-
Rad Laboratories, Hercules, CA, USA) as previously described.9  
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BRAF and KRAS mutation detection 
The BRAF V600E mutation was detected by allelic discrimination as previously 
described.15 KRAS mutations were assessed by high-resolution melt analysis as 
previously described.16  
CpG Island Methylator Phenotype and MGMT Methylation Status 
CIMP status was determined using the gene panel of Weisenberger et al,17 (CACNA1G, 
IGF2, NEUROG1, RUNX3, SOCS1) as previously described.9, 18 CIMP-high required >2 
markers to be methylated and CIMP-low 1-2 markers methylated. MGMT methylation was 
determined using the MethyLight technique as previously described.19 
Statistical Analysis 
Categorical variables were compared by Chi-square / Fisher’s exact test and continuous 
variables by Student’s t / Wilcoxon test. A p-value of ≤0.05 was considered significant. 
Inter-rater agreements of diagnoses by the study pathologists were estimated using Light’s 
kappa. SPSS version 19, R version 3.0.2 and GraphPad Prism version 6.02 were used for 
statistical analyses. 
RESULTS 
Clinicopathological data and diagnostic concordance 
Twenty-seven polyps from the consecutive series (cohort 1) fulfilled the selection criteria 
for sTVA, representing 7% of all TVAs. The Light’s kappa value for agreement between 
the 4 study pathologists in the diagnosis of the 3 categories of polyp, was 0.85 (Bootstrap 
95% confidence interval; 0.80-0.89), indicating excellent diagnostic concordance. Twenty-
nine cases achieved consensus for advanced histology (8 cases from cohort 1 and all 21 
cases from cohort 2), including 27 with high-grade dysplasia and 7 with invasive 
carcinoma (Table 1). Five cases had high-grade dysplasia and early carcinoma. Of the 27 
cases with high-grade dysplasia, 2 had a conventional pattern, 12 had some serrated 
features but insufficient to meet the WHO criteria for serrated dysplasia and 13 had 
180
serrated dysplasia. Of the 7 cases with invasive carcinoma, 1 had a conventional pattern 
and 6 had serrated morphology. 
The clinicopathological data for cohorts 1, 3 and 4 are presented in table 2. The sTVAs 
were larger, more often proximal and more often displayed advanced histology than the 
cTVAs. Compared to BRAF wild-type TSAs, sTVAs were more likely to be proximal. 
Immunohistochemistry 
The immunohistochemical profiles of the non-advanced components of cohorts 1, 3 and 4 
are presented in table 3. In particular, nuclear β-catenin staining is more frequent in the 
sTVAs than the BRAF wild-type TSAs (Figures 4A&B). The staining patterns of all of the 
sTVAs (cohorts 1 and 2), comparing the low-grade dysplasia components with the 
advanced components are presented in table 4. Nuclear p53 staining is more common in 
the advanced components of the sTVAs.  
BRAF and KRAS mutation profiles 
The BRAF and KRAS mutation status of cohorts 1, 3 and 4 are presented in table 2. No 
cases were BRAF mutated. The sTVAs were more likely to harbour a KRAS mutation than 
the cTVAs.  
Methylation analysis 
The CIMP status and MGMT methylation status of cohorts 1, 3 and 4 are presented in 
table 2. Of note, the sTVAs are less likely to be CIMP-negative than the cTVAs but more 
likely to be CIMP-negative than BRAF wild-type TSAs. The sTVAs show similar levels of 
MGMT methylation to the cTVAs but more frequent methylation than BRAF wild-type 
TSAs.  
DISCUSSION 
Although the TVA with architectural serration has been mentioned in textbooks and 
abstracts,5, 20 to the best of our knowledge there have been no previous reports in the 
peer-reviewed literature. Pai et al, examined the morphology of conventional adenomas 
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occurring in patients with synchronous serrated polyps and found several distinctive 
features including mild serration, cytoplasmic eosinophilia, dilated crypt bases and low-
level methylation when compared to control cohorts. However, most of these polyps were 
TAs and none showed a KRAS mutation.21 Kakar et al, assessed the molecular features of 
a series of TAs, TVAs and VAs, not selected for serrated architecture and identified a 
KRAS mutation in only 9% of TVAs.22 More recently, Tsai et al, studied 60 TSAs with 
either high-grade dysplasia or carcinoma.13 In that cohort, 19 polyps were designated as 
TVA with serrated features, which appear to resemble the polyps in our series, although 
with more features of TSA than our cohort. Interestingly they have similar rates of KRAS 
mutation (79%) but have infrequent nuclear β-catenin staining (11%) and rarely give rise to 
serrated morphology carcinomas.13 Finally Hafezi-Bakhtiari et al, identified discriminating 
histological features useful for separating TVAs from TSAs.10 They found that ECFs were 
common in both cohorts, although more numerous in TSAs. In contrast, slit-like serrations 
were highly sensitive and specific for the diagnosis of TSA. Several other studies have 
demonstrated an association between KRAS mutation and adenoma size, villosity and 
high-grade dysplasia, but have not addressed the issue of serrated architecture.23-25 
In this study we established baseline histopathological features for the diagnosis of sTVAs 
and applied them to a consecutive series of 412 TVAs to develop a study cohort (cohort 
1). The diagnostic criteria used, although to some extent arbitrary, required at least 50% 
histological serration to ensure that this was the dominant pattern in the study polyps.  
Although sTVAs and TSAs both have architectural serration, the epithelium of sTVAs 
typically showed uniform conventional-type dysplasia, similar in appearance to cTVAs, but 
quite distinct to the eosinophilic cells of the TSA. Because many pathologists would 
currently diagnose these sTVAs as TSAs, the first aim of this study was to determine if 
they could be reproducibly diagnosed. Thus our diagnostic criteria were designed to 
ensure that the study polyps had 1) a prominent serrated architecture to separate them 
from cTVAs and 2) lacked TSA-type cytology and slit-like serrations, thus distinguishing 
them from TSAs. Similar to the recent study of Hafezi-Bakhtiari et al, we allowed a minor 
component (<10%) with TSA-type morphology, in recognition that small components of 
this nature are commonly present in otherwise typical serrated and conventional polyps.10  
Using these criteria, we found that sTVAs can be reliably diagnosed and are distinct from 
both TSAs and cTVAs. Compared to cTVAs, the sTVAs were larger, more often proximal 
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and more frequently displayed advanced histology. In addition, they more frequently 
harboured a KRAS mutation and showed more frequent CIMP. Compared to BRAF wild-
type TSAs the sTVAs were more often proximal, showed less CIMP, more frequent MGMT 
methylation, more frequent nuclear β-catenin staining and less frequent CK7 staining.  
 
Thus BRAF wild-type TSAs and sTVAs represent separate precursors of the KRAS 
mutated, MSS subtype of colorectal carcinoma.7 The order in which polyps develop Wnt 
and MAP kinase pathway activation may be critical to polyp morphology and biology. The 
BRAF wild-type TSAs seem to be initiated by KRAS mutation and develop Wnt pathway 
activation late.9 In contrast, sTVAs develop early Wnt pathway activation as demonstrated 
by nuclear β-catenin staining (which in this context most likely reflects APC mutation) and 
then develop a serrated signature, presumably as a consequence of subsequent KRAS 
mutation.  Thus we envisage BRAF wild-type TSAs are more closely aligned with the 
serrated pathway and that the sTVAs are more closely aligned with the traditional 
pathway.  
 
The second component of this study was to assess the morphology and pathways by 
which sTVAs progress to malignancy and to compare these with the other polyp subtypes. 
We found that the high-grade dysplasia and invasive carcinomas arising in sTVAs 
frequently demonstrated serrated morphology. Although possibly controversial, this finding 
is not unexpected. In his original description of serrated morphology carcinomas, Makinen 
assessed carcinomas arising from serrated adenomas.26 At that time serrated adenomas 
were not a clearly defined entity and likely included TSAs, SSAs with dysplasia and almost 
certainly sTVAs.1 In a subsequent work from his group, it was shown that serrated 
morphology carcinomas very frequently show MAP kinase pathway activation, and that 
this was more frequently due to KRAS rather than BRAF mutation.27 Thus we are not 
surprised to find serrated morphology in the majority of the carcinomas arising from these 
polyps.7  
 
Using immunohistochemistry, loss of expression of the mismatch repair enzyme MLH1, as 
expected, was not found in any sTVAs, as MSI secondary to MLH1 promoter methylation 
is strongly correlated with BRAF but not KRAS mutation.28 In contrast, strong nuclear p53 
staining (indicative of TP53 mutation 29) was more frequent in the advanced components 
of the sTVAs. Also, sTVAs did not show loss of p16 staining, suggesting that loss of 
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function of CDKN2A is not important in the progression of these carcinomas.9 An outline of 
the proposed pathways to carcinoma for the various polyp types is shown in Figure 5.  
 
In the current literature, ECFs, predominant villous architecture and distal location are 
emphasized in the diagnosis of TSAs.1, 30-32 All of these features are shared with sTVAs 
making misdiagnosis easy. The absence of the typical TSA-type cytology and slit-like 
serrations is key to making the correct diagnosis.9, 10 In day-to-day practice, the diagnosis 
of sTVAs as a distinct entity may not be necessary, as the surveillance guidelines for TVAs 
and TSAs are currently the same.33 However, it may be helpful to provide the additional 
information in certain scenarios. The presence of an sTVA component adjacent to an 
invasive carcinoma would make a KRAS mutation likely and may be helpful to direct 
molecular testing if targeted therapy is being considered. Also, TSAs are included in polyp 
counts to diagnose serrated polyposis syndrome, whereas TVAs are not. In our opinion 
sTVAs should not be included as part of this syndrome. Finally, it is only through precise 
histological diagnosis that the molecular spectrum of colorectal neoplasia can be fully 
elucidated. Thus strict diagnosis is an important part of ongoing research. 
 
This paper does have limitations. Firstly, we set clear boundaries to separate the 3 polyp 
cohorts and this is reflected in the excellent level of diagnostic reproducibility. In practice a 
small subset of polyps will fall somewhere between the criteria we have used in this study 
and will remain difficult to precisely classify. However, in a proof of principle study such as 
this, we believe it is best to begin with clearly defined cohorts and strict diagnostic criteria. 
These can be refined over time as more information comes to light. Secondly, we do not 
have follow-up information on the patients included in this study to determine the clinical 
significance of these lesions in terms of the risk of subsequent polyps and colorectal 
carcinoma. The presence of frequent advanced histology would suggest close follow-up is 
warranted but needs to be addressed in a dedicated study in the future. 
 
In summary, we find that sTVAs can be reliably diagnosed and represent an important 
precursor of KRAS mutated, MSS subtype colorectal carcinoma. In particular, KRAS 
mutation appears to be associated with the development of morphological serration. 
Serrated TVAs should not be diagnosed as TSAs due to significant differences in their 
underlying biology.  
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Table 1. Non-advanced and advanced status of the study cohorts 
Cohort Non-advanced Advanced 
 Low-grade 
dysplasia 
High-grade 
dysplasia 
Carcinoma Total 
Cohort 1 
(n=27) 
19 (70%) 8 (30%) 0 8 (30%) 
Cohort 2 
(n=21) 
0 19 (90%) 7 (33%) 21 (100%)* 
Cohort 3 
(n=50) 
46 4 (8%) 0 4 (8%) 
Cohort 4 
(n=66) 
50 13 (20%) 6 (9%) 16 (24%)* 
*Some cases in cohorts 2 and 4 had both high-grade dysplasia and 
carcinoma. 
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Table 2. Clinicopathological and molecular features of the study and control cohorts. 
Feature Serrated TVA 
(n=27) 
Conventional TVA 
(n=50) 
P-value BRAF wild-
type TSA 
(n=66) 
P-value
Age 63.4 59.9 0.2460 63.8 0.9163 
Female 9 (33%) 22 (44%) 0.4667 34 (52%) 0.1687 
Size 21.6 13.4 <0.0001 18.9 0.4684 
Distal  16 (59%) 45 (90%) 0.0027 57 (89%) 0.0104 
Advanced 8 (30%) 4 (8%) 0.0200 16 (24%) 0.6089 
BRAF mutant 0 0 NA 0 NA 
KRAS mutant 18 (67%) 9 (18%) <0.0001 43 (65%) 1.0000 
CIMP high 1 (4%) 0 0.3506 11 (17%) 0.1694 
CIMP low 6 (22%) 3 (6%) 0.0590 30 (46%) 0.0594 
CIMP negative 20 (74%) 47 (94%) 0.0279 25 (38%) 0.0026 
MGMT 
methylation 
12 (44%) 20 (40%) 0.8097 9 (14%) 0.0023 
P-values of less than 0.05 are indicated in bold; TVA – tubulovillous adenoma; TSA –
traditional serrated adenoma; CIMP – CpG island methylator phenotype
190
Table 3. Immunohistochemical features of the non-advanced components of the study and 
control cohorts. 
Immunohistochemical 
stain 
Serrated 
TVA (n=27) 
Conventional 
TVA (n=50) 
P-value BRAF wild-
type TSA 
(n=66) 
P-value
Nuclear β-catenin 19 (70%) 42 (84%) 0.2384 16 (24%) <0.0001 
P53 4 (15%) 3 (6%) 0.2322 12 (18%) 0.7723 
P16 24 (89%) 40 (80%) 0.5248 52 (79%) 0.3772 
MLH1 loss 0 0 1.000 0 1.000 
Ki67 9 (33%) 45 (90%) <0.0001 47 (71%) 0.0010 
CK7 1 (4%) 8 (16%) 0.1488 27 (41%) 0.0003 
CK20 23 (85%) 46 (92%) 0.4404 65 (99%) 0.0238 
P-values of less than 0.05 are indicated in bold.
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Table 4. Immunohistochemical features of low-grade dysplasia components versus 
advanced components of the 48 serrated tubulovillous adenomas 
Immunohistochemical 
stain 
Low-grade 
dysplasia (n=19) 
High-grade dysplasia/colorectal 
carcinoma (n=29) 
P-value 
Nuclear β-catenin 10 (53%) 23 (79%) 0.064 
P53 2 (11%) 12 (41%) 0.0264 
P16 16 (84%) 28 (97%) 0.2864 
MLH1 loss 0 0 1.000 
Ki67 9 (47%) 19 (66%) 0.2446 
CK7 1 (5%) 2 (8%) 1.0000 
CK20 15 (79%) 21 (72%) 0.7395 
P-values of less than 0.05 are indicated in bold. 
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FIGURE LEGENDS 
Figure 1. (A) A low power image of a serrated tubulovillous adenoma. (B) A medium power 
image of the polyp in (A) showing prominent undulation of the glandular epithelium. (C) 
Ectopic crypt formations (arrows) with absence of traditional serrated adenoma cytology. 
This is the same polyp as illustrated in figure 3. (D) A medium power image from the polyp 
in (A) showing ‘maze-like’ growth with prominent arborizing and right-angled branching of 
the glandular epithelial lumens. 
Figure 2. (A and C) Low and medium magnification images of a conventional tubulovillous 
adenoma. Note the lack of epithelial serration. (B and D) Low and medium magnification 
images of a traditional serrated adenoma. Note the characteristic cytology, abundant ‘slit-
like’ epithelial serrations (arrows) and ectopic crypt formations.  
Figure 3. (A) Low magnification image of a serrated tubulovillous adenoma giving rise to 
an invasive adenocarcinoma. (B) High magnification image of the carcinoma showing 
serrated morphology, i.e. serration of the epithelium, abundant eosinophilic cytoplasm, 
basally located vesicular nuclei, prominent nucleoli and lack of dirty necrosis. 
Figure 4. β-catenin immunohistochemistry. (A) Serrated tubulovillous adenoma showing 
moderate to strong nuclear staining in most of the epithelial cells. (B) A non-advanced 
traditional serrated adenoma showing membranous staining but lack of nuclear staining 
(the normal pattern). 
Figure 5. Proposed precursors and pathways of sporadic colorectal carcinogenesis. 
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Chapter 6 – Final Discussion: 
The serrated neoplasia pathway is a relatively recently described molecular route to 
colorectal carcinoma that accounts for 20-30% of all colorectal carcinoma.1, 2 As such the 
serrated pathway is a major source of gastrointestinal cancer and a major health and 
economic burden. While the precursors of the conventional pathway to colorectal 
carcinoma are well characterised, the precursors of the serrated pathway are much less 
understood. This has significant implications, as endoscopic removal of the pre-malignant 
polyps is an effective method to prevent the development of cancer. Thus a detailed 
understanding of serrated colorectal polyps may allow for more informed decisions about 
the management of serrated polyps.  
Chapter 2 addresses two important issues. First we assessed a large consecutive series 
of colorectal polyps with the primary aim of determining how frequent sessile serrated 
adenomas are in our community. Second, through a detailed histological and clinical 
appraisal we attempted to provide evidence for the diagnostic threshold of the sessile 
serrated adenoma. These issues are related and are important for several reasons. For 
pathologists it is important to know how frequently we should be rendering specific 
diagnoses. At present the rates of sessile serrated adenoma diagnoses in the literature are 
widely variable,3-9 making it difficult for the practicing pathologist to know what is 
reasonable. Furthermore, the diagnostic threshold for the sessile serrated adenoma 
continues to change, with a definite trend to relaxed criteria.10, 11 However these decisions 
have been made mostly on the basis of expert opinion rather than based on experimental 
evidence.  
In our practice, we were using the diagnostic criteria of the 4th edition of the WHO 
classification of tumours of the digestive system.10 We felt that we were diagnosing sessile 
serrated adenomas more frequently than had been reported in the literature. In addition, a 
consensus paper from a panel of international experts had recently suggested relaxing the 
diagnostic criteria beyond the recommendations of the WHO.11 Thus we undertook to 
determine our rate of sessile serrated adenoma diagnoses and to compare the clinical 
features of sessile serrated adenomas when divided according to the number of sessile 
serrated adenoma-type crypts per polyp. We found that polyps with even one typical 
sessile serrated adenoma-type crypt had gender and distribution characteristics more 
similar to other more ‘typical’ sessile serrated adenomas than to microvesicular 
hyperplastic polyps. Using this diagnostic threshold, we found that sessile serrated 
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adenomas represented 14.7% of all colorectal polyps received at our practice. This figure 
represents the highest in the reported literature. This result likely reflects the relaxed 
diagnostic threshold utilised but probably also reflects the experience of the referring 
colonoscopists. Brisbane has been a centre of research into the serrated neoplasia 
pathway for many years and as such local gastroenterologists may be more aware of the 
salient features of sessile serrated adenomas than in other regions. As such the high rate 
of sessile serrated adenomas reported in our series may not be entirely reflective of the 
experience of other centres. Regardless, sessile serrated adenomas should be a common 
diagnosis to both gastrointestinal and general anatomical pathologists.  
Interval colorectal carcinoma accounts for approximately 5% of all colorectal carcinoma 
diagnoses and is defined as a cancer developing within the colonoscopic surveillance 
interval.12 Serrated pathway carcinomas are over-represented in series of interval 
colorectal carcinomas.13, 14 There are several reasons why this may be the case. First are 
missed polyps at colonoscopy. Sessile serrated adenomas are predominantly proximal 
and can be very subtle, particularly when compared to conventional adenomas.  Second, 
there is a hypothesised potential for sessile serrated adenomas to progress rapidly to 
malignancy.2 Third, sessile serrated adenomas are frequently incompletely excised at 
colonoscopy.9 It is probable that all of these factors play some role in the occurrence of 
interval colorectal carcinoma. Another factor that had not been previously reported is 
under-diagnosis of sessile serrated adenomas by pathologists. The diagnosis of the 
sessile serrated adenoma overlaps with microvesicular hyperplastic polyps. Microvesicular 
hyperplastic polyps are benign and do not have significant malignant potential. As such no 
specific surveillance is recommended for these polyps. Overly stringent diagnostic criteria 
will result in a proportion of sessile serrated adenomas being diagnosed as microvesicular 
hyperplastic polyps with the potential for inadequate recommendations for surveillance 
colonoscopy and thus contributing to the development of interval colorectal carcinoma. 
We hope that the finding of chapter 2 will assist pathologists by reinforcing that sessile 
serrated adenomas are common and by providing some basic evidence for the relaxed 
diagnostic criteria proffered by the expert panel. 
Chapter 3 is a detailed analysis of the traditional serrated adenoma. These rare polyps 
have not been thoroughly categorised. In this chapter we detail the clinicopathological and 
molecular features of the traditional serrated adenoma and provide insights into the 
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molecular pathways by which traditional serrated adenomas progress to colorectal 
carcinoma. At present, there are several issues of contention regarding these lesions to 
the extent that some authors do not accept that the traditional serrated adenoma is part of 
the serrated neoplasia pathway.15 In some countries, traditional serrated adenomas are 
considered to be exclusively distal and are required to have a protuberant or exophytic 
growth pattern for diagnosis.16 Many series from various regions have described precursor 
microvesicular hyperplastic polyp or sessile serrated adenomas at the edge or base of 
traditional serrated adenomas,17-19 however this is still not broadly accepted. Furthermore, 
the rates of KRAS and BRAF mutation and CpG island methylator phenotype of traditional 
serrated adenomas is widely variable in the literature.20-22 Finally the molecular steps in 
malignant transformation have not been thoroughly assessed.  
 
In our series we aimed to address these issues. Our series comprised 200 traditional 
serrated adenomas with strict inclusion criteria. We identified slit-like serrations as a very 
helpful histological feature for making the diagnosis of traditional serrated adenoma, and in 
particular for separating these polyps from serrated tubulovillous adenomas. In addition we 
were able to perform a clinicopathological and molecular assessment of all of the cases 
included in the study. The rigorous inclusion criteria, the size of the series and the 
complete assessment of all of the cases allowed us to identify statistically significant 
features of traditional serrated adenomas that had not been previously recognised. 
 
We found that most traditional serrated adenomas harbour a BRAF mutation and that the 
dichotomy between BRAF mutated and KRAS mutated traditional serrated adenomas 
underlies important differences in the clinicopathological and molecular features of these 
polyps. In particular, BRAF mutated traditional serrated adenomas frequently arise from 
either a microvesicular hyperplastic polyp or sessile serrated adenoma, whereas KRAS 
mutated cases do not. Second, BRAF mutated traditional serrated adenomas regularly 
occur in the proximal colon. These proximal traditional serrated adenomas are often 
sessile and this may relate simply to a difference in intraluminal pressures rather than to 
any intrinsic factor of the polyps, especially because distal BRAF mutated traditional 
serrated adenomas are no more likely to be flat than the distal KRAS mutated traditional 
serrated adenomas. Third, the BRAF mutated traditional serrated adenomas are much 
more likely to be CpG island methylator phenotype high. This is expected as BRAF 
mutation is known to be tightly correlated with the CpG island methylator phenotype. More 
recently a mechanistic link between BRAF mutation and methylation has been 
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demonstrated.23 Finally, BRAF mutated traditional serrated adenomas showed much more 
frequent loss of expression of p16 by immunohistochemistry than other cases and likely 
reflects the methylator phenotype of the BRAF mutated polyps.  
 
Thirty-eight of the cases in this series had developed an area of either overt cytological 
dysplasia or of malignancy. Interestingly, loss of mismatch repair enzyme function was 
very rare, even amongst the BRAF mutated cases. This has been described by other 
groups and represents an important distinction in the mode of progression of traditional 
serrated adenomas compared to sessile serrated adenomas.24 As discussed above, BRAF 
mutated polyps were more likely to lose immunohistochemical expression of p16, but the 
rates in BRAF and KRAS mutated lesions for TP53 mutation and WNT pathway activation 
were very similar.  
 
BRAF mutated microsatellite stable colorectal carcinomas are known to have a poor 
prognosis.25, 26 Fortunately these cancers are rare, accounting for approximately 5% of all 
colorectal cancer.27 BRAF mutated traditional serrated adenomas appear to be an 
important precursor of these cancers. Thus, although they are rare, traditional serrated 
adenomas give rise to an aggressive subtype of colorectal carcinoma. Thus any patient 
with a traditional serrated adenoma with overt cytological dysplasia should be closely 
followed by colonoscopy. Whenever carcinoma is found to be arising in a traditional 
serrated adenoma, partial colectomy should be seriously considered regardless of the 
presence or absence of other adverse factors. 
 
Chapter 4 addressed the same aims as chapter 3, but this time focussing on advanced 
sessile serrated adenomas. Unlike traditional serrated adenomas, sessile serrated 
adenomas are common and as such account for the bulk of the cancer burden of the 
serrated neoplasia pathway.28 As has already been discussed, they are also likely to be 
the cause of many interval carcinomas. Despite the frequency of sessile serrated 
adenomas, cases with dysplasia or early carcinoma, i.e. sessile serrated adenomas 
“caught in the act” of malignant transformation, are rare.29, 30 As a result there have been 
no thorough studies of a large series of polyps of this type.  
 
Although much can be inferred about the clinicopathological and molecular features of 
these polyps by study of either ordinary sessile serrated adenomas or of BRAF mutated 
colorectal carcinomas,3, 31, 32 inevitable gaps will remain. Particular issues that cannot be 
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resolved include the proportion of cases that are mismatch repair deficient versus 
mismatch repair proficient, the size of the polyps when they develop dysplasia or 
carcinoma and the nature of the dysplasia (size, growth pattern). In addition, study of 
BRAF mutant colorectal carcinomas will not capture the small but significant subset of 
BRAF wild type sessile serrated adenomas.  
For this chapter we collected a prospective series of 137 advanced sessile serrated 
adenomas. Importantly all of the cases were rigorously diagnosed, paying particular 
attention to exclusion of tubular adenoma contaminating an ordinary sessile serrated 
adenoma and the more recently recognised traditional serrated adenoma (or early 
traditional serrated adenoma-type change) arising in a sessile serrated adenoma. Other 
studies that are based on database review, without central review and without strict 
histopathological criteria must be interpreted with caution.  
As a group, the advanced sessile serrated adenomas tended to be small polyps. The 
median size was 9.5mm. Most occurred in the proximal colon and in women. In the 
majority the advanced component was flat. We found that 75% of advanced sessile 
serrated adenomas are mismatch repair deficient. This occurs via silencing of the MLH1 
gene by methylation of the promoter region.33 Thus loss of MLH1 function was the most 
common molecular event in the neoplastic progression of these polyps. Furthermore, the 
mismatch repair enzyme status underscored key differences in the clinicopathological and 
other molecular features of these polyps. 
Mismatch repair deficient polyps occurred more frequently in the proximal colon and more 
often in women. They were more likely to be CpG island methylator phenotype high and 
were less likely to have a TP53 mutation. Loss of p16 expression and WNT pathway 
activation were similar between the two groups.  
These findings are important. The proximal location, small size of these polyps and the 
frequent flat nature of the advanced components have implications for colonoscopists. 
Proximal polyps are more difficult to detect and remove than distal ones due to technical 
issues and the anatomy of the colon.34 Adding to the difficulty, sessile serrated adenomas 
are subtle. They are close in colour to the surrounding normal mucosa, often have 
indistinct borders and the type II pit pattern is not as striking as the type III and IV pattern 
of conventional adenomas.35, 36 In addition they are often obscured by mucin or adherent 
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debris. While this can be a helpful feature to the knowledgeable, lack of awareness of this 
phenomenon is problematic for others. Finally, the frequent small size of these polyps 
means they can be easily missed. Thus even diligent and knowledgeable colonoscopists 
will inevitably miss a proportion of sessile serrated adenomas. If the missed lesion 
contains a focus of dysplasia or early carcinomas this can easily become an interval 
carcinoma. Sessile serrated adenomas with dysplasia have a hypothesised potential for 
rapid malignant transformation. Although not proven, indirect evidence supports this 
position. First, the majority have lost mismatch repair enzyme function allowing for a rapid 
accumulation of mutations in tumour suppressor genes with mono or bi-nucleotide 
repeats.37, 38 Second, the CpG island methylator phenotype allows progressive silencing of 
important tumour suppressor genes. Third sessile serrated adenomas are common and 
BRAF mutated colorectal carcinomas are common, but advanced sessile serrated 
adenomas are rare.39 This would suggest that they are present only briefly in the large 
bowel before progressing to cancer. Finally, the mean age of patients in this series with 
sessile serrated adenomas with dysplasia was not significantly different to cases with 
cancer, but both were significantly older than the reported mean ages of ordinary sessile 
serrated adenomas in the literature.39, 40 This suggests that the lag between dysplasia and 
cancer is very short. Thus whenever an advanced sessile serrated adenoma is missed, 
there is a substantial risk of interval cancer. 
The separation of advanced sessile serrated adenomas into distinct mismatch repair 
deficient and mismatch repair proficient subsets has not been previously demonstrated; 
however the finding is not unexpected based known differences between BRAF mutated 
microsatellite unstable and stable carcinomas.31, 32 As discussed above, BRAF mutated 
traditional serrated adenomas are an important precursor of the aggressive BRAF mutated 
microsatellite stable subtype of cancer, however the majority are probably derived from 
these mismatch repair proficient advanced sessile serrated adenomas. Thus up to one 
quarter of advanced sessile serrated adenomas will become the aggressive BRAF 
mutated, microsatellite stable molecular subtype of cancer and these will be over-
represented amongst males and amongst distal polyps. 
Chapter 5 evolved in part from the work on chapter 3. While gathering the series of 
traditional serrated adenomas we identified many polyps with tubulovillous growth and 
ectopic crypt formations. However, they did not have the typical cells with eosinophilic 
cytoplasm and did not show slit-like serrations. Instead they had uniform cytological 
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dysplasia of conventional type and other features of serration, such as undulation of the 
epithelium and a distinctive maze-like growth pattern. Some of these polyps had been 
diagnosed as traditional serrated adenomas based on the work of Torlakovic et al, from 
2008.16 However, after central review they were excluded. It was unclear to us if these 
serrated tubulovillous adenomas should be classified as traditional serrated adenomas, 
tubulovillous adenomas or as a separate category. Thus we undertook to gather a 
consecutive series of these polyps, with appropriate control cohorts to assess their 
clinicopathological and molecular features.  
We found that the serrated tubulovillous adenomas had distinctive histological features 
and could be reliably distinguished from both traditional serrated adenomas and from 
conventional tubulovillous adenomas. Furthermore the serrated tubulovillous adenomas 
had clinicopathological and molecular features distinct from the two control cohorts. In 
particular they had a very high rate of KRAS mutation suggesting that serrated morphology 
may be linked to KRAS mutation. This is a concept first raised by Jeremy Jass41 but that 
has not been conclusively demonstrated in an experimental setting. The serrated 
tubulovillous adenomas had relatively little methylation. It seems likely that these polyps 
are a progressed form of tubulovillous adenoma and that the prominent serrated 
architecture develops after the acquisition of a KRAS mutation; however this theory 
requires more intensive and directed investigation. 
In conclusion this thesis has addressed many aspects of serrated colorectal polyps. We 
have determined the frequency of sessile serrated adenomas in a community pathology 
practice based on varied criteria for these polyps. In addition we have validated by clinical 
data the single crypt criteria for the diagnosis of sessile serrated adenomas. Next we have 
performed an in-depth clinicopathological and molecular appraisal of traditional serrated 
adenomas and advanced sessile serrated adenomas and have identified novel 
histological, clinicopathological and molecular features of these polyps, many of which are 
relevant to clinical practice. Finally we have assessed the features of a serrated variant of 
tubulovillous adenomas and have shown they have distinctive features warranting 
separation from traditional serrated adenomas. 
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